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AD activation domain 
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ALK activin receptor-like kinase 
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photobleaching 
FRET fluorescence resonance energy transfer 
FSH follicle-stimulating hormone 
FTICR Fourrier-transform ion cyclotron 
resonance 
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GAF guanine nucleotide activating factor 
GATA zinc-finger transcription factor 
GDP guanine diphosphate 
GEF guanine nucleotide exchange factor 
GFP green fluorescent protein 
G3PD glyceraldehyde 3-phosphate 
dehydrogenase  
GR glucocorticoid receptor 
GSF genital skin fibroblast 
GTF general transcription factors 
GTP guanine triphosphate 
HAT histone acetyl trandferase 
HDAC histone deacetylase complexes 
HGP human genome project 
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HMS- 
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 ibonucleoprotein 
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MAPK mitogen-activated protein 
kinase 
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substance 
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virus-luciferase 
MR mineralocorticoid receptor 
MS mass spectrometry 
MSDB matrix science data base 
MudPIT multidimensional 
protein identification 
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NCBI national center for 
biotechnology information 
N-CoR nuclear receptor co-
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NR nuclear receptor 
NTD NH2-terminal domain 
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PAGE polyacrylamide gel electrophoresis 
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PC prostate cancer 
PCR polymerase chain reaction 
pI isoelectric point 
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PR progesterone receptor 
PRK protein kinase C-related kinase 
PSA prostate specific antigen 
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RAR all-trans retinoid acid receptor 
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dissociation inhibitor 
RNA Pol II RNA polymerase II 
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SF1 Steroidogenic factor 1 
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SRC steroid receptor co-activator 
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TFIIF transcription factor II F 
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Introduction 
Androgens regulate a large number of developmental processes, starting in fetal life and 
going on all the way through puberty. The action of androgens is essential for development 
of the male genital tract in the embryo, and development of secondary male characteristics 
at puberty. In addition, androgens are important for maintenance of normal male functions 
in adulthood, such as spermatogenesis, sexual libido, and other aspects of the male 
phenotype. Lack of androgens or androgen action during embryonic development inevitably 
results in partial or more complete lack of virilization or feminization of the genital tract. 
Primary sex determination is strictly chromosomal, while gonadal hormones and their 
downstream effects are responsible for differentiation of genital tract tissues. This chapter 
describes the ontogeny of sex determination and differentiation, and the factors involved in 
androgen-regulated genital tract development. Furthermore, androgen receptor function and 
mechanism of action is described in more detail, as well as the involvement of the androgen 
receptor in different pathological conditions. Mouse models are being widely used to study 
processes and factors involved in genital tract development, and therefore throughout this 
thesis the situation for the mouse will be outlined and, where applicable, observations in 
humans will be referred to. 
 
1.1 Sex determination 
Development of a new individual starts with fertilization of an oocyte by a sperm cell. 
While the genome resulting from the two meiotic divisions in the oocyte will always contain 
an X chromosome, the sperm cell contains either an X or a Y chromosome. The subsequent 
sex determination of the embryo depends on the two inherited sex chromosomes. XX 
individuals are genetically predetermined to become females, whereas the presence of a Y 
chromosome determines male sex. The Y chromosome harbors the testis-determining 
region, to which the Sry gene was mapped, which triggers the undifferentiated gonads to 
develop as testes 1. Regardless of chromosomal sex, sexual development in the embryo is 
preceded by an indifferent stage, in which bipotential gonads and anlagen for both the male 
and female reproductive tract, Wolffian and Müllerian ducts respectively, are present. At this 
stage, the bipotential gonad can still develop into either an ovary or a testis, depending on 
the regulatory mechanisms 2-4. In humans, embryonic and fetal development of a new 
individual takes 9 months, with the critical period of gonadal development between days 37 
and 43, whereas development in mice takes 19-21 days, in which development of the 
gonadal anlage occurs around embryonic day 9 (E9) to E11. Morphologically, the gonads 
are formed as part of the urogenital system, which is derived from the intermediate 
mesoderm and can be divided into the pronephros, mesonephros, and metanephros, and 
associated duct systems. The indifferent gonads originate from a thickening of the 
ventrolateral surface of the embryonic mesonephros, the so-called genital ridge, which is 
visible in mice at E10. The genital ridge is composed of somatic cells and primordial germ 
cells, which originate from the epiblast, and move to the extraembryonic ectoderm in the 
yolk sac, from where they migrate to the site of the genital ridge 5,6 (Figure 1.1). Genotype 
analysis of human sex-reversed individuals, mutation analysis, and genetically engineered 
mouse-model systems, have revealed that the formation of the gonads and the process of 
sex determination and differentiation is tightly controlled by genes. What role these genes 
play in sex determination is not always clear, but it is likely that multiple factors collaborate 
in a network that activates downstream targets, which in turn feed back on upstream factors. 
So far, at least four autosomal genes, Sf1, Wt1, Lhx9, and Lim1, have been identified that are 
 Chapter 1 
14 
required for proper development of the indifferent or bipotential gonad, and more are being 
identified for which a role in gonadogenesis is implicated but not yet completely 
understood, as reviewed in 3,4,7,8. 
  
Mesonephros
Genital ridge
Primordial germ
cells
A B
Mesonephros
Mesonephric (Wolffian) duct
Paramesonephric (Müllerian)
duct
Metanephros
Indifferent gonad
 
Figure 1.1. Schematic representation of urogenital tract development 
A) Migration of the primordial germ cells from the yolk sac to the genital ridges. 
B) The genital ridges, which are composed of somatic cells and primordial germ cells, develop into indifferent 
gonads. Figure adapted from Larsen, 1993 9. 
 
Genes involved in gonad formation 
Expression of steroidogenic factor 1 (SF1) is associated with tissues and organs of 
endocrine function, such as gonads, adrenals, pituitary, and hypothalamus. SF1 is detectable 
in genital ridges of both sexes from approximately E9 10 and is essential for gonadogenesis, 
since Sf1 gene knockout mice lack adrenal glands and gonads 11,12. SF1, encoded by the Fushi 
tarazu factor 1 (Ftz-f1) or Sf1 gene, belongs to the family of orphan nuclear receptors (see 
Chapter 1.3) and regulates expression of a variety of steroidogenic enzymes in adrenal 
glands and gonads 13. The exact role of SF1 in gonadal development remains unclear, since 
Sf1 gene knockout mice develop genital ridges which are colonized by primordial germ cells, 
but the gonads subsequently fail to develop further after E11.5 and degenerate due to 
apoptosis 11. Recent studies in humans with mutated SF1 revealed that SF1-dependent 
developmental pathways are exquisitely sensitive to gene dosage 14. 
The Wilm’s tumor-associated gene (Wt1) is very complex and encodes a variety of 
protein products with different functions. The WT1 proteins are zinc-finger containing 
factors, which are homologous to members of the early growth response (EGR) family, and 
can act either as repressors or activators of transcription 15. WT1 mRNA is detected in the 
genital ridge of both male and female mice as early as E9.5 and remains highly expressed 
during gonadal development 16. The involvement of WT1 in gonadal development is 
demonstrated by Wt1 knockout mice, which show an arrest in gonadal and kidney 
development 17. While heterozygous Wt1 +/- mice are unaffected, children with a 
heterozygous mutation in the Wt1 gene exhibit genital malformations and are predisposed 
to developing Wilm’s tumors, a childhood tumor of the kidney 18. These studies in humans 
suggest that WT1, like SF1, functions in a gene-dosage dependent manner. 
The LIM homeobox domain gene Lhx9 is essential for mouse gonadal development, 
since lack of Lhx9 function results in absence of gonads, and consequently male-to-female 
sex reversal and infertility 19. In both sexes, Lhx9 is expressed in the genital ridge from E9.5 
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onwards, and by E13.5 Lhx9 is highly expressed in the mesothelial layer and outer part of 
the testis. In the E13.5 ovary, Lhx9 is mainly expressed in the cortical region 19. Lhx9 
expression is down-regulated at the time that epithelial cells in the gonads differentiate into 
either Sertoli or granulosa cells. Therefore, Lhx9 expression can be inversely correlated with 
the commitment into a differentiation pathway 20. Unlike other genes important for 
gonadogenesis, such as Wt1 and Sf1, knocking out Lhx9 does not result in any other major 
developmental defects, implicating a specific role for Lhx9 in gonadal development. 
Furthermore, Lhx9 seems to function upstream of SF1 in the developmental cascade, since 
SF1 is not detected in Lhx9-deficient genital ridges 19. 
Other homeobox proteins such as LIM1, Pax2 and EMX2 are also involved in early 
gonadal development 21-23,  but their precise role is not yet determined. Like the other genes, 
Lim1, Pax2, and Emx2 are expressed in the urogenital region during early urogenital 
development. Lim1 knockout mice fail to develop kidneys and gonads 24, Pax2-deficient 
mice lack kidneys and urogenital ducts, but the gonads and adrenals are formed 22, and 
Emx2 knockout mice also show impaired gonadal and kidney development 23.  
 
Genes involved in gonadal sex determination 
Once the gonads have been established from the genital ridge, they are morphologically 
identical for XX and XY mouse embryos until E12, and then they develop into either 
ovaries or testes, a process that is tightly controlled by programmed gene expression. The 
gonads harbor three cell lineages that have a bipotential fate depending on the sex of the 
organ. The supporting cell precursors give rise to Sertoli cells in the testis and granulosa cells 
in the ovary, the steroidogenic cell precursors differentiate into sex hormone producing 
Leydig cells or theca cells, respectively, and the connective cell lineages contribute to the 
formation of the organ as a whole. While testis formation is morphologically visible in the 
mouse at E12.5 by the appearance of testis cords, which include the primordial germ cells, 
differentiation of the ovary takes place later, and is morphologically visible in the mouse by 
E14.5 3.  
Sry is the only Y-chromosomal gene necessary for male sex determination. This was 
shown by experiments in which the genomic fragment, containing the Sry gene and flanking 
sequences, induced male sexual development in transgenic XX mice 25. SRY is expressed in 
the urogenital ridge between a limited time window of E10.5-E12.5 26,27. This expression 
along the genital ridge occurs in a dynamic wave. As a result, individual cells are exposed to 
SRY at different time points and for a different length of time 28. The action of SRY is at 
least three-fold: 1) triggering Sertoli cell fate for cells that would otherwise become 
granulosa cells 29, 2) inducing migration of cells from the mesonephros into the gonad 30, 3) 
inducing proliferation of cells within the genital ridge 31. These actions are most likely 
mediated at the level of transcriptional control, since SRY is capable of bending DNA, by 
binding of its HMG (high-mobility group) domain, a domain which is also found in other 
transcription factors 32,33, to specific sequences. Although SRY acts as a switch for Sertoli 
cell identity, it is not involved in maintaining this identity, because its expression is only 
transient. Therefore, other genes downstream of SRY must be involved. One gene directly 
regulated by SRY is SOX9. 
SOX9 (SRY-related HMG box) resembles SRY as it contains a similar HMG domain, 
but additionally two transcription activation domains are present within the SOX9 protein 
34,35. During early gonadal development, SOX9 is expressed at a low level in both male and 
female genital ridges. Around E11.5, following the onset of SRY, SOX9 is up-regulated in 
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the male gonad and down-regulated in the female, and continues to be expressed in Sertoli 
cells of the developing testis 36,37. Because SOX9 is male-specifically up-regulated just before 
testis development and subsequently in Sertoli cells, it was proposed that SOX9 is a 
downstream target of SRY in the male-sex determining pathway. However, since females do 
not have SRY but do express SOX9 initially in the genital ridges, there must be other factors 
involved in switching on SOX9 38. All species tested so far show a conserved male-specific 
expression pattern of SOX9, which implies that SOX9 is a pivotal sex determining gene in 
all vertebrates. Ectopic expression of SOX9 in XX mouse gonads showed that SOX9 is 
sufficient to induce male development and indicates that it can substitute for SRY function 
39. 
Female sexual development has long been considered a default pathway, since XY 
embryos show male-to-female sex reversal in the absence of male determining factors. 
However, the identification of proteins like DAX1 and Wnt4 has changed this view, since 
they are considered to be necessary for the initiation of the female pathway of sex 
determination. DAX1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical 
region on the X-chromosome, gene 1) is expressed in the genital ridge of both sexes at the 
same time as Sry, at E10.5, and becomes ovary-specific after E12 40. Duplication of the X-
chromosomal region where Dax1 resides is associated with dosage-sensitive sex reversalin 
humans, causing XY femaleness 41. This suggests that DAX1 functions as an ovary-
determining factor. However, Dax1-/- female mice have normally developed ovaries with 
only minor defects observed in the adult ovary, but Dax1-/- male mice have impaired 
spermatogenesis 42. In addition, crossing Dax1-/- mice to a mouse strain known to be 
susceptible to XY sex reversal because of an altered Sry allele, resulted in anovulatory XY 
females 43. Thus, DAX1 appears to play a role in both ovary-determination, as well as testis 
development, and these effects are highly dosage-sensitive. DAX1 is an X-linked member of 
the nuclear hormone receptor family 44, and is shown to inhibit transcriptional activation by 
SF1 in vitro 45. This inhibition most likely occurs through protein-protein interaction between 
DAX1 and SF1. The interaction functionally opposes the effect of WT1 on testis 
development mediated by SF1 transactivation 46. It is proposed that a double dose of DAX1 
inhibits the effects of SF1 and SRY, resulting in ovary development 43,47, whereas a single 
dose DAX1 stimulates SOX9 to induce testis development, and as a result absence of 
DAX1 results in defective testis development 43. In the developing ovary, Dax1 gene 
transcription is activated by β-catenin, a key signal transducing protein in the Wnt signaling 
pathway, acting in synergy with SF1 48. Dax1 expression is down-regulated in Wnt4-gene 
disrupted female mice, which show masculinized internal genitalia, because of activation of 
steroid biosynthesis in the fetal ovary 49. Wnt4-null ovaries, however, do not express Sertoli 
cell-specific genes, indicating that Wnt4 is not a general repressor of testis determination but 
rather a suppressor of steroidogenesis. Thus, Wnt4 signaling mediates increased expression 
of DAX1 in the differentiating ovary and is crucial for female sexual development 48,49. 
More and more factors are being identified that appear to play a role in sex 
determination and differentiation, acting either upstream and/or downstream of Sry. One 
such a factor is GATA4, a member of the GATA zinc-finger transcription factors, that is 
present in the developing gonads around E11.5 in both males and females. GATA4 is highly 
expressed in developing Sertoli and granulosa cells, but is down-regulated in the XX embryo 
at E13.5 during histological differentiation of the ovary 50. Although Gata4 deficient mice 
die in utero between E8.5 and E10.5, before gonadal development takes place 51, studies in 
mice transgenic for a mutated Gata4 show defective gonadogenesis due to an abbrogated 
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interaction with FOG2 (friend-of GATA 2), a co-factor for GATA4 52. Furthermore, in 
both Gata4 mutated mice as well as Fog2 -/- mice, SRY, SOX9, and steroidogenic enzymes 
could not be detected, while WT1 and SF1, which act upstream of SRY, were still expressed. 
Wnt4 expression in the developing ovaries was also unaffected 52. These studies indicate that 
an interaction between FOG2 and GATA4 is required for gonadal development and that 
GATA4 has a role in male sex differentiation. 
Disruption of the M33 gene, encoding the M33 protein, in mice results in retardation of 
genital ridge development and male-to-female sex reversal. Gonadal growth defects are 
obvious at the time of Sry gene expression, suggesting that M33 may act upstream of SRY 53. 
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Figure 1.2. Factors involved in mouse gonad formation and differentiation 
In both male and female gonadogenesis, formation of the genital ridge and indifferent gonad is under the control 
of the same set of genes. Around E11.5, male and female specific genes are either turned on or off in the 
respective tissues resulting in the development of ovaries and testes. Sex-specific up-regulatied genes are marked 
in bold.   
 
Another gene that may function as a sex-determining factor in vertebrates, is Dmrt1, 
which is probably a target for Sox9 54. DMRT1 is a protein with a DNA-binding motif (so-
called DM domain), which is related to the sex-determining DM-domain proteins MAB3 in 
the nematode Caenorhabditis elegans and Double-sex in the fruitfly Drosophila melanogaster. 
DMRT1 is expressed at E9.5 exclusively in genital ridges of both XX and XY embryos but 
becomes male-specific during gonadal differentiation and its expression is restricted to the 
testis 55. Dmrt1 null mutations cause severe defects in testis differentiation, demonstrating 
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that its role is relatively downstream in mammalian sex-determination 56. Recently, other 
DM-domain proteins have been identified, of which DMRT3 is highly expressed in males 
and DMRT7 is more highly expressed in females 57. Thus, DM-domain proteins may be 
involved in both male and female sexual differentiation. 
Other factors involved in fetal testis development include fibroblast growth factor 9 
(FGF9) and desert hedgehog (Dhh). Fgfs regulate embryogenesis of several organs, 
including lung, limb, and anterior pituitary. FGF9 plays an important role in testicular 
embryogenesis, since lack of FGF9 results in male-to-female sex reversal in mice 58. Dhh is 
expressed in Sertoli cells and Patched 1 in Leydig cells and peritubular cells 59,60. Absence of 
Dhh in mice results in male infertility. Dhh-/- mice fail to up-regulate SF1, which results in 
defective Leydig cell differentiation and impaired spermatogenesis 61. 
Recently, screening of sex-specific libraries has resulted in identification of 13 male and 
2 female specific clones, of which 60% were novel sequences 62. This implies that sex 
determination and differentiation involves many factors of which only a few have been 
identified so far (depicted in Figure 1.2). 
 
1.2 Male sex differentiation 
While sex determination is strictly controlled by genes, once the gonads have 
committed themselves to either male or female differentiation, gonadal hormones play an 
essential role in maintaining that commitment 2. In the XY embryo that has received proper 
signals, the developing testis starts producing anti-Müllerian hormone (AMH), testosterone, 
and later insulin-like factor 3 (Insl3). AMH causes the Müllerian ducts (MD) to regress, 
while testosterone stabilizes the Wolffian ducts (WD) and triggers their differentiation into 
epididymides, vasa deferentia, and seminal vesicles, as reviewed by 4,63. Insl3, together with 
testosterone, is responsible for the first phase of testicular descent, from the urogenital ridge 
to the abdominal bottom 64,65, which is followed by translocation of the testis into the 
scrotum. In the female genital tract, lack of testosterone results in the regression of WD, 
whereas absence of AMH triggers the MD to develop into Fallopian tubes, uterus and the 
upper part of the vagina. Furthermore, the urogenital sinus (UGS), genital tubercle, genital 
fold and swelling develop into the prostate gland, urethra, and external genitalia in males, 
and in the lower part of the vagina and external genitalia in females 4,63 (Figure 1.3, on page 
21). The transition from the bipotential state to initiation of sex differentiation for murine 
WD and MD occurs at E14-15, while the earliest morphological differences between male 
and female UGS occurs at E17.5, when the prostate starts to differentiate. 
Male development (virilization) of the genital tract starts with testicular production of 
AMH at E11.5 in the mouse fetus 66, which is responsible for the regression of the MD 67-69. 
AMH, or MIS (Müllerian inhibiting substance), expression persists in the Sertoli cells of the 
male gonads and decreases after birth, whereas in female mice AMH is first expressed in 
granulosa cells of the ovary 4 days after birth 66,70,71.  
 
The role of anti-Müllerian hormone 
AMH is a glycoprotein belonging to the transforming growth factor β (TGFβ) gene 
family of growth and differentiation factors 73,74. TGFβ family members mediate their 
actions via a membrane-bound heteromeric typeI/typeII serine-threonine kinase receptor 
complex. The AMH type II receptor is expressed at E15 in mesenchymal cells surrounding 
the MD in both males and females 75,76. Recently, targeted disruption in mice has identified 
the bone morphogenetic protein receptor 1a, activin receptor-like kinase 3 (ALK3), as the 
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predominant AMH type I receptor in Müllerian duct regression 77. It was suggested that 
ALK3 acts together with ALK2, which was previously identified as the type I receptor, to 
mediate AMH signals 77-79. Both ALK2 and ALK 3 are ubiquitously expressed and also 
present in the mesenchymal cells surrounding the MD. The specificity of the AMH signal is 
thus regulated by sex specific, temporal control of the expression of AMH and tissue 
specific expression of its type II receptor in target tissues. The in vivo role of AMH and 
AMH type II receptor in MD regression was shown using knockout mouse models. These 
studies show that AMH is required for elimination of the MD, and also plays a role in male 
fertility by acting as a negative regulator of Leydig cell proliferation 80,81. Regression of the 
MD is induced by AMH indirectly via the AMH type II receptor-expressing mesenchymal 
cells, eventually resulting in apoptosis of the epithelial cells 69. Apoptosis of the duct occurs 
in a cranial to caudal fashion and is accompanied by accumulation of cytoplasmic β-catenin, 
which may mediate the action of AMH 69. 
Expression of AMH during sexual differentiation is regulated by several of the factors 
involved in gonadal development described above (Chapter 1.1). These factors bind to the 
180bp promoter fragment of the Amh gene 82, where SF1 plays a central role in transcription 
activation by cooperative interaction with SOX9 83, GATA4 84, or WT1 46. On the other 
hand, DAX1 interaction with SF1 results in repression of Amh gene expression 46,85, 
consistent with its role in ovary-determination. Recently, another factor, SOX8, has been 
identified that also synergizes with SF1 to enhance Amh expression 86. SRY, SOX8, SOX9, 
and AMH show a similar spatial and temporal dynamic expression pattern in the developing 
gonads, providing a link between these genes in the molecular pathway of testis 
development. 
In the adult testis, AMH is expressed at low levels 66,87, where it may play some role in 
regulating androgen synthesis in the Leydig cells. It has been found that AMH directly 
suppresses transcription of key enzymes involved in testosterone synthesis 88. In the adult 
ovary, AMH may have at least two functions: inhibiting initial recruitment of primordial 
follicles into the pool of growing follicles 71, and decreasing the stimulatory effect of follicle-
stimulating hormone (FSH) on follicle growth 89. 
 
Role of androgens 
Once Leydig cells have developed in the fetal testis, they start synthesizing testosterone 
as early as E13 in the mouse 90. Testosterone is a steroid hormone and its biosynthesis takes 
place in the mitochondria of the Leydig cells through enzymatic conversion of cholesterol in 
a series of steps. Cholesterol is transported through the inner mitochondial membrane by 
the steroidogenic acute regulatory protein StAR, where it is cleaved by the cholesterol side-
chain cleavage enzyme P450scc 91, and further processed by 3β-hydroxysteroid 
dehydrogenase (3β-HSD), 17α-hydroxylase/c17,20-lyase (P450c17), and 17β-
hydroxysteroid dehydrogenase (17β-HSD) 90,92. In certain tissues, testosterone can be 
further reduced into the more potent 5α dihydrotestosterone (DHT) by 5α-reductase type 1 
and type 2 enzymes, or aromatized into estradiol by P450 aromatase. In the fetal testis, all 
steroidogenic enzymes including P450 aromatase can be detected, showing the potential of 
fetal testis to convert androgens into estrogens. Although estrogens are not necessary for 
gonadal development or for the male urogenital structures, male mice deficient in estrogen 
receptor α are infertile because of abnormal sexual behaviour and reduced sperm counts 
93,94. Furthermore, mice lacking aromatase display arrested spermatogenesis 95. This suggests 
a direct effect of estrogens on male germ-cell development and fertility 96. In contrast, in 
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fetal ovaries none of the steroidogenic enzymes could be detected except for 3β-HSD 90, 
which explains why developing ovaries are not steroidogenically active.  
Testosterone production and secretion in newborn mice and adult animals is regulated 
by pituitary gonadotropins and luteinizing hormone (LH), unlike initial fetal testosterone 
synthesis, which appears to be independent of LH since it already occurs before LH 
transcripts are detected in the pituitary 97. Thus, testosterone dependent male fetal sexual 
differentiation does not require pituitary hormones 98. Rather, initiation of steroidogenesis is 
considered to be regulated by sex determining factors, with SF1 as key regulator, because 
promoters of most of the genes encoding steroidogenic enzymes have binding sites for SF1 
12.  
Testosterone delivery to its target tissues may proceed in two ways: 1) passive diffusion 
from the testis into the lumen of the epithelial duct, which results in a concentration 
gradient of hormone that is relatively high cranially in the WD and lower in the caudal 
region of the duct, or 2) secretion into the circulation, thereby reaching the UGS in only low 
amounts 99. Testosterone is the principle androgen preventing the WD from regression by 
apoptosis, promoting differentiation of the WD into epididymis, vas deferens, and seminal 
vesicle. DHT is the major androgen involved in differentiation of the UGS, and tubercle 
into prostate gland, urethra, and external genitalia. However, conflicting data from human 
and rodent studies indicate that this concept of differential roles of testosterone and DHT is 
rather simplistic, and may not be true for all mammalian species.  
Conversion of testosterone into DHT is catalyzed by two distinct isozymes, 5α-
reductase type 1 and type 2 100,101. The type 1 and 2 enzymes have different biochemical and 
pharmacological properties, in a tissue-specific and cell type-specific manner 102,103. The type 
2 enzyme is expressed predominantly in tissues of the male urogenital tract and is thought to 
have a developmental anabolic role, whereas type 1 appears to be expressed mainly in 
peripheral androgen target tissues and has a catabolic role in androgen metabolism 103-105. 
Furthermore, the type 1 enzyme seems to have a greater role in female development, as 
compared to the type 2 enzyme 106. In the male urogenital tract, type 2 is present in 
mesenchymal cells and shows regional differences in expression level during development. 
The importance of 5α-reductase type 2 and the action of DHT in the developing UGS and 
external genitalia is observed in human individuals with steroid 5α-reductase type 2 
deficiency. In this type of male pseudohermaphroditism, there is defective virilization of the 
external genitalia, and the prostate gland is underdeveloped, whereas WD structures have 
developed normally, demonstrating dependence of WD differentiation on testosterone 
101,107,108 (Chapter 1.4). 
In mice at E14.5 and at birth, very little type 2 activity is detected in the testis and in the 
cranial portion of the WD, the future epididymis. The caudal portion of the WD, which is 
to become the seminal vesicle, has much higher enzyme activity, and the middle portion, the 
prospective vas deferens, has intermediate enzyme activity. In the UGS, high type 2 activity 
can be measured 102. Thus, along the WD a gradient of type 2 activity can be measured, 
increasing in cranial to caudal fashion, resulting in comparable high levels of DHT in the 
caudal WD and UGS. From these experiments in mice it was concluded that DHT may 
indeed be the major androgen responsible for virilization of the UGS, but also for initiation 
of seminal vesicle development, whereas both testosterone and DHT could be responsible 
for cranial WD development, although testosterone must have a dominant role because 
DHT levels may be too low 102,109. 
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Figure 1.3. Schematic representation of sex differentiation of male and female internal and external 
genitalia  
A) Early genital tract development is characterized by the presence of bipotential gonads, and the anlagen of 
both the male (Wolffian) and female (Müllerian) duct systems. Once the gonads differentiate into testes, 
testicular hormones are produced. AMH production causes regression of the Müllerian duct, whereas 
testosterone production results in the stabilization and development of the Wolffian duct into epididymis, vas 
deferens, and seminal vesicle. Absence of AMH and testosterone production by the ovaries results in the 
regression of the Wolffian duct and stabilization and development of the Müllerian into Fallopian tubes, uterus 
and the upper part of the vagina. 
B) Development of the male and female external genitalia from the urogenital sinus, genital tubercle, genital fold, 
and genital swelling. Figure adapted from Carlson, 1999 72. 
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However, gene knockout experiments targeting both type1 and type 2 enzymes in the 
mouse resulted unexpectedly in quite complete virilization of male mice 110. Double-
knockout males have only mild virilization defects, marked by a reduction in size of the 
accessory sex organs, while females were not affected. This phenotype demonstrates that, in 
mice, testosterone is sufficient for virilization of internal and external sex organs, and 
suggests that the conversion of testosterone to DHT represent a signal amplification 
mechanism, which is not of crucial importance in mice. For rats, this was already suggested 
by studies using 5α-reductase inhibitors 110,111. Thus, the role of testosterone and DHT in 
male sex differentiation may be somewhat different between humans and rodents. 
Although testosterone and DHT may act in different target tissues, they both bind to 
and exert their action through the same intracellular receptor, the androgen receptor (AR) 
112,113, which will be discussed in more detail in Chapter 1.4. DHT binds to the AR with 10-
fold higher affinity and biological efficacy than testosterone 114,115. This explains how DHT 
can function as a signal amplifier of testosterone in tissues where the androgenic signal is 
low. However, when present at a high concentration, testosterone can interact with the AR 
in a similar manner as DHT 116. 
During differentiation of the WD and UGS, the AR is expressed initially only in the 
mesenchymal cells surrounding the epithelial duct and sinus. In the mouse, AR expression is 
first detected at E12.5, prior to testosterone secretion by the testis, and this first expression 
is thus independent of androgens 117,118. Continued AR expression, however, is androgen-
dependent 119. The differentiation of the WD occurs in a spatio-temporal and cranial to 
caudal fashion, starting with the development of the epididymis at E14.5, followed by the 
vas deferens and finally the formation of the seminal vesicle rudiment at E16.5. 
Development of the UGS starts at E17. During the initial period of WD and UGS 
development, no epithelial AR can be detected, although action of androgens at this stage is 
essential for virilization. Epithelial AR expression starts in the efferent ductules (located 
between the testis and the epididymis) at E16, becomes detectable in the epididymis at E19, 
in the seminal vesicle 1 day after birth, and in the prostate gland 4 days after birth. 117,118. 
This observation led to the hypothesis that androgenic effects must be mediated through 
paracrine interactions between the AR-positive mesenchyme and the AR-negative 
epithelium 120,121. Tissue recombination experiments using urogenital tract epithelium and 
mesenchyme from either wild-type mice or mice carrying a non-functional AR (testicular 
feminization mice, Tfm) have provided valuable information about the inductive nature of 
the mesenchyme. For example, seminal vesicle mesenchyme induces morphological and 
functional seminal vesicle development of epithelium from the embryonic and postnatal 
WD, regardless whether it is the caudal or the cranial part of the WD 109,122. Even 
differentiated epithelium from the adult urinary bladder can be induced by urogenital sinus 
mesenchyme to undergo prostatic development 123. These studies demonstrate that the 
mesenchyme is a key androgen target tissue during development, and many androgenic 
effects in the epithelium are elicited through paracrine influences from the mesenchyme 
(Figure 1.4). In addition, it has been shown that androgens regulate differentiation of a 
smooth muscle layer in the developing prostate, which is formed by differentiating 
mesenchymal cells probably in response to epithelial signals 124. Differentiation of this 
smooth muscle layer may regulate signaling between mesenchyme and epithelium. 
 
 
 
 
                                                                                                                                           General introduction 
  23
AR positive
mesenchyme
AR negative
epithelium
Growth and Differentiation
T
T
KGF
FGF10 EGF??
 
Figure 1.4. Schematic representation of mesenchymal-epithelial interaction  
Androgens exert their actions on the developing genital tract tissues through the AR positive mesenchymal cells. 
Upon an androgenic signal, the mesenchymal cells produce and secrete paracrine factors, such as KGF, FGF10, 
and EGF, that act on the adjacent epithelial cells. It is believed that the epithelial cells also communicate with the 
mesenchymal cells. 
 
Which and how paracrine factors are actually regulated by androgens is not yet clear. In 
the developing prostate several members of different growth factor families, such as insulin-
like growth factors, platelet-derived growth factor, nerve growth factor, heparin-binding 
growth factor, transforming growth factor β, hepatocyte growth factor, epidermal growth 
factor (EGF), and fibroblast growth factors (FGFs), have been suggested to play a role in 
mesenchyme-epithelium interactions 122,125. FGF7, also known as keratinocyte growth factor, 
was shown to play a key role in seminal vesicle 126 and ventral prostate development 127. 
FGF7 is synthesized and secreted by mesenchymal cells and acts as a mitogenic factor upon 
adjacent epithelial cells of seminal vesicle and prostate, which express its receptor 
FGFR2iiib 128. In vitro studies have shown that FGF7 can be regulated by androgens 129, but 
the gene is not a direct target for androgen action in vivo, although FGF7 may interact with 
androgen signalling 128. Furthermore, Fgf7 gene knockout mice do not appear to have an 
impairment of male reproductive tissues 130. Thus, although FGF7 plays an important role in 
epithelium-mesenchyme interactions in the prostate, it is not regulated by androgens in vivo. 
FGF7 displays high homology and biochemical similarities with its family member FGF10 
131, which could make them functionally interchangeable and redundant. FGF10 is also 
expressed in mesenchymal cells and is associated with areas of active epithelial growth. In 
addition, FGF10 was shown to be regulated by androgen in vitro 132, but this observation 
does not hold for the in vivo situation 133, and it is not likely that the Fgf10 gene is a direct 
target for androgens. However, FGF10 is a key factor in seminal vesicle and prostate 
development, as deletion of the Fgf10 gene results in loss of these organs 134. It can be 
concluded that FGF10 functions as a paracrine regulator of growth and development of 
seminal vesicle and prostate 133. 
The growth factor EGF was shown to be up-regulated by androgens in androgen 
responsive tissues, where it plays an important role in sex differentiation 135-139. From E14 to 
E16, EGF is expressed in both epithelial and mesenchymal cells of the developing WD, but 
by E18 predominantly in epithelial cells 140. EGF induces stabilization and differentiation of 
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the WD by binding to its receptor, EGFR, which is expressed in epithelial cells 141. The 
involvement of EGF/EGFR in WD development was demonstrated in an in vitro organ 
culture system, where anti-EGFR antibodies blocked WD differentiation 142. EGF may 
mediate the effect of androgens by acting as a paracrine factor on epithelial cells, but it 
could play a role in enhancing androgen-induced transcriptional activity in the mesenchymal 
cells, to potentiate the testosterone-effect 143. 
Although many questions remain to be solved regarding the factors that are regulated 
by androgens in mesenchymal cells and the mediators that act on the epithelial cells, it is 
likely that many factors are involved in androgen-regulated development and differentiation 
of the male genital tract. 
 
1.3 The androgen receptor 
The androgen receptor (AR) belongs to the super-family of nuclear receptors (NRs), 
which regulate gene expression through their function as transcription factors, reviewed in 
144-146. The super-family of NR, sharing more than 150 different members, can be sub-
divided into three classes on the basis of sequence homology and functional properties: class 
I) the steroid hormone receptors (SHR), to which the glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), progesterone receptor (PR), estrogen receptor (ER), and 
AR belong; class II) the receptors for thyroid hormone (TR), vitamin D (VDR), and 
retinoids (RAR, RXR); class III) the so-called orphan receptors, for which no apparent 
ligands have been identified so far, and of which some may represent constitutive 
activators/repressors of transcription 145. Within the SHR class, the ER is more distinct than 
the GR, MR, PR, and AR, in the sense that it shows less sequence homology and recognizes 
hormone response elements different from those of the latter group (Chapter 1.3.2). NR 
homologues are present in multiple species, ranging from plants and insects to vertebrates. 
Therefore, it is believed that they have a common evolutionary history dating back at least 
tens of millions of years 147. 
The first SHRs to be cloned were the GR 148, ER 149, and PR 150, which was followed by 
the cloning of the human AR by several groups 151-154, and the cloning of the rat 151,155 and 
mouse AR 156-158. Alternative splicing occurs for the GR, resulting in the functionally 
different receptor isoforms GRα, GRβ, GRγ, and GRP 159-161. For the PR, two distinct 
promoters were identified, which give rise to two mRNA products resulting in the 
expression of PR-B and a shorter PR-A 162,163. For the ER, two distinct genes were cloned 
encoding ERα and ERβ 164,165, which have distinct functions in vivo. The AR is encoded by a 
single-copy gene 166. It was reported that alternative initiation of translation results in a 
shorter AR protein product in genital skin fibroblasts, constituting 7-15% of total AR 167. 
However, no functional role in vivo has been described for such an alternatively initiated AR 
protein product. 
The AR gene is located on the human X chromosome at q11-q12 168, and contains 8 
exons spanning more that 90 kilo base (kb) 166 (Figure 1.5). Two mRNA species of 
approximately 10.6 kb and 8.5 kb, respectively, arise from the AR gene 153,169. Both mRNAs 
contain a 1.1 kb 5’-untranslated region (UTR), and a 2.7 kb open reading frame (ORF) 169,170. 
While the 10.6 kb transcript contains a very long 3’-UTR of 6.8 kb, the 8.5 kb transcript 
lacks part of the 3’-UTR 170. The promoter region does not have typical TATA-box and 
CAAT-box sequence motifs, but it contains a long homopurine stretch, and a short CG-rich 
region, which is a recognition site for the transcription factor SP1. Two transcription 
initiation sites TIS I and TIS II are present in a 13-base pair (bp) region. While SP1 binding 
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to the GC-box initiates transcription through TIS II, initiation through TIS I depends on 
sequences downstream the SP1 recognition site 170,171.  
The protein encoded by the AR gene has a variable length of amino acid residues 
between individuals, due to the presence of a highly variable poly-glutamine stretch and a 
less variable poly-glycine stretch, located in the NH2-terminal part of the protein 172,173. 
Therefore, the AR has been described as a protein with either 910 173, 917 154,166, 918 174, or 
919 amino acid residues 152 with a calculated molecular mass between 98 and 100 kilo 
Dalton (kDa) and an apparent molecular mass of 110 kDa. On SDS-PAGE, the AR can be 
detected in the presence of androgens as a 110-112-114 triplet, which represents several 
phosphorylated isoforms of the receptor 175-177. The numbering of the AR described 
throughout this thesis is based on 919 amino acids (Figure 1.5), according to the AR 
database (www.mcgill.ca/androgendb/) 178. The AR protein is expressed in the male and 
female reproductive tract, and in non-reproductive target tissues 179. AR protein expression 
is regulated by androgens at the transcriptional and post-transcriptional levels, and by 
follicle-stimulating hormone (FSH) 180-182. 
 
1.3.1 Functional domains of the androgen receptor 
 Like other NRs, the AR has a well characterized, unique modular structure, consisting 
of a DNA-binding domain (DBD), a ligand-binding domain (LBD), a hinge region, and an 
NH2-terminal domain (NTD), which harbors several activation functions (AFs) (Figure 
1.5). Each domain has a specific role in the functioning of the receptor. The DBD of the 
AR shows high homology (around 80%) to the DBDs of PR, GR, and MR, and to a lesser 
extent to ER; the LBDs of steroid hormone receptors are moderately conserved (around 
50%), whereas the NTDs show no obvious homology (less than 15%). 
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Figure 1.5. Genomic organization, and protein domains of the human androgen receptor  
The AR gene is located on human chromosome Xq11-12, containing 8 exons, and spanning more that 90 kb. The 
gene encodes a protein of 919 amino acid residues and harbors several distinct domains, such as the NH2-
terminal domain (NTD), the DNA-binding domain (DBD), the Hinge region, the ligand-binding domain (LBD), 
activation functions (AF), and a poly-glutamine and a poly–glycine stretch. 
NH2-terminal domain 
The NTD is encoded by exon 1 of the AR gene, which translates into the first 557 
amino acid residues of the AR 166,173. Besides the poly-glycine and poly-glutamine stretches, a 
large number of acidic amino acid residues are present in the NTD, between residues 100 
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and 325 173,183. In other proteins and transcription factors, acidic regions, which can form an 
amphipatic α-helical structure together with basic regions, have been shown to be involved 
in transcription regulation 184-186. Deletion mapping of the AR NTD has revealed that amino 
acids 51-217 are involved in transcription activation, designated as activation function 1 
(AF1) 187. AF1 regions have been described for the other SHR, but their location within the 
NTD and amino acid composition varies. The AR NTD is the major determinant for 
androgen-specific regulation 188. Furthermore, a COOH-terminally truncated AR displays 
constitutive transactivation activity which is regulated by a different region in the NTD, AF-
5, located between residues 376-510 189. This indicates that the COOH-terminal domain has 
a repressive function in the full length AR in the absence of ligand, via AF5.  
 
DNA binding domain 
The DBD of the AR is encoded by exons 2 and 3, representing the central part of the 
receptor consisting of amino acids 557-623 166,183. The DBD is characterized by two zinc-
cluster structures that are organized by three α-helices 1, 2, and 3 190. A zinc-cluster is 
formed by four conserved cysteine residues, which coordinate binding of a zinc-atom in the 
form of a tetrahedron, and facilitates binding to DNA and dimerization to a second AR 
144,191. Helix 1 in the first zinc-cluster contains the so-called proximal (P)-box and in addition 
residues that are involved in sequence recognition and specificity, and is inserted into the 
major groove of DNA 191. The second zinc-cluster harbors helices 2 and 3, which contain 
the distal (D)-box and most of the residues involved in DNA-dependent dimerization 190,192. 
Moreover, the DBD has been implicated in nucleo-cytoplasmic shuttling using a non-
classical nuclear export signal, which is both sufficient and necessary for nuclear export 193. 
Transcription factors in general are characterized by their ability to bind DNA at 
specific sites in promoter or enhancer regions of genes. The steroid hormone receptors AR, 
GR, PR, and MR are able to bind as homodimers to DNA at so-called steroid response 
elements (SRE), which are organized as inverted repeats of 5’-TGTTCT-3’ like sequences 
with a three nucleotide spacer 194. ER and other nuclear receptors recognize a specific 
estrogen response element (ERE) with the sequence 5’-AGGTCAnnnTGACCT-3’ 195,196. 
Since DBDs of steroid hormone receptors are highly conserved and recognize the same 
SREs, much attention has been focused on factors that determine receptor specificity. Using 
chimeric AR-GR DNA binding domains, it was postulated that AR specificity for response 
elements depends on the dimerization interface, which enables a head-to-tail dimerization of 
two AR proteins on a specific androgen response element (ARE) instead of a tail-to-tail 
dimerization on non-AR specific SREs 197 (Figure 1.6). Such alternative dimerization is only 
possible on direct repeat AREs. Furthermore, most SREs and AREs do not exactly fit the 
consensus, allowing individual sequence variations to increase specificity of gene regulation. 
Until now, numerous response elements in promoters of androgen-regulated genes have 
been analyzed, and based on these studies a classification of AREs has been proposed. Four 
different types of AREs represent: high affinity selective (A) and non-selective (B), and low 
affinity selective (C) and non-selective (D) elements 191. Recently, it was determined that AR 
conformation varies depending on the bound response element, which in turn modulates 
AR function by adjusting responses to co-factors 198.  
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Figure 1.6. AR-DBD dimerization on direct and indirect repeat AREs 
AR-DBD dimerization modeled as a head-to-head dimer on AR non-specific inverted repeat SREs, and as a 
head-to-tail dimer on AR-specific direct repeat AREs. Figure adapted from Claessens et al., 2001 191. 
 
Ligand binding domain 
The LBD is encoded by 5 exons, exons 4-7, and part of exon 8, and is located between 
amino acids 671-919 166,183. All nuclear receptor LBDs share the same 3-dimensional 
structure, which consists of 10-12 α-helices and 2 anti-parallel β-sheets that are folded into a 
triple layered α-helical sandwich, which is unique for the NR family. Crystallographic studies 
of several NR have revealed that the liganded receptor is more compact than the unliganded 
receptor. Upon ligand binding, a conformational change is induced, which causes helix 12 to 
fold back into the core of the LBD, thereby forming a lid of the ligand-binding pocket 
(LBP) 199. The crystallographic structure of the AR LBD has been solved for the receptor 
complexed with the natural ligand DHT or with the synthetic androgen R1881 200,201. These 
crystal structures are very similar to previously proposed models of the AR LBD, with the 
exception that the COOH-terminal helix 12 is much longer than predicted from data 
obtained from other NRs, covering amino acids 892-908 200-202. Furthermore, the AR LBD 
consists of 9 α-helices, two 310 helices, and four short β-strands associated in two anti-
parallel β-sheets. One striking difference in the structure of AR LBD liganded with DHT or 
R1881 is the continuity of helix 12, which is split into two shorter helical segments in the 
presence of R1881 200,201. This shows that the AR LBD is a dynamic structure, whose 
conformation depends on the absence or presence of ligands and antagonists. Such dynamic 
conformations of the AR were already proposed based on limited proteolytic digestion 
experiments, in which digestion of AR complexed with either agonist or antagonist resulted 
in protection of protein fragments of different sizes 203. 
An important function of the LBD is binding of androgen in the ligand binding pocket 
and transducing the signal via activation function 2 (AF2). As mentioned above, the 
conformational change induced by ligand binding repositions helix 12 onto the pocket as a 
lid, resulting in formation of an interaction surface for AR partner proteins and 
consequently in an active state of the receptor. If, however, the pocket is occupied by an 
antagonist, the AR LBD will have an altered conformation, which will be more suitable for 
recruitment of repressive co-regulators and consequently results in repression of activity. 
Most NRs have a strong ligand-dependent AF2 transactivation region, with a conserved 
sequence constituting an activation domain core region mapped to residues in helix 12 199,204. 
In contrast, the AR exhibits only a weak AF2 function, as was determined by deletion 
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studies 187. However, the AF2 activation domain core region that contains the conserved 
sequence 893-Glu-Met-Met-Ala-Glu-Ile-Ile-Ser-900 appears to be essential for interaction 
with the NH2-terminal part of the receptor, and this interaction is necessary for maximum 
activation of the full-length receptor upon ligand binding 205-207. 
The first implications for an interaction between the AR LBD and NH2-terminal 
domain came from the observation that AF1 becomes active in the presence of a ligand-
bound LBD, whereas in a COOH-terminally truncated AR lacking the LBD, AF5 becomes 
active 189. Subsequently, yeast two-hybrid interaction assays and functional transactivation 
assays in Chinese hamster ovary (CHO) cells showed that the AR NTD and LBD interact 
functionally in the presence of androgen, the so called N/C-interaction 208,209. Deletion 
mapping and mutation analyses have revealed that the AF2 AD core domain interacts with a 
specific 23-Phe-X-X-Leu-Phe-27 (FXXLF) motif in the NTD 205,210,211. This motif is part of 
a long amphipatic α-helix, which can bind in the hydrophobic interaction surface of the 
LBD by multiple charge interactions. Charged residues on either side of the hydrophobic 
cleft interact with oppositely charged residues flanking the FXXLF motif to mediate the 
ligand-dependent N/C-interaction 212. Not only in in vitro transactivation assays is the N/C-
interaction important for full-length AR activity, but it has been reported that N/C-
interaction is a prerequisite for transcriptional activity on AR target gene promoters 
harboring non-specific AREs 213,214. 
The AF2 region in the AR LBD is also involved in interaction with co-regulatory 
proteins (see 1.3.2), such as steroid receptor co-activators 1 and 3 (SRC1, SRC3), and 
transcription intermediary factor 2 (TIF2), which belong to the family of p160 co-activators 
205,215,216. Many co-activators possess a leucine-rich LXXLL signature motif, similar to but 
different from the FXXLF motif in the AR NTD, which facilitates binding to NRs 217,218, 
although some co-activators have been reported to contain an FXXLF motif with which 
they interact with the AR 219. Interaction of LXXLL motif-containing co-activators with 
AF2 occurs in a similar fashion as for the FXXLF motif, using charged residues flanking the 
signature motif 212. Co-activator binding facilitates an active state of the AR and enhances 
the ligand-dependent transcriptional activity through AF2 216.  
  
Hinge region 
The LBD and DBD are connected by a flexible domain called the hinge-region, 
encoded in part by exons 3 and 4, which is poorly conserved between SHRs 144. The hinge 
region of the AR contains a bipartite nuclear localization signal (NLS) located between 
residues 626-646, which directs nuclear transport of the receptor upon ligand binding 220,221. 
Furthermore, an inhibitory domain between residues 628-646 has been identified that 
inhibits AF2 activity, either directly or indirectly, which can explain why AF2 function in the 
AR is rather weak compared to other SHR 222. Mutations in this inhibitory region result in 
an enhancement of AF2 trans-activation by TIF2, suggesting that this domain exerts an 
inhibitory effect on co-activator-mediated AF2 function in the AR LBD 222. 
 
1.3.2 Transcription regulation by the androgen receptor 
The AR regulates transcription of androgen target genes, and the mechanism of 
regulation is in principle similar to that of other steroid hormone receptors, as illustrated in 
Figure 1.7. Testosterone enters the target cell by diffusion and binds, either directly or after 
reduction to DHT, to the intracellular AR. In the absence of androgen, the AR resides 
mostly in the cytoplasm 187,221, where it is held in an inactive state by an associated heat-
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shock protein complex of HSP90, HSP70 223,  and FKBP52 224, which mainly binds to the 
LBD . In the unliganded state, the receptor is constitutively phosphorylated on serine 
residue 94 225. Upon ligand binding, the HSP complex dissociates from the receptor 223, after 
which the AR becomes hyperphosphorylated which involves at least serine residues 16, 81, 
256, 308, 424, and 650 225. The ligand-bound AR simultaneously translocates to the nucleus 
187,220,221 where it dimerizes and binds to specific or non-specific AREs in promoter regions 
of target genes 216,226.  
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Figure 1.7. Mechanism of action of androgens 
Circulating testosterone enters the cell via passive diffusion and binds either directly or after metabolism into the 
5α-reduced DHT to the AR. Upon hormone binding, the HSP complex dissociates, the AR becomes 
phosphorylated and translocates to the nucleus. In the nucleus, dimerization and DNA binding takes place in the 
promoter region of target genes. In addition, general transcription factors, RNA polymerase II and other co-
factors are recruited to initiate transcription activation. 
 
Transcription initiation of androgen-regulated genes 
One of the most studied androgen-regulated genes is the gene encoding prostate 
specific antigen (PSA). Its promoter has been characterized extensively 227-230, and the 
information obtained from studies performed on the PSA gene promoter has provided 
valuable clues as to how androgen regulates transcription via the AR. 
Genetic studies have revealed that the PSA gene has a proximal promoter containing a 
TATA box and two AREs: ARE I and ARE II 227. Furthermore, an enhancer element was 
identified, located approximately 4 kb upstream of the promoter, which harbors another 
ARE: ARE III 231. Upon AR binding to ARE, general transcription factors constituting the 
transcription initiation complex, including RNA polymerase II (RNA Pol II), transcription 
factor II F (TFIIF), and the TATA box-binding protein are recruited, which interact with 
the AR NTD 232. 
Using chromatin immunoprecipitation assays (ChIP), it has been recently described that 
AR recruits RNA Pol II preferentially to the PSA enhancer 229,230, which entirely depends on 
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the presence of androgen-liganded AR, and p160 and p300 cofactors (discussed below). 
These cofactors possess enzymatic activities, such as histone acetyl transferase (HAT) or 
methyltransferase that induce decompaction of local chromatin and thus allows for the 
transcription initiation complex to access DNA of the target gene. Histone acetylation has 
been correlated with transcriptionally active genes, whereas histone deacetylation is 
associated with a state of gene repression 233,234. It has been postulated that, upon androgen-
stimulated recruitment of the transcription initiation complex, the 4kb region between the 
enhancer and promoter is being “looped-out”, facilitating an interaction between the 
enhancer and the promoter 228-230. On the other hand, recent data by Louie et al (2003) 
suggest that the transcription initiation complex is cross-linked to the PSA enhancer, which 
facilitates tracking of the complex over the entire region to interact with the PSA promoter 
230. The occupancy of the PSA promoter and enhancer region by the AR transcription 
complex is transient and a cyclic process, and is mediated by protein degradation through 
the proteasome 228,229. Using ChIP assays, it was demonstrated that the AR is recruited to 
the region within 15 minutes after hormone treatment, reaching a maximum at 45 minutes. 
A second cycle of AR recruitment started at 105 minutes after treatment, and lasted 45 
minutes. RNA Pol II recruitment followed the same cyclic pattern but started approximately 
15 minutes after AR binding 228. 
 
Androgen receptor interacting proteins  
Transcription regulation is dependent on the presence of multiple co-factors that 
interact either directly or indirectly with the androgen receptor. In the past few years a 
multitude of factors that modulate activity of the AR have been identified, reviewed in 216,235-
237. These AR interacting co-regulators are presented in Table 1.I according to the following 
categories: a) proliferation/apoptosis-associated proteins, b) RING proteins, c) LIM-domain 
proteins, d) co-activators, e) general transcription factors (GTFs), f) SET proteins, g) 
cytokine-associated proteins, h) chaperone-associated proteins, i) actin/cytoskeleton-binding 
proteins, j) membrane proteins, k) proteins involved in chromatin remodeling and 
acetylation, l) proteolysis/ubiquitination proteins, m) HMG proteins, n) RNA 
transcripts/protein interacting RNAs. 
The different factors involved in regulating AR mediated transcription interact at all 
kinds of different levels within the AR signaling pathway: from chromatin remodeling to 
proteolysis of end products of gene expression. Most of the co-regulators identified so far 
interact with multiple NRs and only a small number shows specificity and selectivity for the 
AR, such as FHL2 238. Chromatin remodeling is achieved by factors that possess HAT or 
methyltransferase activity, or by factors that belong to ATP-dependent nucleosome 
remodeling (SWI/SNF) complexes, which unwind chromatin and make DNA more 
accessible for transcription factors 239-241. p/CAF, CREB binding protein (CBP) and p300 
have such intrinsic HAT activities and influence transcriptional activity of many classes of 
sequence-specific transcription factors 235, functioning in part by acting as molecular 
scaffolds, and in part by acetylating multiple substrates (Figure 1.8).  
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Table 1.I Androgen receptor co-regulators 
Cofactor Alternative name Binding region Comments References 
 
ANPK 
 
PKY 
 
DBD 
 
Enhances AR protein stability. 
 
242 
ARA24 a Ran NTD Interacts with the NTD polyglutamine repeat. 243 
BRCA1 a - NTD, LBD Interacts with CBP and enhances AR transcription 
synergistically with ARA70 and ARA55. 
244 
Cyclin E a - NTD Enhances AR transcriptional activity independent of cell 
cycle progression. 
245 
pRb a - NTD, DBD Tumor suppressor. Enhances transcription by AR and 
interacts with the TR co-activator Trip230 to repress TR 
transcription. 
246 
ARA54 b - LBD Ligand dependent co-activator. Contains a RING finger. 
Also co-activates PR. 
247 
SNURF b RNF4 DBD RING finger protein; may recruit the chromatin 
remodeling factor HMGI(Y). Also interacts with ER and 
PR. 
248 
ARA55 c Hic5 LBD Ligand dependent co-activator. Contains a LIM domain. 
Also co-activates GR and PR. 
249,250 
FHL2 c DRAL, Slim3 Requires intact AR Prostate-specific and ligand-dependent co-activator of 
the AR.LIM only protein without LXXLL motif.  
238 
ARA70 d RFG, ELE1 DBD, LBD Ligand dependent co-activator. Bridging factor to p/CAF 
and TFIIB.  Also co-activates PPARγ, and enhances ER 
and GR transactivation. 
251,252 
E6-AP d,l - Unknown Contains separable co-activation and ubiquitin ligase 
domains. Also interacts with PR, GR, and ER. 
253 
Gelsolin d,i - LBD Enhances AR transcription in prostate and muscle cells. 
Also functions as an actin filament severing and capping 
protein. 
237 
SRC-1 d NcoA-1, p160 NTD, DBD, LBD Enhances AR N /C- interactions, and interacts with 
CBP/p300. General nuclear receptor co-activator. 
Possesses weak acetyltransferase activity. 
254-256 
SRC-3 d Rac3, ACTR, 
AIB1, p/CIP, 
TRAM1, NcoA-3 
Unknown Interacts with CBP/p300 and possesses acetyltransferase 
activity. Also enhances transcription by TR, PR, and 
RAR. 
257-260 
TIF2 d GRIP1, NcoA-2, 
SRC2 
NTD, DBD, LBD General nuclear receptor co-activator. Facilitates N/C-
interaction. 
205,261-263 
Ubc9 d,l - DBD, Hinge Covalently links the ubiquitin-like molecule SUMO-1 to 
target proteins. This activity is separable from co-
activation. Also interacts with GR. 
264 
Zac-1 a,d,o - LBD Can function as a co-activator of AR in HeLa cells but as 
a co-repressor in 1471.1 cells. Also interacts with ER, 
TR, and GR. In HeLa cells, co-activation is synergistic 
with TIF2. 
265 
ARA160 e TMF NTD Functions synergistically with ARA70. Also enhances GR 
and PR. 
266 
ARA267 f Nsd1 NTD, LBD Contains SET and PHD domains. Also interacts with 
RAR, RXR, ER, TR. 
267,268 
ARIP3 g PIASαx DBD Facilitates N/C-interaction. Represses trans-activation of 
the probasin promoter at high ratios. 
269 
PIAS1 g - DBD,LBD Expression in the rat testes coincides with the onset of 
spermatogenesis. Also co-activates GR but functions as a 
co-repressor of PR. 
270 
BAG-1L h - Unknown Enhances AR function, and also functions to regulate 
HSP70. 
271 
HSP40 h dnaJ, ydj1p LBD Member of the chaperone heterocomplex. Mutation of 
hsp40 in yeast reduces AR transcriptional activation. 
272 
β-Catenin i  - Unknown Ligand dependent co-activator. Interacts also with FHL2 
to activate Wnt-responsive genes, independent of AR 
trans-activation. 
273,274 
Filamin-A i,o - Hinge region Involved in AR translocation to the nucleus. A Filamin-A 
fragment represses AR function by interfering with N/C-
interaction and competing for TIF2. 
275,276 
 Chapter 1 
32 
Cofactor Alternative name Binding region Comments References 
Supervilin i  NTD, LBD Actin-binding protein. Also interacts with GR. 277 
Caveolin-1 j - NTD, LBD Membrane protein associated with caveoli membrane 
structures. 
278 
CBP k p300 NTD, DBD Facilitates N/C-interaction, possesses acetyltransferase 
activity, interacts with members of the SRC family. Co-
activates multiple transcription factors. 
256,279,280 
RIP140 k - NTD, DBD, LBD Functions as a co-activator at low receptor-co-activator 
ratios, but as a repressor at a high ratio. Influences the 
transcriptional activity of ER, PPARγ, and PPARα. 
281 
Tip60 k - Hinge, LBD Member of the MYST/SAS family of histone 
acetyltransferases. Also co-activates PR and ER. 
282 
HMG-1/-2 m - Unknown Enhances DNA binding of AR, PR, ER, and GR. Is 
found as an abundant chromatin-associated protein that 
does not bind a specific DNA recognition sequence. 
283 
PGC-1 n LEM6 Unknown General nuclear receptor co-activator. 284 
SRA n - Unknown Functions as an RNA transcript and associates with an 
SRC-1 containing co-regulator complex. Also enhances 
transcription by PR, GR, and ER. 
285 
Cyclin D1 a,o - Unknown Reduces AR ligand-dependent transcription in a cell 
cycle-independent manner. Functions as a co-activator 
for ER. 
286,287 
HBO1 o - DBD, LBD Ligand-dependent co-repressor. Member of the 
MYST/SAS family of proteins. 
288 
SMRT o - LBD Ligand-dependent co-repressor by inhibiting the N/C-
interaction and competing for p160 co-activators. 
289 
NcoR o  - LBD Antagonist-dependent co-repressor, competes with TIF2. 205 
DAX1 o,q  LBD, AF2 Inhibits ligand-dependent trans-activation as well as 
N/C-interaction. Capable of relocalization of AR in 
cytoplasm and nucleus. Also inhibits SF1 and ERs. 
290 
Calreticulin o,p - DBD Inhibits DNA binding and transcription. Also co-
represses RAR, RXR, and, GR. 
291,292 
RAF p IDE NTD Enhances AR and GR DNA binding. 293 
Modified from Heinlein and Chang, 2002 237 and Hermanson et al,  2002 236.  
a = proliferation/apoptosis    i = actin-binding cytoskeleton protein 
b = RING proteins     j = membrane protein 
c = LIM-domain proteins     k =chromatin remodeling and acetylation 
d = co-activators     l = proteolysis/ubiquitination 
e = GTF      m = HMG protein 
f = SET protein     n = RNA/RNA-interacting protein 
g = cytokine-associated protein    o = co-repressor 
h = chaperone-associated protein   p = DNA-binding 
      q = orphan nuclear receptor 
 
The p160 co-activators, to which steroid receptor co-activator 1 (SRC1 254-256), SRC3 257-
260, and TIF2 261,263 belong, belong to the first family of proteins identified to interact with 
NRs and to associate with CBP. In addition, it has been reported that the COOH-terminal 
domains of SCR1 and SRC3 itself possess a weak HAT activity, which probably functions 
differently from CBP/p300 294. Furthermore, it has been suggested that p160 cofactors 
recruit other factors, such as methyltransferases to their COOH-terminus 207. Based on 
studies performed on p160 proteins, it was proposed that bona fide co-activators should have 
the ability to interact directly with NR activation domains in an agonist-dependent manner, 
resulting in enhancement of receptor activation. Furthermore, they should interact with 
components of the basal transcription machinery and should not enhance basal 
transcription activity by their own, although they contain an autonomous activation function 
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and a NR interaction domain 263,295. The p160 family members harbor the LXXLL signature 
motif in the NR interaction domain 217,218, which facilitates binding to the NR. Not only is 
the agonist-bound receptor conformation a prerequisite for co-activator binding, but for the 
PSA gene it was established that co-activator-receptor complexes are preferentially recruited 
to the enhancer region, indicating that the context of the response element is important as 
well 229.  
Another class of co-activators consists of large multi-subunit mediator complexes. 
These mediator complexes were first identified as thyroid hormone receptor-associated 
proteins (TRAPs) 296 and vitamin D receptor-interacting proteins (DRIPs) 297, and are 
almost indistinguishable from compounds of the activator-recruited cofactor (ARC) 
complex 298. The TRAP/DRIP/ARC complexes contain 9-12 proteins ranging in size 
between 33 and 250 kDa. The proteins in one mediator complexe are highly homologous or 
identical to the proteins in the other mediator complexes. The TRAP/DRIP complex was 
shown to interact with NR AF2 domain in a strictly ligand-dependent manner 299. The high 
homology between TRAPs and DRIPs suggests that they function as mediators of 
transcription activation for all NR, albeit at slightly changed composition dependent on the 
NR they interact with 216,299. Moreover, the ARC complex mediates transcription activation 
of other classes of transcription factors 298, and therefore it is thought that 
TRAP/DRIP/ARC mediators play a more general role in transcription regulation by 
directly contacting the basal transcription machinery 299,300. Indeed, knocking-out a subunit 
of the TRAP/DRIP complex results in an embryonic lethal phenotype 301. The promiscuous 
nature of p160 and p300 co-activators and the TRAP/DRIP/ARC mediators suggests that 
selectivity of transcriptional control of the different NRs lies in a combination of subtle 
differences in the particular composition of multi-protein complexes, the spatio-temporal 
expression of co-activators and receptors, and the context of enhancer/promoter sequences 
in the target genes. Thus, the transcriptional regulation of the AR and other NRs is 
extremely complex, and also very specific and delicately regulated 236,237,299,300. 
While class I type NRs are transcriptionally silent in the absence of ligand because they 
are complexed to HSPs, the class II type receptors TR and RAR/RXR are capable of 
binding to DNA in the absence of ligand and be transcriptionally silenced 196. Co-repressors 
were originally identified as class II type receptor-associated proteins mediating 
transcriptional repression in the absence of ligand, either by formation of a non-productive 
interaction with GTF 302, or by recruiting histone deacetylase complexes (HDAC), which 
compact the chromatin so that the DNA is not accessible for the transcription initiation 
complex 303-305 (Figure 1.8). The two best characterized co-repressors, N-CoR (nuclear 
receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone 
receptor), are very large in size (molecular mass is ~ 270 kDa) and contain a highly related 
NH2-terminal region and at least four autonomous repressor domains 306,307. N-CoR and 
SMRT do not interact with steroid hormone receptors in the absence of ligand but it was 
demonstrated that these co-repressors interact with ER and PR when complexed with an 
antagonist 308,309. Similarly, AR transcriptional activity can be strongly repressed by N-CoR in 
the presence of a partial antagonist, but it is also partially repressed in the presence of 
agonist. N-CoR competes with TIF2 for AR binding sites, and therefore an equilibrium 
model has been proposed, in which the level of co-activator and co-repressor expression 
determines whether AR activity will be enhanced or repressed (Berrevoets et al., unpublished 
observations). A similar competition has been described for SMRT, which inhibits the N/C-
interaction and competes with TIF2 in a ligand-dependent fashion 289. Thus, co-repressors 
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prefer an antagonist-bound conformation for AR repression, while co-activators prefer an 
agonist-bound conformation. Furthermore, it was shown by ChIP analysis that the co-
repressor/HDAC complex is preferentially recruited to the promoter region of the PSA 
gene, and not to the enhancer region as is the case for co-activator complexes 229. Since N-
CoR and SMRT interact with multiple NRs, a general transcription regulatory role has been 
ascribed to these co-repressors, and indeed the N-CoR knockout mouse has an embryonic 
lethal phenotype 310. It has been speculated that naturally occurring antagonist-like 
compounds must exist that exert N-CoR recruitment by SHRs. 
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Figure 1.8. AR interacting protein complexes facilitating either activation or repression  
A) Agonist-bound AR provides a conformation suitable for recruitment of p160 co-activators, p300/CBP, and 
P/CAF, which have histone acetyltransferase activity and enable transcription activation.   
B) Antagonist-like compounds induce a conformation that is more suitable for the interaction with co-repressors 
and histone deacetylases, which repress transcription.  
Dotted lines represent as yet unidentified factors taking part in larger complexes. Modified from Robyr et al, 
2000 295. 
 
Androgen regulated genes 
Since androgens play an essential role not only in fetal sex differentiation but also in 
pubertal and adult physiology and pathophysiology (Chapter 1.4), much effort has been 
undertaken to identify genes that are targets for regulation by the AR, in order to understand 
which players are involved in the androgen signaling pathway. The tissues studied have been 
mainly the testis, the epididymis, vas deferens, and the prostate. Castration and subsequent 
hormone replacement experiments in male rats and mice has resulted in identification of 
many androgen-regulated proteins in neonatal and adult epididymis and vas deferens, which 
are listed in Table 1.II. Many of these proteins appear to be involved in sperm cell 
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maturation, transport, and motility, and are secreted into the luminal fluid. Furthermore, 
they show a regional and temporal expression along the epididymis and vas deferens.   
 
 
 
Table 1.II Androgen-regulated proteins identified in epididymis and vas deferens 
Protein Expression Function Reference
Acidic epididymal 
glycoprotein 
(AEG) or Protein 
DE 
Secreted by the 
epididymal 
epithelium into the 
lumen 
Product of the Crisp-1 gene. Glycoprotein 
that associates with maturing sperm. 
Expression is under the control of 
androgens and several AR binding sites are 
present in the promoter region. 
311,312 
AR Mesenchyme and 
epithelium of 
epididymis, vas 
deferens, prostate 
gland, and many 
peripheral tissues 
Transcription factor, up-regulated by 
androgens. Stromal cells in the epididymis 
are more sensitive to regulation of AR 
levels than epithelial cells. 
313 
Calcium binding 
proteins, CaBPs 
All along the 
epididymis 
CaBPs play an important role in 
maintaining cellular Ca2+ homeostasis. 
Circulating androgens are involved in 
regulation of intracellular Ca2+ in 
epididymal epithelium.  
314 
Carbonic 
anhydrase II, IV 
Predominantly in 
corpus epididymis 
epithelium 
Contribute to acidification of epididymal 
fluid necessary for regulation of sperm 
maturation and motility Androgen-
dependent expression. 
315 
Clusterin/Sulfated 
glycoprotein-2, 
SGP 
All along the 
epididymis 
Secreted by principal cells of the caput 
epididymis and binds to spermatozoa. In 
corpus and cauda epididymis, clusterin is 
down-regulated by androgens. 
316 
Cyclooxygenase 
1,and 2, Cox-1, 
and Cox-2 
Epithelium of distal 
vas deferens and 
epididymis 
Enzymes involved in prostaglandin 
synthesis. Androgen-dependent expression. 
Cox-1 is involved in anion secretion by 
epididymal epithelia. 
317,318 
Epididymal 
protein 2, EP2 
Specific expression 
in the proximal 
caput epididymis 
Epididymis-specific secretory protein. 
Expression dependent on circulating 
androgens. 
319 
EPI-EPS Predominantly in 
mouse epididymis 
and vas deferens, 
low expression in 
seminal vesicle, 
kidney, and 
submandibular 
gland 
Defective, endogenous murine leukemia 
proviral sequence. Highly androgen-
regulated in both reproductive and non-
reproductive tissues, due to its integration 
near a highly tissue-specific and androgen-
regulated genetic locus. 
 
 
320 
Estrogen 
sulfotransferase, 
EST 
Leydig cells of testis, 
epithelium of corpus 
and cauda 
epididymis, and 
luminal epithelium 
of vas deferens 
Catalizes sulfoconjunction and inactivation 
of estrogen. Androgen-dependent 
expression in epididymis and vas deferens. 
Plays a physiological role in maintaining 
functional integrity of epididymis by 
regulating luminal estrogen homeostasis.  
321 
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Protein Expression Function Reference 
Germ cell nuclear 
factor, GCNF 
High in testis, low in 
epididymis, brain, 
liver,  kidney. 
Expressed by corpus 
principal cells 
Orphan nuclear receptor, involved in 
spermatogenesis, neurogenesis, 
differentiation, embryo development. 
Down-regulated by androgens. 
322 
Glutathione 
peroxidase 1, 
GPx1  
All along the 
epididymis and 
nearly all other 
tissues in a broad 
range of species 
The family of GPx enzymes catalyze the 
reduction of organic hydroperoxidases and 
hydrogen peroxide, using gluthatione as a 
reducing agent. GPx-1 is cytosolic and 
androgen-repressed in the epididymis.   
314 
Glutathione 
peroxidase 1, 
GPx3  
Epididymis, vas 
deferens, kidney, 
and many other 
organs 
Secretory enzyme, has a putative role in 
protecting sperm from the deleterious 
effect of reactive oxygen. In the 
epididymis, GPx3 is spatially and 
temporally regulated by androgens. 
323,324 
Glutathione 
peroxidase 1, 
GPx5  
Caput epididymis 
specific 
Secretory enzyme, androgen-dependent 
expression. 
323 
Glutathione S-
transferases 
Principle and basal 
cells of epididymal 
epithelium 
Androgen-dependent expression. Forms 
part of the epididymal antioxidant system 
that protects luminal spermatozoa from 
oxidative damage.  
314,325 
Mouse epididymal 
retinoic acid 
binding protein, 
mE-RABP 
Secreted into the 
luminal fluid of the 
mid/distal caput 
epididymis 
Lipocalin involved in retinoic trafficking. 
Contains two AR binding sites in the 
promoter region, and is regulated by 
circular androgens. 
326 
Metallothionein I, 
II, III 
Basal cells of all 
epididymal regions, 
testis 
Cytosolic proteins involved in cellular 
stress response. Androgen-dependent 
expression. 
327 
Mouse vas 
deferens protein, 
MFDP 
High levels in vas 
deferens, adrenal 
glands, ovary, and 
low expression in 
other tissues 
Aldo-keto reductase1-B7 protein, 
responsible for detoxification of 
steroidogenesis byproducts. Expression in 
the adrenal cortex under control of ACTH, 
whereas it is strongly androgen-dependent 
in the mouse vas deferens. 
328-330 
Pem Testis and 
epididymis 
Homeodomain transcription factor. 
Androgen is necessary but not sufficient 
for Pem expression. Regulatory sequences 
in the Pem gene drive expression in 
different subregions of the epididymis. 
331,332 
Prostaglandin D2 
synthase, PGDS 
Predominantly in 
corpus and cauda 
epididymis, and 
testis 
Secreted lipocalin, androgen-dependent 
expression. Increasing luminal 
concentration from distal caput to cauda. 
333,334 
Transforming 
growth fector β 
(TGF-β) 1, 2, 3 
Epididymis and 
ventral prostate 
Androgen-repressed gene. Androgen 
modulates expression in an isoform- and 
tissue-specific manner. 
335 
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Androgen-regulated gene expression in the prostate has been the focus of much 
research, because of its involvement in prostate cancer (Chapter 1.4). Mostly, prostate 
cancer cell lines, and in some cases microdissected prostate tissue, have been used to 
identify androgen-regulated proteins 336-340. Large-scale cDNA microarray studies (Chapter 
3) covering ~ 20.000 distinct human genes showed that ~ 8.000 of these genes are 
expressed in the human prostate cancer cell line LNCaP, and approximately 2% of these 
genes are regulated by androgen 338,340. However, the identified androgen-regulated genes in 
LNCaP cells are quite different from the genes that are regulated by androgens in 
epididymis and vas deferens, suggesting that androgens regulate the expression of different 
proteins depending on the target tissue and the pathway that needs to be turned on. 
Therefore, it is conceivable that androgen-regulated proteins involved in genital tract 
development are expressed in the epididymis and vas deferens primarily during a particular 
developmental time window, and may be different from the androgen-regulated proteins 
expressed in the adult epididymis and vas deferens. 
 
Non-genomic actions of androgens 
Apart from the AR signaling pathway that leads to transcription regulation, an 
increasing body of evidence suggests that androgens, like progestins and estrogens, can 
excert rapid, non-genomic effects, which are mediated by steroid receptors 341,342. In prostate 
and breast cancer cells, it has been shown that androgens, progestins, and estrogens trigger 
the association of AR, PR, ERα, or ERβ with Src and stimulate the Src/RAF1/ERK 
(extracellular signal-regulated kinase) signal transduction pathway 343-346. Src is normally 
targeted to the inner surface of the plasma membrane, and has a tyrosine kinase activity that 
is auto-inhibited by interaction of the tyrosine kinase domain and the Src homology 2 (SH2) 
and SH3 domains. Proteins that bind to these SH2 and SH3 domains disrupt the 
intramolecular interaction of Src, which results in activation of the Src kinase. Src, Raf and 
ERK are upstream regulators of the mitogen-activated protein kinase (MAPK) signaling 
pathway, which is involved in multiple cellular processes, such as proliferation and 
differentiation 347. It has been reported that AR binds to the SH3 domain of Src through its 
proline-rich sequences in the NTD, in response to androgen. Simultaneously with AR 
binding, either ERα or ERβ can bind to the SH2 domain of Src, through interation of 
phosphotyrosine 537 (or Y443 for ERβ) 343. This AR-ER-Src ternary complex is stimulated 
by androgen and estradiol and couples steroid hormone receptors to the cytosolic signaling 
pathway, inducing cell proliferation. Cross-talk between ERα and PRB has also been 
described. Progestins can activate the Src-Raf-ERK cascade by binding to PRB 348, which in 
turn binds to ERα via two interacting domains 346. Also, a ternary complex can be formed 
with ERα and c-Src through direct binding of the proline-rich sequence of PRB to the SH3 
domain of c-Src, although this interaction is much weaker than that of AR 349. This kind of 
cross-talk regulates the non-genomic proliferative pathways of different steroid hormones, 
though there is also evidence that the non-genomic actions of steroid hormone receptors 
eventually influence transcriptional activity, since the activity of both receptors and co-
activators is enhanced by direct phophorylation by MAPK 350,351. 
In addition to non-genomic effects induced by steroid hormones and their intracellular 
receptors, some reports also indicate that membrane-bound receptors may be involved 342, 
which could be sex hormone-binding globulin 352,353 or G protein-coupled 7 transmembrane 
receptors 354.  
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1.4 Androgen receptor disorders 
Androgen insensitivity syndrome 
One of the causes of male pseudohermaphroditism is a defect in androgen exposure. 
The profound importance of androgen action in development is evident from observations 
on individuals who develop male pseudohermaphroditism. Male pseudohermaphroditism is 
characterized by partial or complete sex reversal of internal and/or external genitalia, except 
for the testes, in XY individuals. Disorders of androgen action can be caused by a defective 
AR, resulting in insensitivity of the target tissue, or by defective androgen synthesis or 
testosterone metabolism. Androgen insensitivity syndrome (AIS) is the clinical entity of a 
non-functioning AR leading to feminization of a 46,XY individual, described extensively in 
several reviews 179,355-359.  
AIS is a relatively rare disorder caused by a heterogeneous group of defects in the AR 
gene and the incidence is probably between 1:40,800 and 1:99,000 male births 360. 
Mutational defects in the AR gene result in either a partial or a complete non-functioning 
receptor protein, or a low expression level or complete absence of the protein, giving rise to 
a wide spectrum of defective masculinization in 46,XY individuals. The complete form of 
AIS (CAIS) is characterized by a seemingly completely feminized phenotype with normal 
breast development, but with absence of axillary and pubic hair, and with presence of testes 
in the abdomen. Due to the production of anti-Müllerian hormone, the Müllerian duct 
derived tissues are absent, and due to the defective action of androgens development of the 
Wolffian ducts does not occur. On the other end of the AIS spectrum mildly affected 
individuals show subtle undervirilization or infertility 361. In between are individuals with 
partial AIS (PAIS) who show different degrees of virilization, ranging from a predominantly 
female external phenotype with clitoromegaly and labial fusion, and a phenotype with 
ambiguous genitalia, to a male phenotype with a micropenis or hypospadias, and 
gynecomastia. PAIS phenotypes can have either remnants of WDs or fully developed WD 
derived structures, depending on the degree of insensitivity. If the testes remain in situ in 
individuals with PAIS, virilization and/or feminization may occur at puberty, depending 
upon the hormonal milieu of the individual 179. Furthermore, testicular tumors of germ cell 
like carcinoma in situ and occasionally seminomas, and non-germ cell precursors (Leydig- 
and Sertoli cells), occur with an increased frequency of 6-9% 362. In cases of CAIS, 
testosterone, which is circulating at high levels, is aromatized into estradiol, resulting in 
feminization of breasts and body contours.  
Most defects in the AR gene are the consequence of single nucleotide substitution, 
although single nucleotide insertions and deletions as well as larger deletions have been 
reported 355,363. A few hundred different mutations in the AR gene have been reported so 
far, and most of these are compiled and described in the AR database 
(http://www.mcgill.ca/androgendb) 178,364. Nearly 90% of the mutations are found in the 
DBD and LBD of the AR, and roughly 10% of mutations are reported in the NTD 365. 
Mutations in the LBD can either completely abolish ligand binding, resulting in CAIS, or 
affect ligand binding in such a way that some residual AR activity remains, which causes 
PAIS. Mutations in the DBD are associated with normal ligand binding but result in 
defective DNA binding or dimerization, and consequently in defective activation of 
androgen-responsive genes. Furthermore, mutations in the DBD can result in premature 
stopcodons. The phenotype of individuals with AR-DBD mutations can be both CAIS and 
PAIS. Mutations detected in the NTD have been predominantly associated with premature 
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stop codons, which results in either a truncated AR protein or in the absence of AR protein 
179,355,357,365. 
Although it was initially believed that the wide spectrum of phenotypic variability in 
individuals with PAIS was the consequence of high variety of mutations in the AR gene, it is 
now clear that also identical mutations can result in significantly different phenotypes, even 
within one family 178,360,366. One possible explanation for phenotypic variability is the 
occurrence of a somatic mutation in the AR gene in specific androgen sensitive tissues. 
Somatic mosaicism was first described in a PAIS patient who revealed a mutation in exon 1 
leading to a premature translational stop, which was previously described to result in CAIS 
due to the absence of AR protein 367. Apparently, in somatic mosaicism, both wild-type AR 
and mutated AR are present, which leads to a higher degree of virilization than would be 
expected from the mutation. The presence of the wild-type allele in somatic mosaicism can 
be due to de novo post-zygotic mutation in the AR gene 368-370. A somatic mosaicism may be 
the cause of 30% of PAIS cases. Additional defects in steroid biosynthesis or steroid 
metabolism, or varying levels of androgen during fetal development may also account for 
phenotypic variation 360. In families with CAIS, phenotypic variation is rarely observed, and 
to date only one family with both CAIS and PAIS resulting from one mutation has been 
reported 366. It can be concluded that molecular defects of the AR are not the sole indicators 
for an AIS phenotype, and that careful study and documentation of every mutation provides 
important information about the role of a specific amino acid residue in AR function. 
Another syndrome in which the AR is involved, is the X-linked spinal and bulbar 
muscular atrophy, or Kennedy’s disease, a neurodegenerative disease 371. Patients with 
SBMA have ARs with an extension of the polymorphic trinucleotide CAG repeat segment, 
present in the NTD of the AR, of 40 or more as compared to a maximum of 38 in healthy 
individuals. The role of AR is not very clear, but it has been proposed that extended CAG 
repeats in general are toxic for motor neurons.   
 
Syndromes caused by defective steroid synthesis and metabolism 
Mutations causing male pseudohermaphroditism have been described that impair each 
of the six enzymatic reactions involved in the conversion of cholesterol into testosterone 
and subsequently DHT 372. 
One such disorder leading to male pseudohermaphroditism is the inherited steroid 5α-
reductase type 2 deficiency. As described in Chapter 1.2, 46,XY individuals with steroid 5α-
reductase type 2 deficiency present with female external genitalia, bilateral testes, normally 
virilized WD structures, and a blind-ending vagina (reviewed by 107,108,358). This phenotype is 
the result of defective DHT production, as was first established by studies in two families in 
Dallas, USA and the Dominican Republic 373,374. The syndrome of steroid 5α-reductase type 
2 deficiency was found to be due to mutations in the steroid 5α-reductase type 2 gene 101. 
Like in AIS, there is a high phenotypic variability between affected individuals with 5α-
reductase type 2 deficiency, ranging from female sex assignment at birth to isolated 
hypospadias 107. Due to the presence of testes, some affected individuals show a variable 
degree of masculinization during puberty when the testosterone level is increased, which can 
result in the acquisition of male gender in patients that were initially raised as girls. 
Gynecomastia as well as growth of beard and pubic hair does not occur in 5α-reductase 
deficient patients, which offers the possibility to distinguish this syndrome from PAIS. 
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 5α-Reductase isozymes are NADPH-dependent enzymes that reduce testosterone into 
DHT. The COOH-terminal domain is the cofactor-binding domain, while both NH2-and 
COOH-terminal domains are involved in substrate binding. More than 40 mutations in the 
type 2 isozyme have been described, located through all 5 exons and affecting either 
cofactor binding, substrate binding, blocked formation of a functional isozyme, or complete 
loss of enzymatic activity 375,376. 
Yet another autosomal recessive disorder leading to male pseudohermaphroditism is 
the deficiency of 17β-hydroxysteroid dehydrogenase-type 3 (17β-HSD3). This disorder is 
very rare in the general population but frequent among highly inbred Arab populations in 
the Gaza strip 377. 17β-HSD3 is the enzyme that converts the precursor steroid 
androstenedione into the active androgen testosterone in the testis. Several other, 
extragonadal, isozymes of 17β-HSD have been identified, of which type 5 also catalyzes the 
conversion of androstenedione into testosterone, although with much lower efficiency 378. 
Mutations in the 17β-HSD3 gene severely reduce testosterone production in the testis, but 
the unaffected or enhanced extragonadal type 5 isozyme, together with 5α-reductase can 
compensate to some extent for this loss of androgen after puberty 378,379. The clinical 
appearance of affected 17β-HSD3 individuals is predominantly female, but also more male 
phenotypes with micropenis and hypospadias have been reported. Testes are always present 
and WD structures are normally developed 375,378,379. When testes are still present at puberty, 
the activation of residual androgen production capacity causes partial virilization, which may 
sometimes result in gender change. In prepubertal patients the 17β-HSD3 deficiency is 
clinically indistinguishable from AIS, but measurement of elevated serum androstenedione 
and reduced testosterone levels can give a correct diagnosis 380. As with AIS, mutations 
found in the 17β-HSD3 do not necessarily correlate with one particular phenotype, but may 
be influenced by residual or extragonadal testosterone formation, or by a somatic mosaicism 
381. 
The above-described deficiencies are only examples of the many known disorders 
leading to incorrect sex differentiation. It clearly demonstrates that many factors are 
involved in androgen-mediated sex differentiation and development, and that disruption of 
one such factor may already have a tremendous effect on phenotypic sex.  
 
Other pathologies involving the AR pathway 
Apart from their role in fetal sex differentiation and maintenance of male physiology in 
the adult, androgens and the AR also play in role in prostate cancer (PC) progression 382-384. 
The incidence of PC varies widely between ethnic populations and countries, being highest 
in the United States, Australia and the European countries, where it is the second leading 
cause of death by cancer in men 385. The majority of prostate cancers expresses the AR, and 
regresses in size upon withdrawal of androgen, demonstrating their dependence on 
androgens for growth. Therefore, hormonal therapy consisting of androgen suppression, 
AR blockage, or both, is widely used in the treatment of prostate cancer. However, growth 
of PC is only temporarily affected by inhibition of androgen action, and eventually the 
tumor relapses in an androgen-independent state (AIPC), thereby becoming untreatable. 
The underlying mechanism of the transition of androgen-dependent prostate tumor cells to 
tumor cells growing independently of androgens is largely unknown, but it is assumed that it 
is selected for by androgen inhibition. Much attention is focused on unraveling the 
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mechanism of the transition to AIPC, so that future therapies will be more effective against 
PC. 
Several possible mechanisms are assumed to be involved in AIPC development, 
reviewed in 386,387. Tumors that continue to depend on both androgens and AR, may 
increase their sensitivity to low circulating androgens by amplification of the AR gene, 
increased levels of co-activators, or increased production of DHT. Another mechanism 
would involve ligand-independent activation of the AR, bypassing the need for androgens. 
This is achieved by “cross-talk” with other signaling pathways, or by mutations in the AR 
causing a broadened specificity to include binding and activation of AR by other steroid 
hormones and even by anti-androgens that are used for androgen-inhibition therapy 388-390.  
During prostate cancer progression, androgens regulate expression of diverse molecules 
involved in the processes of invasion and metastasis, that may lead to positive and negative 
effects on PC cell invasion 391. Eventually, multiple factors play a role in the selection of 
cells with higher aggressive potential, leading to an invasive behavior of prostate cancer cells. 
Comparison of PC with other hormone-sensitive cancers, such as breast and endometrium 
cancer, indicates that development of less differentiated tumors with a poor prognosis is 
often associated with the loss of functional steroid hormone receptors 391. 
 
1.5 Aim and scope of this thesis 
It is clear that androgens play a pivotal role in male sex differentiation, and that this role 
is mediated through the androgen receptor, which regulates expression of specific target 
genes. While the epithelial cells in the embryonic Wolffian duct and urogenital sinus are 
dependent on androgens for their growth and development, they do not express the AR 
during that critical time window. Rather, the AR is found in surrounding mesenchymal cells, 
and many studies have indicated the importance of the mesenchymal cells and their 
paracrine potential to transmit androgenic signals to epithelial cells. To study the effect of 
androgens on gene regulation in androgen target cells and tissues, proper model systems 
such as cell lines derived from target tissue are required. Although many androgen-regulated 
genes have been identified in prostate cancer (cell lines) and adult epididymis, not much is 
known about target genes that are regulated during embryonic development. Identification 
of such genes would help unraveling the androgenic pathway underlying male sexual 
development. In this respect, the following question was addressed in this thesis: 
 
1. Is it possible to develop an androgen-responsive cell line derived from Wolffian duct mesenchymal 
cells, and use it as a model system for studying androgen-induced regulation of gene expression? 
 
Lack of androgenic signals during embryogenesis leads to defective male sexual 
development, causing male pseudohermaphroditism. In individuals with partial androgen 
insensitivity syndrome, the phenotype is only partly determined by the nature of the defect 
of the androgen receptor. Analysis of the effect of mutations in the AR on gene 
transactivation has already provided important clues on the molecular mechanism of AR 
transcriptional activity, but a correlation with the AIS phenotype is not always consistent. 
Therefore, the effect of a mutation in the AR was characterized to address the following 
question: 
 
2. Can detailed functional analyses provide insight into the effect of a novel mutation in the AR gene 
in an individual with PAIS, and do the results of these analyses correlate with the observed phenotype? 
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Regulation of gene expression can be studied at the mRNA and/or protein levels. 
While one mRNA species corresponds with one gene, it does not necessarily correspond to 
one protein product, due to the fact that proteins undergo modifications upon each stimulus 
the cell receives. Each change in gene regulation has the potential to result in a multitude of 
changes at the protein level. To monitor changes in protein expression, the technique of 2-
dimensional gel electrophoresis (2DE) was introduced in 1975 392. In the last decade, 
proteomics has evolved as a research field investigating the total protein complement of the 
genome: the proteome 393. To date 2DE is still commonly used in proteome research in 
combination with advanced technology based on mass spectrometry. In this respect we 
addressed the questions: 
 
3. What are the changes in protein expression patterns of androgen target cells upon treatment with 
androgen as detected by means of 2DE analysis, and can differentially expressed androgen-regulated proteins 
be identified by mass spectrometry? 
 
4. Do the androgen-regulated proteins identified in a cell line play a part in the androgenic signaling 
pathway of a whole organ? 
 
In Chapter 2 the effect of the Q902K mutation in the AR protein on its transactivation 
properties is described, using two different and sensitive functional assays.  
In Chapter 3 the term proteomics is introduced and the evolution from genome to 
proteome research is described. Different techniques used in proteomics are described and 
proteomics research in reproductive endocrinology is highlighted. 
In Chapter 4 the development of a mouse fetal vas deferens (MFVD) cell line is 
described. The MFVD cells have been used to identify proteins that show a differential 
protein expression pattern upon androgen treatment. 
In Chapter 5 proteomic changes in expression profiles of fetal epididymis and vas 
deferens were monitored in vivo during a continual developmental time window, and in vitro 
upon androgen treatment. 
The results described in this thesis will be discussed in a broader context in Chapter 6, 
and answers will be proposed to the questions addressed in Chapter 1. 
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Functional analysis of a novel androgen receptor 
mutation, Q902K, in an individual with partial 
androgen insensitivity
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Abstract 
Androgen insensitivity syndrome (AIS) is caused by defects in the androgen receptor 
(AR) that render the AR partially or completely inactive. As a result, embryonic sex 
differentiation is impaired. Here we describe a novel mutation in the AR found in a patient 
with partial AIS (PAIS). The mutation results in a substitution of a glutamine (Q) by a lysine 
(K) residue at position 902, Q902K. The AR Q902K mutation was investigated in vitro with 
respect to its functional properties. Although the Kd of AR Q902K was not severely 
elevated, transcriptional activity was decreased to 80% of wild type. The response to 
hormone was shifted to a ten-fold higher concentration due to the mutation. Furthermore, 
the 114 kDa androgen-induced phosphorylated AR protein band was not detectable in 
genital skin fibroblasts in the presence of either 1, 10 or 100 nM R1881, but could be 
detected in transfected COS-1 cells overexpressing the mutant receptor and at a hormone 
concentration of 100 nM R1881. Functional assays showed that the interaction between the 
NH2- and COOH-terminus of AR Q902K was reduced to 50% of wild type, and that the 
trans-activation by the co-activator TIF2 (transcriptional intermediary factor 2) was 
decreased 2-3 fold. The half-maximal response in both assays was shifted to a ten-fold 
higher hormone concentration as compared to wild type. These results indicate that residue 
Q902 is involved in TIF2 and NH2/COOH interaction and that the Q to K mutation 
results in a mild impairment of AR function, which can explain the PAIS phenotype of the 
patient. 
 
Introduction 
Androgen insensitivity syndrome (AIS) is a disorder that results from mutations in the 
X-linked androgen receptor (AR) gene 179,357. Several hundreds of different mutations in the 
AR gene have been reported (www.mcgill.ca/androgendb), which result in a wide spectrum 
of clinical phenotypes 179,356,394.  
The AR belongs to the superfamily of nuclear receptors that is well characterized and 
conserved in structure, and function as ligand-inducible transcription factors 145,146,226,235. 
Like other steroid hormone receptors belonging to the same family, the AR is composed of 
distinct domains 363. The variable NH2-terminal domain (NTD) is mainly involved in 
transcription activation through the activation function-1 (AF-1) region. The activation of 
AF-1 is ligand dependent. The COOH-terminal region harbors the moderately conserved 
ligand binding domain (LBD), which is involved in ligand-dependent transcription activation 
through AF-2, and functional interaction with nuclear receptor co-activators and co-
repressors 187,237,397.  
Crystal structures of AR LBD revealed that the LBD is constituted of 11 α-helices and 
one β turn, arranged as an antiparallel α-helical sandwich 200,397. An AF-2 activation domain 
(AD) core region, conserved throughout the nuclear receptor family, was identified in helix 
12, at the C-terminal end of the LBD between residues 893 and 900 199. Upon ligand 
binding, helix 12 repositions, providing an interaction surface that is suitable for co-activator 
interaction and thereby generating transcriptional activity of AF-2 205,215,263,397. Various 
mutations introduced in the AF-2 AD core decrease transcription activation but not 
necessarily ligand-binding 205,215,398. Co-activators like TIF2 and SRC1 have been shown to 
functionally interact with AF-2 AD core via their conserved LXXLL leucine motifs 
205,215,217,398 and enhance AR transactivation. Furthermore, the NTD also functionally 
interacts with AF-2 (the so-called N/C interaction) in a ligand-dependent manner, and 
mutational analysis showed that AF-2 AD core plays an important role in this interaction 
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205,206,208,262. The N/C interaction with AF-2 occurs via an FXXLF motif present in the AR 
N-terminus 210,211. Several mutations found in the AR of AIS patients appear to affect either 
co-activator binding or N/C interaction or both, and therefore such functional analyses are 
very useful in determining AR function after mutation and provide detailed information on 
the mechanism of AR transcription activation. 
Herein we report a novel AR mutation resulting in a Q to K substitution at position 
902 in a patient with PAIS. We have performed functional analyses on the AR to determine 
the effect of the Q902K mutation on TIF2 enhanced transcription activation and N/C 
interaction, in order to explain the phenotype and potential functional activity. 
 
Materials and methods 
Clinical data 
The patient was referred to the clinic at the age of two years because of hypospadias. 
He is the first child of unrelated parents born after an uneventful term pregnancy. The 
46,XY boy had proximal shaft hypospadias and a bifid scrotum. Because of a positive family 
history of genital malformations (uncle and nephew of the mother were known with 
hypospadias, gynecomastia and infertility), the AR gene was screened for a mutation. Single-
strand conformation polymorphism (SSCP) and DNA sequencing analysis identified a point 
mutation in exon 8 of the AR gene (CAA Æ AAA) at amino acid residue 902 (according to 
http://www.mcgill.ca/androgendb/) 178 leading to an amino acid substitution of glutamine 
(Q) to lysine (K). This Q902K mutation was also identified in the mother, grandmother, and 
great grandmother of the patient (Figure 2.1). The boy’s uncle and great-uncle have a 
reported positive history of genital malformation. At the age of three years, the boy 
underwent a chordectomy and hypospadias repair. During this procedure, a genital skin 
biopsy was obtained for genital skin fibroblasts (GSF) culture. 
 
Affected 
Symbol definitions 
Deceased 
Carrier 
Figure 2.1. Pedigree of 
family with AR Q902K 
mutation 
A square symbol represents a 
male, a circle represents a 
female. The arrow indicates 
the boy described in this 
study. 
 
 
 
 
 
 
 
 
Scatchard analysis 
GSFs were cultured in minimal essential medium containing 1% non-essential amino 
acids (Gibco, Life Technologies, Gaithersburg, MD), 10% fetal calf serum (Hyclone, Logan, 
UT), 100 IU/ml penicillin and 100µg/ml streptomycin (BioWhittickar, Vervier, Belgium). 
For ligand binding characteristics, a whole cell assay was performed as previously described 
399. Briefly, the genital skin fibroblasts were cultured to confluency and subsequently placed 
on medium without serum overnight. The cells were than incubated for 1 hour at 37 C with 
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increasing concentrations (0.01, 0.03, 0.1, 0.3, 1.0, 3.0 nM) of 3H-R1881 (New England 
Nuclear, Boston, MA) in the absence or presence of 100-fold non-radioactive steroid, and 
3H-activity was measured in a scintillation counter. Scatchard analysis was carried out to 
determine the Kd using the Kell software package (Radlig, Biosoft). 
 
Site-directed mutagenesis and construction of AR expression vectors  
The Q902K mutation was introduced into the AR using site-directed mutagenesis. The 
human wildtype AR cDNA expression plasmid pAR0183 was used to generate pARQ902K 
in two separate PCR amplification steps, using Pfu polymerase. Sense and antisense Q902K 
primers containing the mutation, which is depicted in lower case lettering, were combined 
with the sense EQ1 and antisense EQ4 primers previously described by Berrevoets et al.205: 
Q902K sense (5’-ATCTCTGTGaAAGTGCCCA-3’) was combined with EQ4 antisense  
(5’-CAAGGGGCTTCATGATGTCC-3’), and Q902K antisense  
(5’-TGGGCACTTtCACAGAGAT-3’) was combined with EQ1 sense  
(5’-ACAGCCAGTGTGTCCGAATG-3’) primer. The generated EQ1 PCR product was 
used as a template for the second PCR using the EQ1 and EQ4 as sense and antisense 
primers. The resulting PCR fragment was directly ligated into the pCR-Blunt II-TOPO 
vector using the Zero Blunt TOPO Cloning kit (Invitrogen, Life Technologies, 
Gaithersburg, MD). The mutated AR fragment was digested with EcoR1 and exchanged for 
the corresponding wildtype fragment in pAR0. 
AR.N1 and AR.C that were used for the N/C interaction and TIF2 activation studies, 
were previously described205. The Q902K mutation was introduced into the AR.C construct 
via the EcoR1 restriction fragment of pARQ902K.  
 
Luciferase assay 
For transcription activation studies, CHO (Chinese hamster ovary) cells were cultured 
in DMEM/F12 medium, supplemented with 5% dextran-coated charcoal-treated FCS 
(Gibco). For all transcription activation studies, CHO cells were plated in 24-well plates 
(Nunc, Brand Products, Denmark) at a density of 2x104 cells per well. After 24 hours, cells 
were transfected using FuGENE reagent (Roche Diagnostics, Basel, Switserland), according 
to the instructions of the manufacturer, at a ratio of 1:2 DNA:FuGENE reagent. The DNA 
mixture was composed of 50 ng/well MMTV-LUC (mouse mammary tumor virus-
luciferase) reporter plasmid, increasing concentrations of wild type AR or AR Q902K (0.3 
ng – 30 ng/well), and carrier plasmid pTZ19 to adjust to a total amount of 250 ng DNA per 
well. 5 hours after transfection, 1 nM synthetic androgen R1881 or vehicle (0.1% ethanol) 
was added to the cells, or in the case of the dose-response curves a range of 1 pM – 100 nM 
R1881 was added. After overnight incubation, cells were lysed in 50 µl lysis buffer (25 mM 
Trisphosphate pH 7.8, 15% glycerol, 1% Triton X-100, 1 mM dithiothreitol (DTT)), and 25 
µl of the lysate was used to measure luciferase activity using Steady-Glo Luciferase substrate 
(Promega, Madison, WI). The data shown are the mean of three independent experiments 
(average +/- SEM). 
 
N/C interaction assay, TIF2 activation assay 
The functional N/C interaction assay and TIF2 activation assay were performed in 
essentially the same way as the trans-activation assay described above, except for the 
constructs that were used. For N/C interaction, 100 ng/well AR.N1 in combination with 
increasing concentrations AR.C or AR.C-Q902K (0.3 ng –30 ng/well) was used. For TIF2 
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activation, 100 ng/well TIF2 in combination with increasing concentrations AR.C or AR.C-
Q902K (0.3 ng – 30 ng/well) was used, in both cases together with 50 ng/well MMTV-LUC 
reporter and pTZ carrier to adjust to 250 ng/ well. 
 
Western blot analysis 
For AR Western blot analysis, GSFs containing wild type AR and the Q902K AR were 
cultured in the presence of FCS for 7 days, as described above. When grown to confluency, 
medium was replaced by medium containing 10% dextran-coated charchoal-stripped-FCS in 
the presence of increasing concentrations of R1881 (0.1-100 nM) or vehicle (0.1% ethanol) 
for 24 hours. Additionally, COS-1 cells were seeded in 80 cm2 culture flasks at a density of 
2x106 cells per well. The next day, cells were transfected with 4 µg pAR0 or pARQ902K 
DNA, mixed with 12 µl FuGENE reagent. After 5 hours, increasing concentrations of 
R1881 (0.1-100 nM) or vehicle (0.1% ethanol) were added to the culture medium. The next 
day, both CHO cells and GSF were washed with PBS, collected in ice-cold PBS and 
centrifuged for 5 minutes at 1200 rpm (Hereaus Christ). The cell pellet was resuspended in 
200 µl ice-cold RIPA buffer (40 mM Tris-HCl pH 7.4, 5 mM EDTA, 10% glycerol, 10 nM 
sodiumphosphate, 10 mM sodiummolybdate, 50 mM NaF, 0.5 mM sodium orthovanadate, 
10 mM DTT, 1% triton X-100, 0.08% SDS, 0.5% deosoxycholate) containing CompleteTM 
protease inhibitors (Roche Diagnostics), and centrifuged for 10 min at 40,000xg. Protein 
concentration was determined using the RCDC Protein AssayTM (Bio-Rad, Hercules, CA). 
From the COS-1 cell lysate, 30 µg protein was used, and from the GSF cell lysate 50 µg 
protein was used to load onto a 7% SDS-polyacrylamide gel. Proteins were separated and 
blotted to nitrocellulose membrane (Schleicher & Schuell, Keene, NH). Western 
immunoblotting was performed using polyclonal antibody SP197 400 and proteins were 
visualized by Western Lightning chemiluminescence detection (Perkin Elmer, Boston, MA). 
 
Protein structure   
The 3-dimensional crystal structure of the AR ligand binding pocket complexed with 
R1881 was obtained from the NCBI structure data bank, accession number 1E3G, 
deposited in the data bank by Matias et al., 2000 200. The stereo diagram showing the ligand 
binding pocket, and selected residues that were subject to mutation, was created using the 
DeepView/Swiss-PDB Viewer 3.7 program. 
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Results 
The AR Q902K mutation displays decreased transcription activation 
The Q902K mutation is located within the LBD of the AR, within helix 12 and next to 
the reported AF-2 AD core domain 199,200. From its position in the LBD, it can be predicted 
that residue Q902 is not part of the LBP, but may play a role in co-activator mediated 
activation of transcription and in the interaction of the LBD with the NTD. Therefore, 
functional studies were performed to address this question. 
First of all, it was determined whether the mutated AR is functionally expressed in 
GSFs obtained from a patient with PAIS. The mutated AR Q902K was detectable at the 
protein level in GSF cells and, in the absence of R1881, showed a similar expression 
compared to the wild type AR in normal GSF cells (Figure 2.2A, lanes 1 and 2). It is well 
known that the AR protein shows a hormone-induced phosphorylated isoform of 114 
kDa176. However, while GSFs expressing wild type AR respond to hormone by expressing 
the hyperphosphorylated 114 kDa protein band (Figure 2.2A, lanes 3, 5, 7), Q902K AR did 
not show the 114 kDa band upon addition of either 1, 10, or 100 nM R1881 (Figure 2.2A, 
lanes 4, 6, 8). Thus, although the mutated residue is not a direct target for phosphorylation, 
it seems that the substitution by a lysine residue at position 902 affects the hormone-
induced phosphorylation status of the AR. 
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Figure 2.2. Expression and ligand-binding properties of AR Q902K in genital skin fibroblasts  
A) Protein expression pattern of wild type AR (wt) and AR Q902K (m) in GSFs in the absence or presence of 1, 
10, and 100 nM R1881. Note the absence of the 114 kDa protein band in the mutated AR. 
B) Scatchard analysis of whole cell binding data obtained from genital skin fibroblasts harboring wt AR or AR 
Q902K. 
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It was then tested whether the Q902K mutation in the AR had an effect on ligand 
binding. Scatchard plot analysis performed on GSFs revealed a Kd value of 0.26 nM 
(normal range is 0.03 – 0.13 nM), suggesting that hormone binding was slightly but not 
severely impaired (Figure 2.2B). To determine whether the Q902K mutation affects the 
transcription activation potential of the AR, the mutation was created in a mammalian 
expression vector, AR Q902K. Transcription activation was determined in a luciferase assay 
using the MMTV-LUC reporter plasmid. Transfections with increasing amounts (0.3, 1, 3, 
10, 30 ng/well) of wt or mutant AR showed that maximum transcription activation was 
reached with 3 ng/well DNA (Figure 2.3A). Higher concentrations of DNA resulted in 
squelching of the signal.  Wild type AR showed a 27-fold induction of activity, whereas the 
mutated AR induced activity to maximally 23-fold, which is 85% of the wt value (Figure 
2.3A). This difference in transactivation was small but significant (p<0.05). Furthermore, the 
dose-response curve showed that the half maximum response of AR Q902K to hormone 
had shifted to a ten-fold higher hormone concentration as compared to wild type. Both 
receptors showed a maximum activity at 1 nM R1881, with the difference that the mutant 
did not reach maximum wild type activity, but varied between 75-85% (Figure 2.3B). Thus, 
the Q to K mutation mildly affects AR transcription activation potential. 
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Figure 2.3. Transcription activation assay in CHO cells  
A) Increasing amounts of wild type AR (wt AR) and mutated AR (AR Q902K) were transfected into CHO cells. 
Luciferase activity measured for wt AR at 3 ng/well was set at 100% and all the other points were calculated 
relative to that. The activities measured in the hormone treated cells are displayed, together with the fold 
induction, which represents the ratio between the activities measured in the absence and presence of hormone. 
Statistical significance was calculated using a Student’s t-test with p<0.05. 
B) Dose-response curves of wt AR and AR Q902K in the presence of increasing amounts of R1881. The activity 
of wt AR measured at 1 nM R1881 was set at 100% and the other points were calculated relative to that.  
C) Protein expression of wt AR and AR Q902K in COS-1 cells. Note the precence of the 114 kDa protein band 
in AR Q902K only when stimulated with 100 nM R1881.  
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Protein expression of AR Q902K in COS-1 cells revealed a slightly different pattern 
than in GSFs. While 1 and 10 nM R1881 only partially stimulated the upshift to the 114 kDa 
phospho-protein band, 100 nM R1881 obviously restored the expression pattern (Figure 
2.3C), although this restoration did not result in higher transcription activation in CHO cells 
(Figure 2.3A). Thus, the Q902K mutation in the AR results in a 15-25% reduced hormone-
induced transcriptional activity, a ten-fold decrease in hormone response and a defective 
ligand-induced phosphorylation. 
 
Decreased N/C interaction due to the Q902K mutation 
It was previously determined that the NH2-terminal domain (NTD) and ligand binding 
domain (LBD) of the AR interact in a ligand-dependent manner (N/C interaction) 208, and 
that the AF-2 AD core domain is important for this functional interaction 205. Since the 
Q902K mutation lies in close proximity of the AF-2 AD core region, we have performed a 
functional N/C interaction assay to study in more detail the effect of the Q902K mutation 
on transcription activation. For the N/C interaction, AR.N1, AR.C, and AR.C-Q902K 
constructs were used  (Figure 2.4A). In the presence of 1 nM R1881, AR.N1 and AR.C co-
expression resulted in transactivation of the MMTV-LUC promoter with a 50-fold 
induction. Maximum activity was reached at 10 ng DNA/well. AR.C-Q902K showed a 50% 
reduced interaction with AR.N at 10 ng DNA/well, and is thus severely affected (Figure 
2.4B). 
The dose-response curve of AR.C showed that functional interaction with AR.N1 is 
first measurable in the presence of 10-10 M R1881, and that the activity is approximately 40% 
of the maximum activity, which is reached at 10-8 M R1881. Interaction between AR.C-
Q902K and AR.N1 was shifted ten-fold in the dose-response curve and maximum activity, 
which was reached at 10-8 M, was 50% of wild type (Figure 2.4C). These results indicate that 
the N/C interaction in the AR is severely impaired by the Q902K mutation. Although 100 
nM R1881 can rescue the impaired N/C-interaction to some extent, wild type activities are 
not reached using supra-physiological doses, since a maximum response is reached at 10 nM 
R1881. 
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Figure 2.4. Functional N/C interaction 
A) Constructs used for the functional N/C interactions. AR.C, N-terminally truncated AR; AR.C-Q902K, N-
terminally truncated AR with Q902K mutation; AR.N1, C-terminally truncated AR. 
B) Functional N/C interaction as measured in CHO cells transfected with 100 ng/well AR.N1 and increasing 
amounts of either AR.C or AR.C-Q902K. The activities measured in the hormone treated cells are displayed, 
with the fold induction indicated above the bars. The activity of AR.C at 10 ng DNA/well was set at 100% and 
the other points were calculated relative to that. 
C) Dose-response curve of the N/C interaction at increasing concentrations of R1881. The activity of AR.C 
measured at 1 nM R1881 was set at 100% and the other points were calculated relative to that.  
 
TIF2 transactivation is impaired by the Q902K mutation 
The AF-2 AD core domain is not only involved in N/C interaction but is also part of 
an interaction surface for the binding of nuclear receptor co-activators 199,205. In order to 
further characterize the effect of the Q902K mutation on AR transcription activation, we 
have studied the transactivation potential of TIF2. Because the effect of TIF2 
transactivation is more pronounced on the NH2-terminally truncated AR 205, we have used 
the AR.C construct for TIF2 experiments. A constant amount of TIF2 was co-transfected 
with increasing amounts of either AR.C of AR.C-Q902K (Figure 2.5A). The maximum 
transactivation enhanced by TIF2 was reached at 10 ng DNA per well, resulting in a 34-fold 
induction of transcription with AR.C and a 13-fold induction with AR.C-Q902K. At higher 
concentrations DNA, auto-squelching reduced the transcription activation, but the 
difference between wild type and mutant AR.C remained 2-3-fold. 
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 TIF2 activation of AR.C and AR.C-Q902K was tested at increasing hormone 
concentrations (Figure 2.5B). Wild type AR.C was activated by TIF2 initially in the presence 
of 10-10 M R1881, which was 30% of the maximum activity measured at 10-7 M.  
In contrast to the dose-response curves of full length AR and the N/C interaction 
(Figures 2.3S and 2.4C, respectively), no maximum activity was reached in the TIF2 
activation assay, even in the presence of 100 nM R1881. Activation of AR.C-Q902K by 
TIF2 was not detectable at hormone concentrations below 10-9 M R1881, and could be 
maximally induced to 50% of wild type activity. Furthermore, alike AR.C, AR.C-Q902K 
response to hormone was not saturated at 10-7 M. In conclusion, TIF2 activation of Q902K 
AR was impaired by approximately 50%. It can be speculated that higher, supra-
physiological concentration of androgen may partly compensate for the decreased TIF2 
transactivation due to the Q902K mutation.  
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Figure 2.5. TIF2 activation of wild type and mutated AR 
A) Transactivation of increasing amounts of AR.C and AR.C-Q902K by TIF2 (100 ng/well). The activity of 
AR.C at 10 ng DNA/well was set at 100% and the other points were calculated relative to that. 
B) Dose-response curve of TIF2 activation assay in the presence of increasing concentrations of R1881 (1 pM-
100 nM). The activity of AR.C measured at 1 nM R1881 was set at 100% and the other points were calculated 
relative to that.  
 
Positioning Q902K in the AR LBD 3D model structure 
We have used the AR LBD model structure structure, deposited in the structure data 
bank by Matias et al., 2000 200, to locate the position of Q902 (Figure 2.6). The 18 amino acid 
residues described to constitute the ligand binding pocket (LBP) are shown in white, 
whereas residues located in and next to the AF-2 AD core domain in helix 12 that have been 
reported to be mutated in AIS patients (V889, I898, V903, and P904) are shown in purple. 
The Q902 residue is shown in green. It is obvious from the 3D model that residue Q902 is 
not located close to the 18 residues that interact with the bound ligand, but may be part of 
the AF-2 AD core domain interacting surface.  
Q902
V903
P904
I898
M895
V889
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R1881
 
Figure 2.6. Model structure of the AR ligand binding pocket and the AF-2 AD core domain 
Amino acid residues constituting the LBP are represented in white, residues in and close to the AF-2 AD core 
reported to be mutated in AIS are represented in purple, the Q902 residue is shown in green, and the ligand 
R1881 is shown in red. Blue, red, and yellow side chains stand for represent the backbone side chains. The 
crystal structure was retrieved from the NCBI structure data bank (accession number 1E3G) and created using 
the DeepView/Swiss-PDB Viewer 3.7 program. 
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Discussion 
The Q902K mutation, described in this study, has not been associated with AIS before, 
but a somatic Q902R mutation has been reported in a patient with androgen-independent 
prostate cancer 401, of which no functional analysis has been described so far. Therefore we 
have studied the effect of the Q902K mutation on AR transcription activation to see 
whether the mutation could be correlated with the PAIS phenotype. 
It was determined that the Q902K mutation leads to a mild impairment of transcription 
activation (15-25%) and to defective hormone-induced hyperphosphorylation of the AR 
protein, leading to the absence of the 114 kDa androgen-induced phospho-protein band on 
Western blots. The phosphorylation pattern of the mutant AR in genital skin fibroblasts 
seems to be more affected, than that of the overexpressed mutant AR in transfected COS-1 
cells. So far, no conclusive role has been ascribed to AR phosphorylation. Some studies 
performed in vitro report that AR phosphorylation is necessary for full transcription 
activation and ligand binding 176,363,402-404, while a more recent study does not find such a 
correlation 405. AR Q902K expressed in COS-1 cells results in hyperphosphorylation upon 
stimulation with a high (100 nM) concentration R1881, but does not coincide with a rescue 
of transcription activation. This finding suggests that, for the Q902K mutation, there is no 
clear correlation between AR phosphorylation and transactivation potential. 
Detailed functional analyses revealed that the Q902 residue plays a substantial role in 
the functional interaction between the LBD and NTD, and in co-activator mediated 
enhancement of transactivation. These functional interactions are not necessarily linked to 
ligand binding, since the Kd of the AR Q902K receptor is only slightly elevated, but N/C 
interaction and TIF2 transactivation are more severely affected. Similar results were 
obtained by Thompson et al., 2001, who described mutations located between helices 3-11 
within the LBD of the AR in PAIS patients that displayed normal or slightly reduced 
androgen-binding activity, but severely impaired N/C interaction, decreased co-activator 
response, and decreased transactivation 406. Recently, another study described that the 
decrease in N/C interaction in mutated ARs correlated with the severity of the AIS 
phenotype, while the Kd was not or only slightly affected by the mutation 407. Thus, loss of a 
functional N/C interaction in the AR may be an important molecular defect in AIS patients 
and screening for such a functional interaction, in addition to hormone-binding studies, may 
be a valuable tool to determine the effect of novel mutations in more detail. 
In addition to inter-domain interactions, disrupted co-activator interactions have also 
been implicated with several forms of AIS. Mild forms of AIS leading to sub-fertility or 
oligospermic infertility in men have been associated with mutations in the AR LBD leading 
to disrupted inter-domain interactions (LBD with LBD, or LBD with NTD) in combination 
with defective co-activator TIF2 activation 408,409. 
Furthermore, CAIS has been reported in an individual where no mutations in the AR 
were found, but where the transmission of the activation signal from AF-1 was disrupted, 
possibly due to the absence of a functional co-activator 410. Thus, a minor disruption of co-
activator binding or a complete loss of co-activator function can result in varying degrees of 
AIS. Our finding that the Q902K mutation leads to 50% decreased TIF2 transcription 
activation in a patient with a PAIS phenotype, is in line with these reports. 
Since the 3D crystal structure of the liganded AR LBD is known 200,411, it is possible to 
make assumptions about the role of certain amino acid residues in AR function. From the 
model structure, it can be predicted that the Q902 residue is in relative close vicinity of the 
ligand binding pocket and the AF-2 activation domain core motif, and that Q902 is 
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surrounded by residues that have been found mutated in individuals with AIS, such as V889, 
M895, I898, V903, P904. Except for V903, which is only conserved between different AR 
species, residues V889, M895, I898, Q902, and P904 are either highly conserved or identical 
between AR, progesterone receptor, glucocorticoid receptor and mineralocorticoid receptor, 
which are other members of the steroid hormone receptor family 412. V889, which is located 
just before the AF-2 AD core domain, has been reported by several groups to be mutated 
into a methionine residue, resulting in either PAIS or CAIS 413-415. Two mutations within the 
AD core domain, M895T and I898T, have been reported in CAIS 368,416; the V903M 
substitution was identified in a patient with PAIS 417, and P904S and P904H mutation have 
been reported to cause CAIS 413,417. Based on these reports, it can be concluded that the 
position of residue Q902 in the model structure is informative but cannot be easily 
correlated to an AIS phenotype. 
 The V889M and I898T mutations have been characterized at the molecular level, and it 
was found that both mutations do not affect ligand-binding affinity, although dissociation 
half times were decreased. Strikingly, the N/C interaction was completely abolished by the 
I898T mutation (leading to CAIS) and severely hampered by the V889M mutation (leading 
to either CAIS or PAIS), which could be rescued only at high ligand concentrations 206,262. 
The TIF2 interaction seems to be unaffected by these mutations. Detailed functional 
analysis of all the above-mentioned mutations in the AR would be needed to determine the 
role of each amino acid residue in inter-/intra-molecular domain interaction, co-activator 
binding, and the relation to AIS. Our results, together with previous reports, indicate that 
residues outside the AF-2 AD core domain can play an important role in functional N/C 
interaction and the severity of this disruption can be correlated with an AIS phenotype. 
Furthermore, although not every residue in and around the core domain is involved in TIF2 
induced activation, amino acid Q902 appears to play an important role in this interaction.  
With respect to clinical relevance, the TIF2 activation study showed that a high level of 
androgen could partially rescue the negative effect induced by the Q902K mutation. Since 
the dose-response curve with TIF2 did not show a saturation level, it can be speculated that 
even higher, supraphysiological concentrations of hormone could have a greater effect on 
activation and thus would be of use as clinical therapy. This study provides further support, 
that detailed functional analyses on mutated ARs not only provide insight in AR 
functioning, but can also show their relevance for clinical therapy. 
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Introduction 
The proteome is a term that was first introduced in the mid 1990s to define “the total 
protein complement of a genome” 418,419. Proteomics covers all the technology currently 
available to analyze the proteome, the global patterns of gene expression at the protein level 
420. The emergence of proteome research was based on of the worldwide rapidly proceeding 
genome projects, as was foreseen in the original proposal of the Human Genome Project. 
The generation of large amounts of sequence data from genomes provided a start for the 
scientific community, to look beyond genes and genomes and to focus on proteins.  
Reproductive endocrinology is a field, in which research was, and still is typically 
focused on identification of proteins and their functions. For example, in search for new 
and better therapies for hormone-controlled cancers in reproductive endocrinology 
(prostate, breast, ovary, and endometrial cancer), large-scale screens of expressed genes and 
the encoded proteins are now widely used. 
As research is constantly evolving by the introduction of new techniques, this chapter 
will describe the scientific evolution from genomics to proteomics research in relation to 
reproductive endocrinology. 
 
3.1 Genomics 
 
3.1.1 Introducing the genome 
Mendel’s description of crucial hallmarks of heredity in 1866 and the subsequent 
rediscovery of his findings in 1900 started an era of scientific quest for understanding the 
nature and content of genetic information 421,422. The cellular and molecular basis of heredity 
was defined with the discovery of chromosomes 423 and the DNA double helix 424, followed 
by the elucidation of the genetic code 425. The introduction of the DNA sequencing 
technique 426, together with the technique of cloning, soon led to the cloning and sequencing 
of the first human gene 427, and further automation of DNA sequencing 428 opened the road 
for the first genome to be fully sequenced, the 1.8 megabase pair genome of the bacterium 
Haemophilus influenzae 429.  
 The genome can be described as the complete set of genetic material (DNA) present in 
an organism. Sequencing the genomes of small unicellular organisms such as bacteriophages 
430 and other viruses 431 quickly led to the idea that global views of genomes could greatly 
accelerate biomedical research. Backed by programs to create physical maps of the yeast 
Saccharomyces cerevisiae 432 and the worm Caenorhabditis elegans 433 genome, and a program to 
create a human genetical map to locate disease genes of unknown function 434, scientists 
proposed the idea to sequence the entire human genome in 1985 435,436. As a consequence, 
the Human Genome Project (HGP) was launched in 1990 as a 15-year program supporting 
a worldwide joint effort to create a genetic, physical, and sequence map of the human 
genome, in parallel with such efforts in key model organisms such as bacteria, yeast, worms, 
flies, and mice, together with the development of technology to support the objectives. 
Initially, the goal of the HGP was to generate high-quality, long-range finished sequence that 
was freely available for public purposes by the year 2005. However, the announcement in 
1998 by the private initiative Celera Genomics Corporation to compete with the public 
HGP 437,438, shifted the goal of HGP to produce a draft genome sequence first 439. Celera 
planned to finish the sequence of the human genome by the end of 2001, market their 
database system and sell it for profit 437. As a consequence, HGP speeded up the process of 
sequencing that resulted in the publication of the HGP and the Celera draft human genome 
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sequences in February 2001 440,441. Although the draft sequences were acquired using 
different methods, both showed gaps in the physical maps and needed to be further 
sequenced to produce a fully finished sequence of the human genome 440,442. Recently, a 
99.9% finished draft sequence has been published, 50 years after the discovery of the DNA 
double helix 443.  
The completion of the working draft of the human genome is a milestone in biomedical 
research, providing information about genes, evolution, and genetic variation in humans, but 
more importantly it serves as a foundation for understanding the function of genes and their 
products. 
 
3.1.2 From genome to transcriptome 
The size of the sequenced euchromatic region of the human genome is between 2.9 441 
– 3.2 440 billion base pairs.  Based on the draft sequence, the estimated number of protein-
coding genes lies between 29,000-36,000 443. Earlier estimates ranged between 30,000 to 
more than 140,000 genes 444-447. The number of protein-coding genes in an organism 
provides a relatively simple, although incomplete, measure of its molecular complexity. The 
unicellular prokaryote E. coli and the eukaryote S. cerevisiae have 4,300 448 and 6,000 genes 449, 
respectively. Comparison of unicellular genomes with multicellular ones leads to the 
conclusion that evolution of multicellularity is apparently accompanied by an increase in 
gene number, since the worm C. elegans has 19,000 genes 450 and the fruitfly D. melanogaster 
has 13,600 genes 451. Therefore, it came as a surprise that humans have only twice as many 
genes. However, the relatively low number of genes can be compensated for by a higher 
complexity of the genes, with more alternative splicing (at least 50% of the genes 440,441,452-
455), transcriptional and translational control, leading to more protein products that are in 
turn subject to post-translational modifications (Figure 3.1).  
 
Figure 3.1 From genome to proteome 
Expression of proteins starts with transcription of DNA into RNA that is processed into mRNA and 
subsequently translated into proteins. Each step is tightly controlled and results in a large diversity of gene 
products. Modified from Banks et al., 2000 456.  
 
With the completion of large amounts of genome sequences came the realization that 
sequence information alone was not sufficient to identify the complete set of genes. 
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DNA RNA mRNA
Transcription Processing Translation
protein
Effects
Epigenetic factors, feedback loops
> 200 known post-translational 
modifications                      
(e.g. phosphorylation,
glycosylation, lipid attachment, 
peptide cleavage)
Post-transcriptional 
control (e.g. 
alternative splicing, 
RNA editing, 
alternative 
polyadenylation
Transcriptional 
control
Translational and 
degradation 
controls, 
translational 
frameshifting Activity 
controls
Catalytic 
activity
 Proteomics applications 
65 
functions. The transcriptome includes all RNAs synthesized in a given system (cell, tissue, or 
organism), including protein-coding, non-protein-coding, alternatively spliced, alternatively 
polyadenylated, alternatively initiated, sense, antisense, and RNA-edited transcripts 457. 
Cataloguing the mammalian transcriptome is based on the assembly of sequences of 
expressed-sequence-tags (ESTs) 458, complemented by the approaches of Serial Analysis of 
Gene Expression (SAGE) 459, open reading frame ESTs (ORESTES) 460, and microarray 
based strategies 461. ESTs represent either 3’ or 5’ short cDNA (reversed transcribed 
mRNA) fragments, SAGE produces short sequence tags that are located adjacent to defined 
restriction sites near the 3’end of the cDNA, and ORESTES produces a high proportion of 
sequence tags that are in the coding regions of the transcripts. Microarray based strategies 
use “exon-scanning” to test sets of annotated or predicted exons across a range of tissues, 
and “tiling arrays” to refine the precise exon structures of genes in a genomic region 461,462. 
Combining the data obtained by all of these approaches provides a closer description of the 
transcriptome and has largely contributed to the annotation of the human genome. 
Which genes are transcribed into mRNA is cell type and tissue specific, and 
furthermore dependent on a multitude of regulatory events within cells. While the genome is 
a static entity (with few exceptions, every cell type and tissue of one organism has the same 
genome), the transcriptome is very dynamic: the expression profile within a certain cell type 
changes upon signals from different stimuli. Therefore, analysis of the mRNA expression 
profiles of cells under different states or comparison of diseased versus normal tissue reveals 
insights into the dynamics of the transcriptome. Recent advances in technology have 
provided micro-array based tools for high-throughput mRNA expression profiling. In this 
way thousands of cDNAs can be monitored under different conditions. However, several 
studies have indicated that mRNA abundance does not correlate very well with the 
corresponding protein levels 463,464. Since proteins, rather than genes or mRNAs, are the key 
players in the cell, they determine the cellular phenotype and response to signals. Thus, a 
poor correlation between protein and transcript might lead to misinterpretation of mRNA 
profiling experiments. The discrepancy between mRNA and protein levels can be partly 
explained by the fact that translation of a large fraction of mRNA is controlled at the 
translational level 465. mRNAs that are fully loaded with ribosomes, so-called polysomes, 
represent actively translated transcripts and can therefore be directly correlated with protein 
synthesis 465. High-throughput expression profiling of mRNA represents more precisely 
changes occurring at the protein level when polysome-bound mRNA is being analyzed, 
although it does not provide any information about post-translational modifications, 
subcellular localization or protein degradation. 
 
3.1.3 Functional genomics 
Deciphering the transcriptome goes hand in hand with identification of gene function. 
Computational analysis is widely used to predict the function of the protein set in humans 
by comparing the human genome with other mammalian (mouse 466) or other eukaryotic (fly 
451 and worm 450) genomes. Methods based on analyses at the level of protein families and at 
the level of protein domains revealed that 40% of the predicted genes did not match any 
ascribed protein function 440,441. This percentage contains new genes not previously 
identified, but also largely represents pseudogenes (inactive gene copies), and genes 
generating non-protein coding RNAs, including rRNAs and tRNAs 466. Based on a recent 
re-evaluation of the human gene annotation, it was estimated that the genome contains 
21,300 pseudogenes, and 1,500 genes coding for antisense RNAs 443. Algorithms that do not 
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rely on amino acid similarities have the potential to assign functions to previously unknown 
proteins by detecting functional linkages between proteins 467. One such approach is the 
phylogenetic profile method, which scores the presence or absence of a given protein in all 
sequenced genomes. If two or more proteins have identical or similar phylogenetic profiles, 
they are likely to be engaged in a common pathway or complex 468,469. The Rosetta Stone 
method analyzes fusion patterns of protein domains, based on the observation that many 
proteins consist of two domains in one organism, whereas the domains are two separate 
proteins in another organism 470. A third computational approach uses the gene neighbor 
method, implying that each set of encoded proteins that is located next to each other on the 
chromosome in multiple genomes tends to be functionally linked 471.   
It is evident that the availability of multiple genome sequences, the enormous amount 
of mRNA expression data, and several computational analyses methods provide a basis for 
understanding the complexity and functioning of cells. However, genomics research does 
not directly provide information about protein function, and therefore the basis of such 
understanding lies within the proteome. As is the case for the transcriptome, the proteome 
is not static but its expression state depends on cellular and environmental factors. 
Unraveling expression level, sub-cellular localization, post-translational modification, and 
interacting protein partners is necessary for complete understanding of function of a given 
protein. Therefore, without extensive proteomics research the benefits of genomics will be 
largely unused. 
 
3.2 Proteomics 
Introduction 
Proteomics usually involves separation of proteins from cells or cell fractions in 2-
dimensional polyacrylamide gels and identification by mass spectrometry. The technique of 
2-dimensional electrophoresis (2DE) finds its roots back in 1975, when it was first 
independently introduced by O’Farrell and Klose 472,473 as a powerful analytical tool 
providing high resolution, sensitivity, and reproducibility, which could, as O’Farrell stated, 
potentially find use in a wide range of investigations 472. The revival of 2DE in the “post-
genomic era” surely found its use in a wide range of investigations, and to date it is still a 
corner-stone technique, although highly potential alternative techniques are under 
development. It was the introduction of mass spectrometry into the field of biology that 
changed proteome research, for it can generate very sensitive structural and analytical 
information on proteins. These data are used to search sequence databases, providing a 
relatively quick and easy way of protein identification 474. 
 
3.2.1 Classical proteomics 
2D gel electrophoresis 
Proteomics research can be divided into a “classical” 2DE driven approach and recently 
rapidly evolving non-2DE approaches (discussed in paragraph 3.2.3). 2DE is still largely the 
basis for proteome research, because of the high-resolving power of 2D-gels for the 
separation of complex mixtures of proteins. High-resolution 2DE is based on two 
independent properties and is conducted in two distinct steps. In the first step, proteins are 
separated according to their isoelectric point (pI) using isoelectric focusing (IEF). In the 
second step, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used 
to separate proteins according to their molecular mass (Mr, relative molecular mass), 
resulting in a 2-dimensional profile of protein spots. When the technique was first 
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introduced, IEF was performed in carrier ampholyte (artificial protein) generated pH 
gradients using self-cast tubing gels 472, typically covering pH ranges from 3 to 10 over a 
distance of 13 cm. Such pH gradients tend to become unstable in time and suffer from 
batch-to-batch manufacturing variations, and as a result are prone to irreproducible results. 
The introduction of immobilized pH gradients (IPG) and pre-cast gels on plastic backings 
greatly enhanced resolution and reproducibility of 2D gels 475,476. The separation of proteins 
in a pH gradient is based on the amphoteric property of proteins; they carry either positive, 
negative, or zero net charge, depending on the pH of their surroundings. The isoelectric 
point is the specific pH at which the net charge of a protein is zero. IEF is performed at 
high voltages (up to 8000 V) providing an electric field in which proteins migrate to the 
position in the pH gradient where their net charge is zero.  
After 2DE, the gels can be stained using Coomassie Brilliant Blue (detection limit of 
25-50 ng), colloidal Coomassie (detection limit of 5-10 ng), silver nitrate stain (detection 
limit of 1 ng), or fluorescent dyes (detection limit of 1-5 ng). Coomassie and fluorescent 
dyes have a linearity over multiple orders of magnitude, whereas silver stain is less linear for 
higher abundance proteins. Using these staining methods, typically 1,000-3,000 protein spots 
are visualized, representing a few hundred distinct proteins. Considering that the human 
genome contains 30,000 genes that yield 3-6 times more proteins 477, which are in turn 
subject to all kinds of post-translational modifications, it is estimated that the human body 
may contain at least 500,000 protein isoforms 456. At the cellular level, where 5,000-10,000 
genes may be expressed, this will still yield an enormous amount of modified proteins. The 
dynamic range of all these proteins is very large, considering that actin, which is the most 
abundant protein in almost all human cells, is present at 108 molecules per cell, whereas 
some cellular receptors or transcription factors may be present at 100-1,000 molecules per 
cell 478,479. As a consequence, analysis of a total proteome in a regular 2D gel will result in the 
visualization of highly (abundant) or moderately expressed proteins. Several ways to 
overcome this problem have been introduced. Improvements in sample preparation such as 
the addition of strong denaturant chaotropes (thiourea in addition to urea) and zwitterionic 
detergents that have zero net charge (like CHAPS) to the lysis buffer result in better 
solubilization of proteins 480. Also, multiple protein extraction steps using different lysis 
buffers provide a broader range of solubilized proteins. Furthermore, subcellular 
fractionation enriches for proteins from specific organelles (Figure 3.2), thereby reducing 
the complexity and diversity of the sample, and allowing for the detection of proteins of 
lower abundance 481. Technical improvements of IEF include higher sample loading (several 
mg of total protein) using IPG gel strips 482-484, increasing the possibility of detecting low-
abundance proteins. The use of large format (up to 24 cm) and narrow-range (covering 0.5-
3 pH units) IPG gels strips allows for higher resolution 478,485, which further increases the 
total amount of visualized proteins and the detection of low-abundance proteins. The 
advantage of overlapping narrow-range IPG strips is that the obtained 2D gels can be 
annealed, resulting in a proteome profile that is resolved in a multitude of 24 cm gels. The 
technical drawback of these improvements is that relative large amounts of sample are 
needed (mg instead of µg), and that the fractionation of the sample in combination with the 
use of multiple overlapping narrow-range IPG strips results in handling of multiple gels 
representing the protein content of one sample. In cases were multiple samples need to be 
compared in order to find differentially expressed proteins, the handling of a large number 
of gels will be difficult. Furthermore, introducing more steps during sample preparation 
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increases protein loses. This is particularly a problem if the sample is unique and not 
available in large amounts.  
 
Figure 3.2. Subcellular prefractionation of MFVD cells  
A microsomal and a nuclear fraction was prepared from the cell lysate and subsequently subjected to 2D-PAGE. 
Note the enrichment of specific proteins in the boxed regions. 
 
Other limitations of 2DE include, that large proteins (> 200 kDa) do not enter the gel, 
that small proteins (< 10 kDa) run too far, and that very acidic or basic proteins (pH< 4 and 
> 8) and hydrophobic and insoluble proteins (such as membrane proteins) are not or rarely 
resolved. Another limitation is that 2DE cannot be automated for high-throughput analysis, 
and thus remains tedious and time consuming. In addition, 2DE is biased to high abundant 
proteins 486. Thus, the usefulness of 2DE for proteome research depends on the question 
that needs to be answered, and the choice of sample preparation and pH range to be used 
will depend on the starting material used. Undoubtedly, some properties of 2DE make the 
technique very strong and unique. For example, 2D gels can very easily distinguish different 
post-translationally modified protein isoforms. Furthermore, protein quantities can be 
determined, either manually or by computer analysis, provided that a linear staining method 
is used. Since post-translational modifications determine the activity of a protein, and 
protein quantity influences the effect of protein function, 2DE is still a powerful tool for 
proteome analysis. 
 
Mass spectrometry 
After 2DE separation, gel plugs are taken containing the proteins of interest, and 
cleaved into smaller peptide fragments using enzymes that recognize a specific restriction 
sequence, such as trypsin, which cleaves C-terminally of lysine and arginine residues unless 
they are followed by a proline. Because of this specific cleavage pattern, which is unique for 
every protein, the masses of tryptic digests can be predicted theoretically for any entry in a 
protein sequence database. Subsequently, the peptide fragments are extracted from the gel 
and analyzed by a mass spectrometer (Figure 3.3). Different types of mass spectrometers are 
available, but they all consist of three essential parts - an ion source, a mass analyzer, and an 
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ion detector. In the ion source, molecules are converted into gas-phase ions. The created 
ions are separated into individual mass-to-charge ratios (m/z; m=mass; z=charge state) in 
the mass analyzer, and subsequently transferred to the ion detector 487. The mass analyzer 
uses a physical property, such as an electric or magnetic field, time-of-flight (TOF), 
quadrupole, ion trap, or Fourier-transform ion cyclotron resonance (FTICR) 488-491, to 
separate ions of a particular m/z value, which are then detected by the ion detector. An 
important innovation for proteomics has been the development of two robust techniques to 
create ions of large molecules: 
MALDI-MS: matrix-assisted laser desorption/ionization mass spectrometry. In a 
MALDI ion source, the peptide samples to be analyzed are embedded in an energy 
absorbing crystalline matrix (α-cyano-4-hydroxycinnamic acid is a frequently used matrix for 
peptide analysis), which is excited by the energy of a laser (337 nm nitrogen or infra-red). 
The excited matrix vaporizes and ionizes by addition of one proton to analyte ions 
(peptides) that in turn convert into gas-phase ions 488-492. The MALDI ion source uses a high 
voltage gradient, which causes the ionized peptides to accelerate into a flight tube. Small 
ions fly quicker to the detector than large ions and therefore time required to reach the 
detector is correlated with the m/z value, which is determined by measuring the time it takes 
ions to move from the ion source to the detector (time-of-flight). Deconvolution of the m/z 
value results in the exact mass of the compound analyzed. The accuracy of such 
measurements is given in ppm (parts per million). In MALDI, peptides are generally single 
charged. 
ESI-MS: electrospray ionization mass spectrometry. ESI creates a continuous ionization 
source by application of a potential to a flowing liquid causing the liquid to charge and 
subsequently spray. The electric field generates small, charged droplets of solvent-containing 
analyte. The solvent is removed by heat or drying gas, resulting in the formation of multiply-
charged ions 493. The introduction of nano-electrospray has made it possible to analyze very 
small amounts of analyte, e.g. 1 µl can give a stable spray for 40-60 min 494,495. ESI can be 
easily coupled to all kinds of mass analyzers. 
The acquired peptide mass maps by TOF-MS are used for peptide mass fingerprinting, 
in which the experimentally observed m/z values are compared with the theoretical m/z 
values predicted after in silico digestion of each protein in the database with the site specific 
enzyme used (e.g. trypsin) 496,497. Furthermore, database search programs can allow for 
protein modifications during the search, such as oxidation, methylation, or phosphorylation, 
which change the m/z value of a peptide (Figure 3.3).  
The quality of the mass spectrum, which is determined by mass accuracy and 
resolution, determines the number of peptide matches in the protein sequence and the 
positive identification of a protein 498. Peptide mass fingerprinting requires that the full-
length sequences be present in the protein sequence databases. Therefore, the completeness 
of a database determines the success rate for protein identification using peptide mass 
fingerprinting.  
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Figure 3.3 2DE driven proteomics  
Proteins are separated by 2D-PAGE, a protein of interest is cut from the gel and cleaved into peptide fragments. 
The peptides are analyzed by MALDI-TOF-MS resulting in a peptide mass fingerprint. Selected peptide masses 
are submitted to the protein database and the results are represented as a statistically determined Probability 
Based Mowse Score. When the score is above the threshold (shaded area), the identification is significant. The 
database search provides information about the accession number, mass, pI, number of matched mass values, 
and sequence coverage of the identified protein. Detailed information is given in the table concerning the 
matched peptide experimental mass (Mr exp) and calculated mass (Mr calc), the sequence, position, and possible 
modification. 
Match to: Q99K93; Score: 121
PDZ and LIM domain 1 (elfin)-
Mus musculus
Nominal mass (Mr): 35752 
Calculated pI: 6.38
Number of mass values matched: 11
Sequence coverage: 32%
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Peptide mass maps are created by single-stage mass spectrometers, such as a MALDI-
TOF or ESI-TOF (Figure 3.4). However, several different mass analyzers, such as a 
quadrupole or hexapole, can be coupled to an ion source, separated by a collision cell. In 
general, such mass spectrometers are called tandem mass spectrometers, because they 
generate peptide mass maps as well as peptide fragmentation patters (MS/MS spectra). The 
MS/MS analysis is performed on an individual ion with a particular m/z value that was 
selected from the peptide mass map, which dissociates in a collision cell. The dissociated 
products are subsequently analyzed in the second mass analyzer, generating peptide 
fragmentation data of that specific peptide, from which amino acid sequence data can be 
derived 487,499,500 (Figure 3.4). Tandem mass spectrometry (MS/MS) is technically more 
complex and less scalable than peptide mass fingerprinting, but the sequence information is 
more specific for one particular protein. In addition, fragmentation data can be used to 
search protein sequence databases as well as nucleotide, EST, and raw genomic sequence 
databases. 
 
 
Figure 3.4 Principle of mass spectrometry and tandem mass spectrometry 
A) The sample analyte is ionized in the ion source, transferred to the mass analyzer and detected on the detector 
according to the mass to charge ratio (m/z). This results in a peptide mass fingerprint.  
B) The tandem mass spectrometer first creates a peptide mass fingerprint, and subsequently a peptide with a 
particular m/z value is dissociated in a collision cell and further analyzed in the second mass analyzer. This 
provides a peptide fragmentation patterns from which the amino acid sequence can be deduced. Adapted from 
Yates, 2000 487. 
 
Mass spectrometric identification of gel-separated proteins (either 1D of 2D) has been 
a major breakthrough in proteomics and has found its applications in a whole variety of 
research fields.  
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3.2.2 Proteomics in reproductive endocrinology 
Protein identification in the male genital tract 
After the introduction of 2DE, this technique was quickly adapted in endocrine 
research. In the context of the present thesis, proteins in epididymis and vas deferens have 
been studied in detail with respect to their role in tissue function. The developmental 
process of epididymis and vas deferens is under control of androgens, and also maintenance 
of function of the organs in the adult 4,501. Epididymis, vas deferens, and luminal fluid 
secreted by the epididymis and vas deferens provide a microenvironment, which is suitable 
for sperm maturation and storage 502. It has been reported that epididymal fluid proteins 
interact with spermatozoa and bind to the sperm membrane 503. 2DE has been used to 
investigate the effect of androgens on protein synthesis and secretion in various regions of 
the epididymis and vas deferens 504-506. These early studies characterized proteins of specific 
pI and Mr, established their regional expression and dependence or independence of 
androgens, but could not reveal the identity of these proteins. Later studies have used 
measurements of enzyme activity 501, immunoblotting 507, or Edman degradation amino acid 
sequencing 508,509 for the identification of specific proteins. Enzyme activity measurements 
and immunoblotting can only be used in cases where the proteins of interest are already 
known. Edman degradation, on the other hand, can be applied for sequence information on 
any unknown protein. It does, however, require larger amounts of pure peptide, skill and 
time before a sequence can be retrieved 510,511.  
Technological developments on mass spectrometers lead to an enormous progress of 
identification of epididymal proteins. Prostaglandin D2 synthase was identified as an 
epididymal fluid protein using MALDI-MS and nanoESI-MS/MS. 2DE showed multiple 
protein isoforms of Prostaglandin D2 synthase in the gel (pI 6.5-8.8 and Mr 20-25 kDa) and 
treatment with N-glycanase resulted in one protein isoform, demonstrating post-
translational N-glycosylation of the protein 334. MALDI-TOF-MS identification of rat sperm 
membrane proteins separated by 2DE, revealed the presence of heat shock protein 70, 
disulfide isomerase ER60, and subunits of the proteasome on the membrane (Ooms and 
Vreeburg, unpublished observations). Surprisingly, these proteins were also identified as 
sperm membrane antigens, against which antisperm antibodies are directed, causing human 
immunological infertility 512. Furthermore, one major rat sperm membrane protein, 
synthesized in late spermatogenesis, was recently extracted from 2D gels that were 
processed 10 years ago and was identified as hexokinase (Ooms and Vreeburg, unpublished 
observations). This finding demonstrates that proteins can be identified from 2D gels even 
after long-term preservation and storage.  
An interesting approach that is currently being undertaken to determine protein profiles 
of regions of the epididymis, is the use of imaging MALDI-TOF-MS. In a recent study, 
caput and cauda epididymis cryostat tissue sections were either blotted on a PE membrane 
and spotted with matrix, or directly mounted on a target plate and subsequently spotted or 
coated with matrix. MALDI-TOF-MS was performed on these tissue sections providing 
protein profiles and optical images of the epididymis 513. Comparing the protein profiles of 
caput and cauda epididymis revealed that specific m/z signals were present, providing 
information about protein distribution within the epididymis. Furthermore, optical imaging 
of the different m/z values in the epididymis sections shows the spatial distribution of that 
specific protein corresponding to the m/z value 513.  
As described in Chapter 1, androgens play an essential role in embryonic development 
of genital tract tissues. 2DE driven proteomics was also used to identify androgen-regulated 
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proteins in embryonic epididymis and vas deferens tissues (Chapter 4) and the vas deferens 
cell line MFVD (Chapter 5). In MFVD cells, androgens induced post-translational 
modification of mElfin and CBF-A (Figure 3.5), two actin-binding proteins that are possibly 
involved in recruitment of signaling molecules 514. Embryonic epididymides and vasa 
deferentia that were cultured in the presence of androgen showed post-translational 
modification of triosephosphate isomerase, a glycolytic enzyme, heterogeneous nuclear 
ribonucleoproteins hnRNP A2/B1 and hnRNP A1, and RhoGDI, a signaling protein 
(Chapter 5). To understand the role of these proteins in genital tract development, more 
detailed proteome analysis and functional analysis will be needed. 
 
Figure 3.5. Post-translational modification of proteins upon androgen treatment 
MFVD cells show regulation of mElfin (1) and CBF-A (2) upon androgen treatment. Both proteins shift towards 
the acidic part of the gel (1a and 2a) upon R1881treatment for 24 hours but this effect is reversed within 48 
hours. 
 
2D gels have already greatly contributed to the field of reproductive endocrinology, but 
the emergence of state-of-the-art proteomics techniques (paragraph 3.2.3) will provide new 
possibilities for large-scale studies on androgen-regulated proteins that are expressed in the 
genital tract and sperm, in order to better understand the physiology of fertility.  
 
Expression profiling in health and disease 
While androgens and androgen-regulated proteins are involved in growth, development 
and maintenance of male physiology, they also play a role in the development of 
malignancies, such as prostate cancer. Not only for prostate cancer, but also for a whole 
variety of diseases, much effort is now being put in understanding pathogenesis at the 
protein level, and in the development of effective strategies for early diagnosis and 
treatment, using applications in disease proteomics 515. For prostate cancer several different 
approaches were undertaken to identify tumor specific marker proteins involved in 
transition from androgen-dependence to androgen-independence, and marker proteins 
representing different stages of tumor progression. 
In one such study, 2D maps of normal prostate tissue were compared with 2D maps of 
malignant prostate, and 20 proteins were identified that were lost during the transition to 
malignancy. These proteins included PSA (prostate specific antigen) and other proteins 
known to be involved in prostate cancer, but also proteins not previously described in this 
process, like NEDD 8, calponin, and follistatin-related protein 516. Nelson et al., 2000 used 
the prostate cancer cell lines LNCaP and M12AR to study androgen-regulated protein 
expression. Androgen-stimulation resulted in the up-regulation of human nucleoside 
diphosphate kinase A, which is a tumor metastasis suppressor protein 336. This finding 
coincides with the observed decrease in invasion and metastasis of LNCaP and M12AR cells 
compared to the prostate cancer cell line M12 that does not express the androgen receptor 
and is highly tumorigenic and metastatic.  
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Although studies in cell lines can be very informative, it is becoming increasingly clear 
that protein expression patterns of tumor cell lines do not accurately correspond to 
expression patterns of primary tumors. While 2D maps of prostate cancer cell lines are 
rather similar, they differ substantially from microdissected prostate tumor cells. Even cell 
lines that were derived from a tumor showed altered protein expression profiles when 
compared to the primary tumor 517. Thus, one should be careful in drawing conclusions 
from studies performed on cell lines, since the results may not precisely represent the 
expression profile of the tumor. However, analysis of tumor samples is difficult to interpret 
because of their heterogeneity. Solid tumors may represent tumor cells, stromal cells, normal 
epithelial cells, endothelial cells, inflammatory cells, including macrophages, and extracellular 
matrix, which complicates the biological interpretation of the analysis. To overcome these 
problems, several approaches are now being used to obtain pure populations of cells, such 
as antibody-based flow-cytometric sorting, and laser microdissection (LCM) 518. It appears 
that microdissected prostate tumor cells have a different protein expression pattern as 
compared to microdissected normal or stromal cells 517. Although LCM microdissected 
tumor material does not yield high amounts of protein (µgs of protein from 100,000 cells), it 
seems feasible to perform 2DE and subsequently MS/MS to identify numerous proteins 
that are differentially regulated between tumor cells and normal prostatic epithelial cells 339. 
LCM purified cancer cells have also been analyzed using a new type of affinity-based mass 
spectrometer, surface-enhanced laser desorption/ionization (SELDI) mass spectrometry. 
The underlying principal of SELDI is surface-enhanced affinity capture through the use of 
protein chips consisting of chemical characteristics (hydrophobic, hydrophilic, cationic, 
anionic, etc.) or biological ligands (proteins, receptors, antibodies, DNA oligonucleotides). A 
complex protein mixture (cell lysate or body fluid) is directly applied on the surface, non-
specific binding partners are washed away, and the retained proteins are subsequently 
analyzed by time-of-flight MS 519.  
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Figure 3.6 SELDI expression profile of different stages of prostate cancer samples 
A)  Mass profile of prostate normal epithelium, prostatic intraepithelial neoplasia, tumor, and stroma. 
B) A gel-like image of the raw mass data shown in a).  Note the changes in expression level of proteins A (28 
kDa) and B (32 kDa) between the different samples. Adapted from Petricoin and Liotta, 2000 520. 
 
Comparison of prostate tumor cell lysates from different stages (benign hyperplasia, 
intraepithelial neoplasia, and prostate cancer) showed altered protein expression profiles 
between the stages of disease and can be distinguished from each other according to their 
profile 521-523 (Figure 3.6). SELDI-TOF mass spectra have also been generated for breast 524, 
ovarian 519,525, and several other cancers 526. Such SELDI expression profiles can be used in 
screens for biomarker discoveries, because it is very suitable for high-throughput analyses in 
a relatively short time, which may lead to the development of new diagnostic tests for early 
detection of cancer. However, the proteomic patterns that are generated have a low 
resolution and thus low mass accuracy, and the biomarkers cannot be routinely identified 
because of the lack of TOF-MS/MS possibilities. Furthermore, although biomarker 
discovery seems successful in the low-molecular weight range of 2-20 kDa, reproducibility is 
a problem with high-molecular weight proteins 526. Thus, the SELDI approach does not 
identify specific proteins that are unique for a particular disease state but merely provides 
information about protein patterns that belong to a certain disease state. 
Screens for biomarker discovery for many disease types, including prostate cancer, have 
already been performed on a large-scale using SAGE and cDNA microarrays 336,527,528. 
However, considering the poor quantitative correlation between mRNA and protein 
expression 337, and the importance of post-translational modifications, there is a growing 
need for other profiling technologies, such as protein arrays and biochips. Pathogenesis will 
be best understood when mRNA expression data can be combined with data on proteome 
alterations, such as protein expression levels, interacting biomolecules, subcellular 
localization, and post-translational modifications. Further technological innovations in 
proteomics are underway to increase sensitivity, reduce sample requirement, increase 
throughput, and more effectively uncover various types of protein alterations 515. 
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3.2.3 State-of-the-art applications 
Non-2DE driven proteomics 
The rapid accumulation of genomic sequences in public databases is putting pressure 
on proteomics research to establish large-scale high-throughput analysis methods for the 
functional annotation of all these genomes 474,487. Although 2DE based protein 
identifications have already provided valuable information, this method is labor intensive 
and difficult to automate, in addition to other limitations mentioned in paragraph 3.2.1 (e.g. 
not all proteins focus in the gel and there is a bias towards high-abundant proteins). 
Therefore, a great effort is being put in developing non-2DE driven proteomics tools that 
separate, quantitate and analyze complex protein mixtures and identify the proteins of 
interest in one analysis run, using only a small amount of sample. Such approaches use 
complex mass spectrometers and require strong bioinformatics tools and data mining. Some 
of the recent advances in quantitative proteomics will be outlined. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS): LC-MS/MS is 
a method to directly identify proteins from complex mixtures. Mixtures of proteins such as 
cell lysates or body fluids are digested with an enzyme (e.g. trypsin) producing a large 
collection of peptides. Such peptide mixtures can be separated by microcolumn reversed-
phase liquid chromatography (RPLC), which is directly coupled to the tandem mass 
spectrometer, resulting in a large number of mass spectra 529. Several variations on this 
theme have been presented, such as multidimensional chromatography-coupled tandem 
mass spectrometry (LC/LC-MS/MS), which combines a strong cation exchange with RPLC 
providing a two-dimensional separation prior to MS/MS. Database searches on the MS/MS 
spectra using special algorithms provides a multidimensional protein identification 
technology, named MudPIT 530. MudPIT performed on the yeast S. cerevisiae proteome 
revealed the identification of 1,500 proteins covering proteins of low-abundance, proteins 
with extremes in pI and Mr, and integral membrane proteins, in an analysis time of 90 hours 
using 1.32 mg protein 530,531. A MudPIT approach was also used for a comprehensive 
proteomic view of the malaria parasite P. falciparum life cycle. Over 2,400 proteins were 
identified from four different stages of the life cycle, and functional profiling of the proteins 
agrees with the physiology of each stage 532. Other non-gel based 2D-separations include the 
coupling of high performance liquid chromatography (HPLC) with RPLC 533, or capillary 
isoelectric focusing  integrated with capillary RPLC 534. Transferring isoelectric focussing 
from gel to capillary format contributes to a high-resolution protein separation with pI 
differences as small as 0.005 pH units, and analysis of low-abundance proteins with a 
concentration factor of 50-100 times 534. The combination of capillary IEF with capillary 
RPLC not only results in high-resolution protein/peptide separation but also provides 
information on pI.  
Quantitative isotope labeling: a significant advance in quantitative proteomics is 
differential isotope labeling. Two sets of proteomes to be compared can be labeled at 
different points in the sample preparation pathway. First of all, metabolic labeling can be 
performed during e.g. cell growth, using 14N containing medium in one condition and 15N 
enriched medium in the other condition 535,536. Labeling can also be performed after protein 
extraction using a commercially available isotope-coded affinity tag (ICATTM) reagent. The 
ICATTM reagent consists of a biotin affinity tag, a reactive group with specificity towards 
thiol groups (cysteines), and a linker that can incorporate stable isotopes. The ICATTM light 
reagent contains 8 hydrogen atoms, whereas the heavy reagent contains 8 deuterium atoms, 
creating a mass difference on the mass spectrometer of 8 Da for singly charged ions and 4 
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Da for doubly charged ions. ICATTM light and heavy reagents can be used to label cysteine 
residues in two separate protein pools. The two samples are subsequently combined and 
enzymatically cleaved into peptide fragments, the tagged peptides are isolated by avidin 
chromatography, and finally separated and identified using multidimensional LC-MS/MS. 
The relative intensities of the signals of two differentially isotopically labeled peptides are 
measured to determine the relative peptide concentration in the two mixtures 537-540. The 
combination of these methods and techniques allows for the detection and quantification of 
proteins of low-abundance over an effective dynamic range of 104 by reducing the 
complexity of the mixture 539. While isotope-tagged peptide mixtures separated by 
multidimensional LC can be identified in a robust, sensitive, and automated fashion by ESI-
MS/MS, it requires continuous sample application, and much time for data collection and 
analysis. The use of MALDI-MS/MS (such as MALDI-quadrupole time-of-flight) reduces 
the experimental time and increases the efficiency of global proteomic comparisons of 
biological cell states, because MS/MS can directly be focused on labeled peptide pairs 
showing interesting changes in relative abundance 540,541. Although reducing the complexity 
of a sample by labeling results in the detection of low-abundance proteins, it also discards 
information on proteins that are not labeled. Future labeling strategies should ideally focus 
on all proteins isoforms present in a mixture. 
Fourier transform ion cyclotron resonance (FTICR): relatively new to proteomics 
is the FTICR mass analyzer, which has an extremely high sensitivity and resolution. A 
detection limit at the low attomole level can be achieved as compared with the low 
femtomole limits with other instrumentation, with a mass accuracy of <1 ppm and a 
resolution of more than 100,000. FTICR-MS has the potential to identify and quantify 
hundreds to a few thousand different proteins in one analysis using the accurate mass of one 
single peptide and sequence database searching 542-544. The accurate mass and time (AMT) 
tag approach is a two-stage stategy that provides increased sensitivity, coverage, and 
throughput. In the first stage a proteome sample is analyzed by high-resolution capillary LC-
MS/MS to identify “potential mass and time tags”, which are subsequently used to validate 
the AMT tag obtained by analyzing the same samples by FTICR. By analyzing a whole 
variety of samples, an AMT tag database is constructed, in which the peptides function as 
markers to identify their corresponding proteins in all subsequent, second stage, 
experiments 545 (Figure 3.7).  
In a single 2.5 hour LC-FTICR-MS analysis an average of 1500 AMT tags are 
identifiable 543. Although the generation of an AMT tag database for a specific organism, 
tissue or cell type will require large amounts of sample, once generated AMT tags will allow 
for peptide identification using only pg amounts of protein 543. Furthermore, combining the 
AMT tag strategy with isotope labeling provides quantitative information of protein 
abundance. Although FTICR-MS has a sub-attomole detection limit, the dynamic range of a 
single mass spectrum is about 103. To further increase the dynamic range in FTICR-MS 
measurements, a dynamic range enhancement applied to MS (DREAMS) methodology is 
applied. DREAMS involves an alternate acquisition of a normal mass spectrum and a 
subsequent spectrum of the first spectrum from which the most abundant ion peaks are 
removed. This approach extends the dynamic range of FTICR by 10 to 100 fold and allows 
for the detection of 35% more peptides in a single analysis run 546,547.  
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Figure 3.7. AMT tag based proteomics 
Stage 1: A proteome sample is analyzed by LC-MS/MS and peptides are identified by the resulting sequence 
information as potential mass and time (PMT) tags. The same proteome sample is than analyzes under the same 
conditions using an FTICR-MS. An AMT tag is established when a peptide elutes at the same time and the 
corresponding mass of the PMT tag initially identified. An AMT database is constructed from a large number of 
different samples. 
Stage 2: For any given proteome that is subsequently analyzed, the peptides in the AMT tag database function as 
markers to identify the corresponding protein. When two samples have been isotopically labels, protein 
abundance rations can be determined. Modified from Pasa-Tolic et al, (2002) 543 
 
It is evident that the current state-of-the-art technologies already offer great sensitivity 
to analyze small amounts of cells (e.g. obtained by laser microdissection) yielding less than 1 
µg of proteins with a dynamic range covering four to six orders of magnitude. The rapid 
evolution of technologies will further increase the applicability of proteomics into medical 
research. 
 
Functional proteomics 
While most of the proteomics efforts are focusing on cataloguing large sets of proteins 
expressed under certain conditions in specific cell types or organisms, it also brings back the 
question of protein function. Protein function is determined by a variety of factors, such as 
sub-cellular localization, stability, post-translational modification, binding (protein) partners, 
and participation in complexes. Furthermore, a single protein may be present in multiple 
complexes and as a consequence be involved in more than one process. As proteins contain 
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many types of information, each of their properties need to be analyzed and put in a 
proteome-wide context in order to understand the physiology of a cell, tissue, or organism 
548.  
One way to determine a protein’s function is the loss-of-function approach, by 
generating knockout mice or using RNA interference. At the cellular level, green fluorescent 
protein (GFP)-tagged proteins and confocal microscopy enable the investigation of specific 
proteins of interest in living cells, providing information on sub-cellular localization, 
dynamics, and interactions with other proteins under investigation, using techniques such as 
fluorescence resonance energy transfer (FRET) or fluorescence redistribution after 
photobleaching (FRAP) 549. Recently, it has been postulated that post-translational 
modifications might be detected by FRET, using anti-phosphotyrosine antibodies coupled 
to a FRET acceptor molecule and measuring tyrosine phorphorylation of the GFP-fusion 
protein 550,551. 
A commonly used method to identify interacting protein partners of a protein under 
investigation is the yeast two-hybrid system, in which a particular library can be screened for 
novel interacting proteins or in which the properties of binding of two known interactors 
can be assessed by mapping the precise region of binding 552,553. As yeast two-hybrid can 
generate false-positive interactions, it is crucial to validate the putative protein-protein 
interaction.  One condition of protein-protein interaction that has to be met is the presence 
of both proteins in the same sub-cellular compartment, and this interaction can be further 
verified by immunoprecipitation and Western blot analysis, using specific antibodies 
directed against the two proteins of interest.  
The functional analysis of proteins using GFP-tags, yeast two-hybrid, or 
immunoprecipitation and Western blot is based on a one-protein-at-the-time approach. 
However, these techniques are now being put in array format and are combined with mass 
spectrometry, which provides a means of analyzing and identifying multiple proteins at a 
time, determine their localization and interacting partners, in a high-throughput manner. For 
example, large-scale analysis of GFP-tagged proteins was performed using a transfected cell 
microarray. This method involves transfection of cells on a glass slide, which contains 
different cDNAs on defined areas. By screening transfected cell microarrays, proteins 
involved in tyrosine kinase signaling, apoptosis, and cell adhesion were identified with the 
simultaneous analysis of their distinct sub-cellular distribution 554. Protein-protein 
interactions can also be studied on a large-scale by performing FRET on transfected cell 
microarrays 551.  
Another high-throughput way to study protein-protein interactions is the yeast two-
hybrid array approach 555, or the high-throughput mass spectrometric protein complex 
identification (HMS-PCI) method 556. HMS-PCI was performed on the yeast proteome 
using 10% of predicted yeast proteins as baits (725 proteins), and identified 3,617 protein 
interactions. Using this approach, many new, previously undescribed, interactions in 
signaling pathways and DNA damage response were identified 556.  
Protein-protein interactions can also be studied, by purification of an entire multi-
protein complex using affinity-based methods, using for example glutathione S-transferase 
fusion proteins, antibodies, peptides, or small binding molecules. The purified protein 
complex can either first be separated on 1D or 2D gels or can be directly identified by mass 
spectrometry 557. Using an affinity-based-MS approach, several large protein complexes have 
been identified 558,559. 
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Relatively new in functional proteomics is the development of protein microarrays, 
which can be used for either analytical of functional analyses. Analytical arrays are typically 
coated with antibodies, antigens, carbohydrates or small molecules, with high affinity and 
specificity, which can be used for monitoring protein expression levels, profiling, and 
diagnostics. Functional arrays are spotted with purified native proteins or peptides, and can 
be used to analyze protein activities, binding properties, post-translational modifications, 
and building biological pathways 551,560,561. As a consequence, functional arrays may be very 
useful in drug discoveries. One of the first large-scale protein arrays reported the 
purification of nearly 6,000 tagged yeast proteins and the identification of interacting 
proteins 562. Antibody arrays were created to screen more than 18,000 recombinant antibody 
clones against 15 different antigens 563. The hurdles to overcome for protein arrays, are the 
production of sensitive and non-cross reacting antibodies, the large-scale purification of 
proteins, and possible changes in protein conformation induced by immobilization, to 
mention just a few 564. Nevertheless, the advantages of protein arrays being scalable, flexible, 
automatable, and easy to perform, will facilitate the high-throughput functional protein 
analysis on a genome-wide level. 
Future applications in proteomics will benefit from the combination of several 
techniques brought together into one, like imaging mass spectrometry and transfected cell 
arrays. As mass spectrometers are being designed for higher sensitivity, resolution, accuracy, 
and automation, the ultimate goal would be to follow the dynamics of the proteome of 
living cells, from protein identification to sub-cellular localization or even post-translational 
modifications. In order to achieve such goals, different disciplines such as physics, 
bioinformatics, chemistry, and biology would have to work together, even more than they 
are doing right now. 
 
Concluding remarks 
The wealth of new technologies emerging in proteomics research goes hand in hand 
with high costs, limited technical expertise, and a high threshold for researchers in the field 
to access state-of-the-art facilities. In order for biomedical research to fully benefit from the 
advances made in proteomics, knowledge and expertise must be joined in institutional or 
national proteomics centers that are easy to access 565. Furthermore, to coordinate large-
scale proteomics efforts, the Human Proteomics Organization (HUPO) was founded in 
2002 as a worldwide organization 566. The goals of HUPO include developing an 
infrastructure in proteomics that facilitate unraveling the complexity of the human proteome 
and that of model organisms 515.  
The impact of proteomics on endocrinology and all other fields has just started, but will 
certainly change the way research was conducted to date to tackle biological mechanisms 567.  
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Summary 
During sex differentiation, androgens are essential for development of the male genital 
tract. The Wolffian duct is an androgen sensitive target tissue that develops into the 
epididymis, vas deferens and seminal vesicle. The present study aimed to identify androgen-
regulated proteins that are involved in development of Wolffian duct-derived structures. We 
have used male mouse embryos transgenic for temperature sensitive Simian virus 40 large T 
at 18 days of gestation, to generate immortalized mouse fetal vas deferens (MFVD) parental 
and clonal cell lines. The MFVD parental and clonal cell lines express androgen receptor 
protein and show features of Wolffian duct mesenchymal cells. Clonal cell line MFVD A6 
was selected for proteomic analysis and cultured in the absence or presence of androgens. 
Subsequently, two dimensional gel electrophoresis (2DE) was performed on total cell 
lysates. Differentially expressed proteins were analyzed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and two 
androgen-regulated proteins were identified as mElfin and CArG-binding factor-A (CBF-A). 
CBF-A and mElfin are known to bind to cytoskeletal F-actin. Both proteins appeared to be 
regulated by androgens at the post-translational level, possibly involving phosphorylation. 
Post-translational modification of mElfin and CBF-A by androgens may be associated with 
a cytoskeletal change that is involved in androgen-regulated gene expression. 
 
Introduction 
Androgens are essential for development and differentiation of the male genital tract. 
Androgen action is mediated by the androgen receptor (AR) that functions as a transcription 
factor by binding to specific DNA sequences in promoter and enhancer regions of target 
genes, thereby regulating their transcriptional activity 237. During male embryonic 
development, testicular testosterone stimulates the Wolffian ducts to develop into 
epididymides, vasa deferentia and seminal vesicles. In the urogenital sinus, 5α-reductase 
converts testosterone into the more potent 5α-dihydrotestosterone, which stimulates the 
urogenital sinus to develop into the prostate gland and external genitalia 568. The importance 
of AR signaling during male sexual differentiation is demonstrated in certain pathological 
situations, in particular androgen insensitivity syndrome (reviewed in 179).  
In the mouse Wolffian duct, AR expression can be detected in mesenchymal cells from 
day 12.5 of gestation (E12.5) onwards 117,118 shortly before testicular testosterone secretion 
starts 569. In contrast, epithelial AR expression first appears in a temporal, cranial to caudal 
fashion, starting in the efferent ductules at E16, immediately after morphological 
differentiation of the Wolffian duct has started. AR protein is not expressed in epididymis 
and vas deferens epithelium before E19, and in seminal vesicle epithelium before postnatal 
day 1 117,118. The transition from AR negative to AR positive epithelium between E18 and 
E19 in the mouse is similar to what is found for fetal reproductive tract development in the 
rat 570. Since androgen dependent development of the genital tract occurs before epithelial 
cells express AR, it was postulated that androgen action in epithelium is mediated by 
paracrine influences from mesenchymal cells 571, suggesting an important role for AR 
expressing mesenchymal cells in the development of the genital tract. Thus, androgen action 
in the developing Wolffian duct is mediated solely by the AR positive mesenchymal cells 
until E18, and from E19 onwards by both the mesenchymal and the epithelial cells. Tissue 
recombination experiments have proven to be successful model systems for investigating 
mesenchymal-epithelial cell interactions in the reproductive tract, and were used to identify 
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growth factors as androgen-induced paracrine factors 126,571. However, it is largely unknown 
which target genes, or other processes, in the mesenchymal cells are regulated by androgens. 
To study androgen regulation of protein expression in mesenchymal cells, we 
developed androgen target cell lines derived from E18 Wolffian duct mesenchymal tissue. 
We used a transgenic mouse line that harbors the DNA sequence encoding thermolabile 
Simian virus 40 large T under the direct control of an β-actin promoter. A clonal mouse 
fetal vas deferens (MFVD) cell line was used for proteomic analysis. Comparative two 
dimensional gel electrophoresis (2DE) was performed and androgen-regulated proteins were 
identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS).  
 
Materials and methods 
Materials 
All media (Glutamax-supplemented DMEM/F12 nutrient mix and Hanks balanced salt 
solution [HBSS]), HEPES, collagenase, trypsin, TRIzol reagent, multiwell tissue culture 
plates (Nunc), and filtertop culture flasks (Nunc) were purchased from Gibco-BRL, Life 
Technologies (Gaithersburg, MD, USA). Fetal calf serum (FCS) was obtained from Greiner 
(Frickenhausen, Germany). A mixture of penicillin, streptomycin and fungizone was 
obtained from BioWhittacker (Walkersville, MD, USA). DNase and Complete protease 
inhibitors were from Roche (Basel, Zwitserland). New England Nuclear (Boston, MA, USA) 
supplied R1881 (methyltrienolone). Schering (Bloomfield, NJ, USA) provided 
hydroxyflutamide (OHF). Antibodies used were SV40 T Ag (Pab 101; Santa Cruz, CA, 
USA), anti-vimentin (clone VIM 3B4; Boehringer Mannheim, Germany), and anti-calponin 
(clone hCP; Sigma, St. Louis, MO, USA). PROTRAN nitrocellulose transfer membranes 
were from Schleicher & Schuell (Keene, NH, USA). West-Pico chemiluminescence 
substrate was purchased from Pierce (Rockford, IL, USA). Sequencing grade trypsin was 
from Promega (Madison, WI, USA). 10x Tris-Glycine-SDS electrophoresis buffer, TEMED 
(N,N,N,N’-tetra-methyl-ethylenediamine), RC DC Protein assay and Prestained precision 
protein standard were from Bio-Rad laboratories (Hercules, CA, USA). Immobiline dry 
immobilized pH gradient (IPG) strips (pH 3-10 NL, 18 and 24 cm), IPG buffer pH 3-10, 
and PlusOne chemicals for isoelectric focussing (IEF) and 2DE and 12.5% w/v acrylamide 
SDS precast gels were purchased from Amersham Biosciences (Uppsala, Sweden). Duracryl 
(30% v/v acrylamide/0.8% v/v BIS) was obtained from Genomic Solutions (Chelmsford, 
MA, USA). Colloidal Blue Staining Kit was from Novex / Invitrogen (Carlsbad, CA, USA). 
Alpha-cyano-4-hydroxycinnamic acid and peptide calibration mix were from Bruker-
Daltonica (Bremen, Germany). 
 
Animals 
Young adult mice, age 10-12 weeks, (B10/CBA strain) were purchased from Harlan 
Winkelmann GmbH (Bohren, Germany). Dr. E. Dzierzak (Department of Cell biology, 
Erasmus MC Rotterdam, The Netherlands) kindly provided the SV 40 large T transgenic 
Tag 5 mice 572. Both mice strains were housed under standard animal housing conditions in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals. This study 
was approved by the Dutch experimental animal committee, protocol number 124-98-03.  
Proteomics of MFVD cells 
87 
Preparation of primary cell cultures 
Timed pregnancies were performed by placing Tag 5 transgenic male mice in individual 
cages overnight with B10/CBA females. Day 0 (E0) of gestation was determined by the 
presence of a vaginal plug in the morning. On day E18, females were sacrificed, uteri were 
removed and fetuses were dissected in a sterile hood in DMEM/F12 medium containing 25 
mM Hepes, 5% v/v dextran-coated charcoal (DCC)-treated FCS and a mixture of 
penicillin/streptomycin/fungizone (PSF). Wolffian duct-derived tissues were isolated and 
vasa deferentia from six animals were pooled and washed twice in Ca2+-and Mg2+-free PBS. 
The tissues were incubated in HBSS with 150 Units/ml collagenase and 1 µg/ml DNase at 
37 C for 30 min, and were further dislodged into a single-cell suspension by pipeting up and 
down. This cell suspension was washed once with DMEM/F12 medium, supplemented 
with 5% (v/v) DCC-FCS and PSF, and the cell number was determined. Cells were 
subsequently seeded into 24 well plates at a density of 5x105 cells per well and cultured at 33 
C in DMEM/F12 supplemented with 5% DCC-FCS, PSF, and 10 nM synthetic androgen 
R1881. 
 
Establishment of vas deferens cell lines 
After one week of culture, medium from the cells was collected, centrifuged and sterile 
filtered through a 0.22 µm filter. This conditioned medium was obtained freshly every week. 
Cells were washed with Ca2+-, Mg2+-free PBS, detached with 0.25% (v/v) trypsin / 0.05% 
(w/v) EDTA by incubating at 33 C for 5 minutes and washed once with medium. 
Subsequently, cells were seeded at a lower density of 5x104 cells/cm2 in medium as 
described above containing 20% (v/v) conditioned medium, until cell crisis was reached. 
During cell crisis, cell density was kept high, 2.5x105 cells/cm2, in order to promote cell 
proliferation. Once the primary culture started proliferating again, it was considered 
immortal. These cells were seeded at a density of 5x105 cells/80 cm2 culture flask. The 
immortalized cell line was designated parental mouse fetal vas deferens cell line (MFVD). In 
order to obtain clonal cell lines, limited dilution cloning was performed on the MFVD cell 
line (passage 10) in a 48-well plate at an average density of 1 cell/well. After one week of 
culture, colony formation had started. Medium was replaced weekly, until the cell number in 
the well was  high enough to be passaged to larger plates. From this point on, addition of 
conditioned medium was omitted and the R1881 concentration was lowered to 1 nM. The 
immortalized cell cultures were passaged once a week. Three clonal cell lines were obtained 
from the parental MFVD cell line, designated clones A5, A6, and E2. 
 
Growth studies 
Growth studies were performed on the MFVD clone A6. At day 0 cells were seeded, in 
duplicate, into 24-well plates at a density of 2x104 cells per well. The cells were grown for 7 
days in the presence of vehicle (0.1% v/v ethanol), 1 nM R1881, or 100 nM anti-androgen 
OHF, at 33 C and 39 C. On day 2, 5, and 7, cells were trypsinized and cell numbers were 
determined using a hemocytometer. 
 
Western blotting and immunoprecipitation  
MFVD parental and clonal cell lines were grown in 80-cm2 culture flasks for 7 days in 
the presence of vehicle or 1nM R1881 at 33 C and 37 C or 39 C. On day 4, medium and 
hormone were replaced. On day 7, the confluent cell layer was washed twice with PBS and 
cells were subsequently collected by scraping on ice in 0.5 ml lysis buffer [40 mM Tris-HCl, 
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1 mM EDTA, pH 7.4, 10% glycerol (v/v), 1% Triton X-100 (v/v), 0.08% SDS (w/v), 0.5% 
sodium desoxycholate (w/v), 10 mM DTT, and Complete protease inhibitors]. The obtained 
lysate was sonicated for 5 seconds to decrease viscosity and centrifuged 10 min at 4 C, 
50,000 rpm. Total protein lysate (25 µg) was subjected to SDS-PAGE, and the proteins 
were blotted onto a nitrocellulose membrane. The AR protein was detected with 
monoclonal antibody F39.4.1 573. Marker proteins were detected using monoclonal 
antibodies against SV40 T Ag, vimentin, and calponin. In addition, AR protein was 
immunoprecipitated from 100 µg total cell lysate with  F39.4.1, and detected on blot with 
polyclonal antiserum against synthetic peptide SP 213 573. Proteins were visualized by 
chemiluminescence detection, according to the instructions of the manufacturer. 
 
Northern blot analysis 
MFVD parental and clonal cell lines were cultured in 80-cm2 culture flasks for 7 days at 
33 C. Total RNA was isolated using TRIZOL reagent according to instructions of the 
manufacturer. 15 µg RNA of each sample was applied on a formamide gel and blotted 
overnight to a PROTRAN nitrocellulose membrane. The Hoxa11 probe was obtained using 
a 300 bp BamHI-BglII fragment of the mouse Hoxa11 cDNA 574 and was labeled with α32P 
dATP. Hybridization was performed at 63 C overnight. RNA was visualized by 
autoradiography. 
 
2DE 
2DE was performed on protein lysates of MFVD A6 cells between passages 12 and 18, 
which were cultured in 80-cm2 culture flasks as described above in the presence of either 
vehicle (0.1% ethanol), 1 nM R1881 or 10 nM testosterone for 24 hours. After 7 days of 
culture, cells were washed twice with PBS and collected in PBS. Cells from five 80-cm2 
culture flasks from the same passage were pooled and centrifuged. Pellets were solubilized 
with 2D lysis buffer containing 7 M urea, 2 M thiourea, 4% w/v CHAPS (3-[3-
(cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate), 40 mM Tris-HCl, 10 mM 
dithiothreitol and Complete protease inhibitors. This lysate was sonicated and centrifuged, 
and protein concentration was determined as described above. For analytical gels 100 µg, 
and for preparative gels 500 µg protein lysate was mixed with rehydration buffer (8M urea, 
2% w/v CHAPS, 0.5% v/v IPG buffer pH 3-10, and a trace of bromophenol blue). 
Immobiline dry IPG gel strips of 18 cm for analytical (n=4) and 24 cm for preparative gels 
(n=1) with a non-linear pH range of 3-10 were actively rehydrated overnight with sample 
containing rehydrationbuffer applying a voltage of 30V per hour (Vh). IEF was performed 
with an IPGphor system (Amersham Biosciences) according to the manufacturer's 
instructions, until 92 kVh was reached. After IEF, proteins in the gel strips were reduced in 
equilibration buffer (6 M urea, 30% v/v glycerol, 2% w/v SDS, 50 mM Tris-HCl, pH 8.8) 
with 60 mM DTT for 20 min, and subsequently carbamidomethylated in the same buffer, 
containing 280 mM iodoacetamide, for 2 min. Resolution in the second dimension was 
carried out in an Ettan-Dalt II system (Amersham Biosciences) on 10% w/v Duracryl gels 
(analytical) or 12.5% w/v SDS precast gels (preparative). The gels were run 20 min with a 
constant power of 3W and subsequently 3,5 hours with a constant power of 180W. During 
the run the temperature was kept constant at 25 C. Prestained protein standards were run 
together with the strips. The gels were fixed overnight in 5% v/v phosphoric acid / 40% 
v/v methanol, and protein spots were visualized by colloidal Coomassie stain according to 
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the manufacturer's instructions. Analytical gels were subsequently silver stained according to 
Morrissey et al 575. 
 
In-gel trypsin digestion and mass spectrometry 
Protein spots of interest were excised out of the gel, were washed briefly in MilliQ 
water, de-stained twice for 20 minutes in 37% acetonitrile (ACN)/2.5 mM ammonium 
hydrogen carbonate, washed again, vacuum dried for 30 minutes, digested overnight with 
sequencing grade trypsin (0.7 U per protein spot) and re-hydrated in 50% v/v ACN / 0.1% 
v/v trifluoro acetic acid. The sample was mixed with a saturated alpha-cyano-4-
hydroxycinnamic acid matrix solution in 100% ACN (one part sample and four parts 
matrix) and 0.5 µl of this mixture was spotted on an anchorchip plate (Bruker-Daltonica, 
Bremen, Germany). Digested peptide fragments were analyzed in a matrix-assisted laser-
desorption/ionization-time-of-flight mass spectrometer (MALDI-TOF-MS) in a positive 
reflectron ion mode using a Biflex III apparatus (Bruker-Daltonica). The obtained peptide 
mass fingerprint spectra were analysed searching the MSDB nonredundant protein database 
(NCBI, USA) with MASCOT software (http://www.matrixscience.com), allowing one 
missed cleavage of trypsin per peptide. After protein identification, the database was further 
searched allowing the peptides to be modified for carbamidomethylation, oxidation of 
methionine and phosphorylation. Peptide mass accuracy was set to a maximum of 200 ppm. 
Upon protein identification, mass spectra of different isoforms of one and the same protein 
were compared to investigate the presence of modified peptides.  
 
Results 
Development of vas deferens cell lines and establishment of their growth characteristics  
An immortalized mouse fetal vas deferens (MFVD) cell line was developed from vasa 
deferentia from E18 mouse fetuses as described in Materials and Methods. From this 
parental cell line, clonal cell lines designated A5, A6 and E2 were derived. All cell lines were 
continuously cultured at 33 C, the permissive temperature of large T. Higher temperatures 
(37 C-39 C) cause degradation of the large T protein and are therefore non-permissive. It 
was described for other immortalized cell lines that cell proliferation at large T permissive 
conditions will stop, whereas cell differentiation will be initiated 576,577.  
Initially, the MFVD parental and clonal cell lines were continuously cultured under 
permissive conditions in the presence of methyltrienolone (R1881), a synthetic androgen. 
Growth studies were performed under variable culture. For this purpose, the MFVD clonal 
cell line A6 was cultured for 7 days at 33 C and 39 C in the absence of AR ligand, in the 
presence of 1 nM R1881, or in the presence of 100 nM of the anti-androgen 
hydroxyflutamide (OHF). Microscopic analysis revealed a difference in morphology 
between cells cultured at 33 C and 39 C (Figure 4.1A and 1B). At 33 C, MFVD A6 cells 
were found to grow to a high density, reaching confluency (Figure 4.1A). At 39 C, the cells 
developed a much larger and flatter appearance and entered a more quiescent stage, 
although cell growth had not completely stopped (Figure 1B). Quantification of cell growth 
showed a difference in growth between cells cultured at 33 C and 39 C (Figure 4.1C). 
Culturing under large T permissive conditions provided sufficient stimuli for cell growth 
(Figure 4.1C, open symbols). However, raising the culture temperature to 39 C resulted in a 
dramatic reduction of cell proliferation (Figure 1C, closed symbols). A reduction in cell 
growth was observed to a lesser extent at 37 C (data not shown). Cell growth at 33 C and 39 
C was neither stimulated by R1881, nor inhibited by OHF. Western blot analysis showed a 
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correlation between growth and large T protein expression. As expected, large T protein was 
highly expressed at 33 C in all cell lines (Figure 4.1D, lanes 1,3,5,7). Shifting the temperature 
to 39 C  (or 37 C; data not shown) resulted in a decline of large T protein expression in the 
MFVD parental cell line, in MFVD clone A5, and most prominent in MFVD clone A6 
(Figure 4.1D, lanes 2,4,6). MFVD clone E2, however, did not show any large T regulation, 
as the protein level remained high under non-permissive conditions (Figure 4.1D, lane 8). 
This may be due to a varying basal level of large T protein between the cell lines and to the 
turnover rate of the large T protein. It can be concluded that differentiation of the MFVD 
A6 clone in particular is dependent on large T protein expression. 
 
 
Figure 4.1 Phase-contrast microscopy photographs of MFVD clonal cell line A6 at passage 20 
The cells were cultured for 7 days at 33 C (A) and 39 C (B). Magnification x200. Note the difference in 
morphology between cells cultured at 33 C and 39 C.  
C) Growth curve of MFVD A6 clonal cell line cultured at 33 C (closed symbols) and 39 C (open symbols) in the 
presence of vehicle (0.1% ethanol) (squares), 1 nM R1881 (rectangles), or 100 nM OHF (triangles). Each point 
represents the standard error of the mean (+/- SEM) of three individual experiments performed in duplicate. 
The number of cells grown for 7 days in the absence of hormone at 33 C was set at 100%, and all individual 
points were calculated relative to this value.  
D) Western blot of large T protein expression in MFVD parental and clonal cell lines.  
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MFVD cells are of wolffian duct stromal origin 
To select for the stromal cells in our vas deferens cultures, the MFVD parental and 
clonal cells were cultured in serum-containing medium. To confirm the stromal origin of 
MFVD cells, some marker proteins were analysed. On Western blots, all clonal cell lines 
were positive for two mesenchymal cell markers, vimentin and calponin (Figure 4.2A, lanes 
1-3) 578,579. In contrast, the cells were negative for the epithelial cell marker pan-keratin (a 
mixture of all cytokeratins) 580. Chinese hamster ovary cells (CHO) were used as a positive 
control for mesenchymal cells (Figure 4.2A, lane 4). The prostate cancer cell line LNCaP 
was used as a control cell line for epithelial cells expressing pan-keratin (Figure 4.2A, lane 5).  
To determine the vas deferens origin of these stromal cells, Northern blot analysis was 
performed with a Hoxa11 probe. This member of the Hoxa complex of homeotic genes is 
expressed mainly in developing limbs and the embryonic kidney (not in adult kidney), and in 
stromal cells surrounding the müllerian and wolffian ducts 574. MFVD parental and clonal 
cell lines expressed Hoxa11 mRNA (Figure 2B, lanes 1-4), as did the embryonic kidney 
(positive control; Figure 4.2B, lane 5), but not the adult kidney (negative control; Figure 
4.2B, lane 6). From these experiments, we conclude that the MFVD parental and clonal cell 
lines have features of fetal vas deferens mesenchyme. 
 
Figure 4.2 Characterization of MFVD parental and clonal cell lines  
A) Protein expression of two mesenchymal cell markers (vimentin and calponin) and one epithelial cell marker 
(pan-keratin). CHO cells were used as mesenchymal control cells. LNCaP cells were used as epithelial control 
cells.  
B) Hoxa11 mRNA expression in MFVD clonal cell lines and mouse fetal kidney. Mouse adult kidney was used 
as a negative control tissue.  
 
AR protein is expressed in MFVD parental and clonal cell lines 
Since cell growth in MFVD cell lines was not stimulated by androgens, we investigated 
the expression level of the AR protein. For that purpose, immunoprecipitation of AR 
protein from MFVD parental and clonal cell lines, cultured at 33 C and 39 C, was 
performed (Figure 4.3A). The parental cell line showed AR protein expression at both large 
T permissive and non-permissive temperatures (Figure 3A, lanes 1,2). All three clonal cell 
lines showed AR expression. While AR expression at 33 C was rather low (Figure 4.3A, 
lanes 3,5,7), it was clearly higher at 39 C (Figure 4.3A, lanes 4,6,8) when cells were not under 
the control of large T and thus in a differentiating state. In all our further studies MFVD 
cells were cultured at 37 C instead of 39 C, to provide a more physiological temperature. AR 
expression was followed in the MFVD A6 clone during a culture period of 20 passages, by 
performing Western blots on whole cell lysates at passages 10 and 20. Figure 3B shows a 
relatively low AR expression at 33 C and 37 C in the absence of R1881 (lanes 1,3,5,7). 
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However, addition of R1881 to the cells resulted in a marked increase in AR protein level 
(Figure 4.3B, lanes 2,4,6,8). This increase is most probably due to stabilization of the 
receptor protein in the presence of ligand 581. In cells cultured at 37 C, AR protein 
expression in the presence of R1881 was more pronounced than at 33 C. The AR protein 
expression was reduced at passage 20 (Figure 4.3B, lanes 5-8) as compared to passage 10 
(Figure 4.3B, lanes 1-4). AR expression was lost at passage 30 (results not shown). From 
these experiments, it was concluded that the AR protein in the MFVD A6 cell line is 
stabilized in the presence of ligand and that  AR protein expression is lost after 30 passages.  
Figure 4.3 Androgen receptor (AR) protein expression  
A) AR immunoprecipitation in MFVD parental and clonal cell lines cultured at 33 C and 39 C. 
B) AR protein expression in A6 cell line at passages 10 and 20. A6 cells were cultured at 33 C or 37 C in the 
presence of vehicle (0.1% ethanol) or 1 nM R1881, as indicated in the figure.  
 
CBF-A and mElfin are differentially expressed in MFVD A6 cells 
In order to identify proteins that are regulated by androgens, the MFVD A6 cell line was 
used for proteomic analysis. MFVD A6 protein lysates from 4 separate experiments were 
used to generate analytical 2DE gels. Typically, silver-stained 2DE gels showed 
approximately 1500 protein spots. Comparison of protein expression patterns of control 
and androgen-treated cells revealed only minor qualitative changes, except for one part of 
the gels which showed, repeatedly (n=4), a differential protein expression in a region 
focussed between pH 6 and 7 and between a molecular mass of 30-35 kDa. In order to 
identify these differentially expressed proteins by MALDI-TOF-MS, preparative 2DE gels 
were run. MFVD A6 cells were either treated for 24 hours with vehicle, 1 nM R1881, or 10 
nM testosterone. A colloidal Coomassie stained gel from cells treated with vehicle is shown 
in Figure 4A. Approximately 400 protein spots could be visualized on these gels. Protein 
expression patterns of the cells cultured under different hormonal conditions were much 
alike, except for the region that is boxed in Figure 4A. A more detailed representation of 
this part of the gel is shown in Figure 4B, for all three culture conditions. Protein spots a, b, 
c, and d represent non-changing anchors which were identified by MALDI-TOF-MS (Table 
4.I). Protein spots 1 and 2 present in the vehicle situation are subject to changes upon 
androgen treatment. While spot 1 is present in the vehicle situation, this protein disappears 
and three other proteins appear at positions 1a, 1b and 1c, upon treatment with either 
R1881 or testosterone. The exposure to R1881 or testosterone resulted in migration of 
protein spot 2 to position 2a and position 2b, respectively. Protein spots 1, 1a, 1b, and 1c 
could all be identified with MALDI-TOF-MS as CArG-binding factor A (CBF-A) (Table 
4.I).  
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Protein spots 2, 2a, and 2b were all found to represent mElfin (Table 4.I). From the 
gels it is apparent that addition of either 10 nM of the natural ligand testosterone or 1 nM of 
the synthetic androgen R1881 has the same effect on the position of the protein spots 
representing CBF-A. However, 1 nM R1881 appears to have a different effect on the 2DE 
migration of mElfin as compared to the effect of 10 nM testosterone. No change in position 
of CBF-A and mElfin was observed when cells were treated with 1 nM testosterone 
(preliminary results, data not shown), which may be the consequence of the lower affinity of 
testosterone for the AR as compared to dihydrotestosterone or R1881. Furthermore, 
addition of 100 nM of an AR antogonist, hydroxyflutamide, together with 1 nM R1881 
blocks the effect of R1881 (preliminary results, data not shown). 
 
Figure 4.4 Colloidal Coomassie-stained 2DE gel of MDVD A6 cell lysate  
A) Part of a 2DE gel from cells cultured in the presence of vehicle (0.1% ethanol) for 24h. Proteins identified by 
MALDI-TOF-MS are encircled and lettered a-o. Boxed is a region with differential protein expression.  
B) The boxed region from A) is shown in more detail. The same region is shown in detail for 2DE gels from 
cells cultured in the presence of 1 nM R1881 or 10 nM testosterone. Differentially expressed proteins are 
numbered as 1 and 2, for cell incubations without ligand (vehicle). In the gels representing the cells incubated 
with either R1881 or testosterone, the differentially expressed proteins are numbered as 1a, 1b, 1c, and 2a or 2b, 
respectively. 
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Proteins a-d in Figure 4B and e-o encircled in Figure 4A were also identified to provide 
a further characterization of MFVD A6 cells and are all listed in Table 4.I, together with 
their molecular mass, theoretical and experimental pI, and Accession number. In some 
cases, proteins did not run in the gel according to their theoretical mass or pI, and these 
proteins may have undergone modifications that change their position in the gel. Using this 
proteomic approach, we have performed a small-scale analysis to further characterize the 
MFVD A6 cell line. Several identified proteins (protein disulfide isomerase ER-60, laminin 
A, laminin C, ATP-synthase β-chain, and mitochondrial stress protein-70) have been 
reported to be expressed in mouse fibroblasts 582. The presence of these proteins in the 
MFVD A6 cell line emphasizes the common mesenchymal characteristics.  
 
Table 4.I. Peptide mass fingerprinting by MALDI-TOF- MS 
Spot*  Protein# MM (kDa) tpI epI  Accession # 
a Chaperonin containing TCP-1β−chain 57 6.0 6.3 BAA81874 
b Ornithine amino transferase precursor 47 6.1 6.1 AAH08118 
c,d α−Enolase 47 6.4 6.4-6.6 P17182 
e β-Actin 41 5.3 5.1-5.4 P02570 
f Vimentin 54 5.1 5.2-5.5 P20152 
g ATP synthase β−chain 56 5.0 5.1 P56480 
h Protein disulfide isomerase precursor  57 4.8 4.8 P09103 
i Mitochondrial stress-70 protein precursor 73 5.5 5.5 P38647 
j Tropomyosin fibroblast isoform 1 33 4.6 4.6 P46901 
k Laminin A 74 6.5 6.7-6.8 P48678 
l Laminin C 64 6.4 6.7-6.8 P11516 
m Mitochondrial matrix precursor protein P1 60 5.4 5.4 P19226 
n γ-Aminobutyric acid A receptor, α-6 32.9 5.7 5.7 AJ222970 
o Proliferating cell nuclear antigen 28.8 4.7 4.7 P17918 
1,1a,1b,1c CARG-binding factor-A 30.8 7.7 6.4-6.8 JQ0448 
2,2a,2b mElfin 35.7 6.4 6.4-6.6 AAH04809 
 * Index according to Figure 4.4. # Proteins identified with a significance of p<0.05 (Mascot software, Matrix 
Science). Accession # according to NCBI Blast. SWISS-PROT ExPASy data base. MM, molecular mass; tpI, 
theoretical pI as calculated from the; epI, experimental pI measured from the gels. 
 
The presence of both CBF-A and mElfin under different culture conditions but at 
changing positions in the gels strongly suggests that these proteins undergo post-
translational modification upon androgen treatment. Comparison of the peptide mass 
fingerprint spectra  of CBF-A isoforms 1, 1a, 1b,  and 1c revealed some differential peptide 
peaks. In isoform 1, 1a, and 1b, a peptide with a mass to charge ratio (m/z) of 1939.71 was 
observed that was not present in isoform 1c. On the other hand, isoform 1c showed a 
peptide with a m/z of 1539.79 that could not be observed in isoform 1, 1a, or 1b. 
According to the MSDB database search, which is based on the peptide masses only and not 
on the precise sequence, both these peptide masses match with CBF-A amino acid residues 
259-274 assuming that the 1939.71 peptide has an extra mass that corresponds with 5 
phosphate residues (Table 4.II). Similarly, a putative phosphopeptide was found with a m/z 
of 1189.58 corresponding to amino acid residues 90-97 with two phosphorylated residues. 
For mElfin, a putative phosphopeptide with m/z 1159.75 was found only in isoform 2. 
Other predicted phosphopeptides that were found in mElfin are listed in Table II, together 
with the putative phosphorylation sites. 
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Table 4.II. Proposed phosphopeptides according to differential MALDI-TOF-MS 
Protein Modified 
peptide m/z 
Unmodified 
peptide m/z 
Sequence Residues Candidate phosphorylation 
sites 
CBF-A 1939.71 1539.70 GSGGGQGSTNYGKSQR 259-274 S260,S266,T267,Y269,S272 
 1189.58 1029.52 DLKDYFTK 90-97 Y94,T96 
mElfin 1159.75 1079.73 CGTGIVGVFVK 261-271 T263 
 1805.94 1565.74 IKGCADNMTLTVSR 70-83 T78,T80,S82 
 2116.89 17.96.82 GDADNMTLTVSRSEQK 72-87 T87,T80,S82,S84 
m/z= mass to charge ratio 
 
 
Discussion 
The present study addresses the development and characterization of conditionally 
immortalized clonal cell lines from mouse fetal vas deferens. Immortalized cell lines from 
mouse urogenital ridge 583 and prepubertal mouse vas deferens epithelium 584,585 have  been 
reported previously. Other studies were performed using primary epithelial cells from adult 
586 and primary mesenchymal cells from fetal reproductive tract 143. However, so far no 
clonal cell line was described originating from fetal vas deferens mesenchymal cells. The 
MFVD A6 cell line is homogeneous because of its clonal background, it is of stromal origin, 
and expresses a functional androgen receptor. Therefore, these cells provide a cellular 
background that is suitable to study androgen regulation of gene and protein expression in 
relation to fetal genital tract development. 
In addition to cDNA microarrays, proteomics is becoming a widely used approach to 
study cellular mechanisms. The study of proteins and post-translational modifications adds 
to what can be learned from genomic studies. Androgenic effects on gene and protein 
expression have been studied for prostate cancer 336,337,517. However, the work presented 
herein is the first proteomics study on the effects of androgens in relation to genital tract 
development. In the MFVD A6 cell line, we have identified CBF-A and mElfin as two 
proteins that are regulated by androgens at the post-translational level.  It is evident that a 
genomics approach would not have provided information about such a functional change in 
protein expression. 
In the differential 2DE analysis of androgen-treated MFVD A6 cells versus untreated 
cells, we primarily focussed on qualitative differences. It was found that both CBF-A and 
mElfin were present in the stimulated and non-stimulated cells, but as different protein 
isoforms. Comparing the peptide mass fingerprint spectra of the different protein isoforms 
resulted in identification of peptide masses that were present in either one or the other 
protein isoform. Peptide phosphorylation could account for these differences in mass, and 
possible phosphopeptides were identified using the MSDB database. In the case of the m/z 
1939.71 peptide, the predicted presence of 5 phosphorylated amino acid residues is 
remarkable. It can, however, not be excluded that some other kind of modification, e.g. 
glycosylation, could result in a peptide of the same mass as the putative phosphopeptide.  
The MALDI-TOF-MS analysis of 2DE gels shows that post-translational modification 
of CBF-A and mElfin occurs upon androgen treatment and that peptide mass fingerprints 
can provide clues as to what kind of modification is taking place. Thus far, no androgenic 
regulation of CBF-A and mElfin at the post-translational level has been described.  
CBF-A belongs to a subfamily of highly homologous A/B-type heterogeneous nuclear 
ribonucleoproteins and functions in both transcriptional and post-transcriptional processes 
of gene regulation 587. CBF-A was originally described as a ubiquitously expressed protein, 
which binds to CArG-box motifs and to single-stranded DNA, and functions as a 
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transcriptional repressor 588. In a different context, the protein was found to interact with 
the SP6κ promoter as a co-activator of transcription 589. In addition, CBF-A activates 
transcription of the Ha-ras promoter in mammary cells, and appeares to bind the Ha-ras 
element 1 with higher affinity than the CArG-box 590. Furthermore, it was postulated that 
CBF-A is subject to post-translational modification 589, and in a recent study it was found 
that multiple modified isoforms of CBF-A associate with actin and are involved in nuclear-
cytoplasmic shuttling of mRNA 591. In MFVD A6 cells, post-translational modification of 
CBF-A might influence the expression of specific androgen target genes. 
mElfin is a family member of the Enigma proteins that possess a PDZ domain at the 
amino terminal and a LIM domain at the carboxyl terminal, which is expressed in a variety 
of tissues 592. Expression of mElfin is found as early as gestational day E8 in the developing 
heart of mouse embryos 593. LIM domains are defined by cysteine-rich sequences that form 
two zinc fingers, and are involved in protein-protein interactions (reviewed in 594). LIM 
domains are found in a variety of proteins with different cellular functions, especially in 
many key regulators of developmental pathways 594. mElfin was found to associate to the F-
actin-rich cytoskeleton by interacting with α-actinin via its PDZ domain, which in turn 
binds to F-actin  592,595,596. It was suggested that mElfin functions as an adapter protein by 
recruiting signaling kinases to the cytoskeleton via its protein-protein interaction motifs 
593,595. A functional relationship between mElfin and the AR pathway can be similar to what 
has been observed for FHL2, a four-and-a-half LIM domain protein which was found to be 
expressed preferentially in the heart 597. FHL2 is also expressed in epithelial cells of the 
prostate, where it overlaps with nuclear AR expression and functions as an AR-specific, 
ligand-dependent co-activator of transcription 238.  
Another functional link to AR signaling may involve the binding of CBF-A and mElfin 
to F-actin. It was described that several proteins initially characterized as actin-binding 
proteins or complexes were found to co-activate transcriptional regulators, including AR. 
The F-actin binding protein filamin has been found to interact with the AR and is involved 
in nuclear translocation of the AR 275. Likewise, β-catenin, which plays a pivotal role in cell-
cell adhesion by linking cadherins to α-catenin and the actin cytoskeleton, and which is a 
downstream effector of the Wnt signaling pathway, was found to enhance androgen 
dependent transcriptional activity of the AR 598. It is tempting to postulate that post-
translational modification of mElfin and CBF-A in the presence of androgens may link a 
change in cytoskeletal architecture to androgen-regulated gene transcription.  
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Summary 
Epididymis and vas deferens form part of the male internal genital tract, and are 
dependent on androgens for their growth and development. To better understand the 
molecular action of androgens during male genital tract development, protein expression 
profiles were generated using 2-dimensional (2D) gels, for rat epididymides and vasa 
deferentia isolated on embryonic days (E) 17-21. Proteins that were differentially expressed 
between E17 and E21 were cut from the gels, digested into tryptic peptides and analyzed on 
a MALDI-TOF mass spectrometer. Using this approach, 20 proteins could be identified 
that were regulated in time and were categorized into cytoskeletal proteins, nuclear proteins, 
transport proteins, chaperones, and enzymes (mainly glycolytic). Furthermore, epididymides 
and vasa deferentia isolated on E19 were cultured in vitro in the absence or presence of 
10nM of the synthetic androgen R1881, for 9, 24, and 48 hours. Under these conditions, 
regulation and post-translational modification were observed for glyceraldehyde 3-
phosphate dehydrogenase, triosephosphate isomerase, hnRNP A2/B1 and hnRNP A3, 
similar to the observed changes in vivo. In addition, post-translational modification of 
RhoGDI1 (also named RhoGDIα) was found in response to androgen. Androgen-induced 
post-translational modification of RhoGDI1 and glycolytic enzymes may be an important 
functional link between signaling pathways and cytoskeletal rearrangements in control of 
growth and development of the male internal genital tract. 
 
Introduction 
Androgens play an important role in regulation of male development and physiology, 
ranging from male sex differentiation during embryogenesis, several aspects of puberty and 
spermatogenesis, to adult male function 179,568,599. The principal androgen testosterone (T) is 
essential for the development of the internal sex organs derived from the Wolffian duct 
system: epididymis, vas deferens, and seminal vesicle. Dihydrotestosterone (DHT), the 5α 
reduced form of T, is involved in development of the prostate and external genitalia from 
the urogenital sinus and the tubercle 2,600. Both T and DHT perform their actions via one 
and the same intracellular receptor, the androgen receptor (AR), but DHT is a more potent 
androgen. Binding of either T or DHT to the AR might be a mechanism to regulate distinct 
androgenic effects in target tissues 600. In humans, the differential action of T and DHT is 
illustrated in clinical syndromes such as androgen insensitivity (AIS) and 5α-reductase type2 
deficiency. Complete AIS patients have a non-functional AR, which results in the absence of 
Wolffian duct and urogenital sinus derived structures, and feminized external genitalia (1). 
In contrast, patients with a 5α-reductase type2 deficiency have normally developed 
epididymides and vasa deferentia but have feminized external genitalia 107. Surprisingly, 
studies in mice deficient for steroid 5α-reductase 1 and 2, have shown that treatment with 
non-reducible T analogues was sufficient for secondary sex organ formation and growth 110. 
Therefore, it seems that in rodents, DHT acts largely as a signal amplifier (5).  In 
experimental setups, the synthetic androgen R1881 (methyltrienolone) is often used because 
it is not further metabolized and exerts both T and DHT effects.  
The AR is a member of the steroid/nuclear receptor superfamily, and functions as a 
transcription factor upon androgen binding 226. Structurally, the AR protein can be divided 
into separate domains, e.g. the N-terminal transcription activation domain, the DNA 
binding domain, and the C-terminal ligand binding domain. The ligand binding domain 
contains a strictly ligand-dependent transcription activation function and interacts with 
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nuclear cofactors 205,601. Upon ligand binding, the AR binds to specific genomic androgen 
response elements, thereby regulating transcription of specific genes.  
AR expression in the developing male genital tract occurs in a strict temporal, and 
cranial to caudal fashion, which is first detected in mesenchymal cells and later in epithelial 
cells. Mesenchymal AR is expressed along the rat genital tract as early as embryonic day 14 
(E14), whereas epithelial expression in the epididymis starts at E18 in the caput epididymis 
and after birth in the cauda epididymis and vas deferens 570. Thus, initiation of androgen-
dependent differentiation of the Wolffian duct system into epididymis and vas deferens 
occurs before epithelial cells express a detectable level of AR protein. During development, 
mesenchymal cells are important androgen targets that elicit androgenic effects in epithelial 
cells via paracrine factors and mesenchymal-epithelial interactions 122,602.  
Morphologically, differentiation of the epididymis is characterized by growth and heavy 
coiling of the epithelial duct. In molecular and mechanistic terms, however, it is not 
completely understood which factors are involved in growth and differentiation of the 
Wolffian duct. We have recently described the effect of androgen on protein expression in a 
mouse fetal vas deferens (MFVD) cell line using a proteomics approach. Stimulation of 
MFVD cells with androgen resulted in post- translational modification of two actin binding 
proteins, mElfin and CBF-A 514.  In the present investigation, we have applied proteomics 
to study and identify proteins that are involved in the androgen-dependent development of 
fetal rat epididymis and vas deferens, using freshly isolated or cultured tissues. Proteins 
regulated during fetal development were categorized as cytoskeletal proteins, nuclear 
proteins, transport proteins, chaperones, and glycolytic enzymes. Androgen-regulation in 
vitro involved post-translational modification of nuclear proteins and glycolytic enzymes, as 
well as RhoGDI1, a signaling molecule. Post-translational modification of proteins by 
androgen stimulation may be a key regulatory event in genital tract development, suggesting 
a functional link between signaling pathways and cytoskeletal proteins. 
 
Materials and methods 
Animals 
Pregnant female Wistar rats (16 to 20 weeks old) were purchased from Harlan 
Winkelmann GmbH (Bohren, Germany); the company determined the day of gestation by 
checking the presence of a vaginal plug in the morning after mating, which is referred to as 
E0. The rats were housed for 1 to 3 days in our in house facilities under standard animal 
housing conditions in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals. This study was approved by the Dutch Experimental Animal Committee, Protocol 
Number 124-01-04.  
 
Tissue preparation 
Rats were sacrificed by CO2 gas and cervical dislocation. Fetuses were removed from 
the uteri and placed in PBS on ice. Epididymides and vasa deferentia were isolated as a 
whole from male fetal rats on embryonic days (E) 17, 18, 19, 19.5, 20, and 21. Dissection 
was performed in PBS in a sterile hood. All tissues were either immediately frozen on dry 
ice or fixed in Bouin’s solution. In addition, tissues from fetuses of E19 were used for organ 
culture studies. Epididymides together with vasa deferentia were placed in a drop of 
medium on a Millicell-CM 0.4 µm culture plate insert (Millipore Corp., Bedford, USA) that 
was floating on top of 0.5 ml medium (DMEM/F12 + 2% v/v charcoal-stripped fetal calf 
serum, 10 µg/ml insulin, 10 µg/ml transferrin, and a mixture of penicillin (100 IU/ml), 
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streptomycin (100 µg/ml), and fungizone (0.6 µg/ml), all from Sigma, St. Louis, USA. in a 
4-well plate (Nunc, Roskilde, Denmark) 64. The two epididymides and vasa deferentia from 
one male were always cultured in either the absence of hormone (0.1% v/v ethanol vehicle) 
or in the presence of 10nM of the synthetic androgen R1881, methyltrienolone (New 
England Nuclear, Boston, MA, USA), for 9, 24, or 48 hours. For each culture condition, 25 
tissues were collected. For the frozen material, 40 tissues of E17 and E18 each and 25 
tissues of E19-E21 were collected. 
 
2-Dimensional gel electrophoresis (2DE) 
All collected tissues from one time point were pooled and lysed in 500 µl 2D lysis 
buffer (7M urea, 2M thiourea, 4% w/v CHAPS, 40mM Tris-HCl, pH8.8, 40mM DTT and 
0.5% v/v Immobilized pH gradient (IPG) buffer pH3-10) using the Sample Grinding kit 
(Amersham Biosciences, Piscataway, NJ, USA). High purity PlusOne chemicals were from 
Amersham Biosciences. Insoluble proteins and cell debris were pelleted at 100 000 rpm for 
10 min at 4 C, using the Optima TLX Tabletop Ultracentrifuge (Beckman). Protein 
concentration was determined using the RC DC Protein Assay kit (Bio-Rad, Hercules, CA, 
USA) and either 75 or 100 µg protein from total tissue lysate was used for isoelectric 
focussing (IEF). IEF was performed in an IPGphor apparatus according to the instructions 
of the manufacturer (Amersham Biosciences) using 24 cm non-linear IPG strips, pH3-10 
(Amersham Biosciences). The strips were actively rehydrated overnight in rehydration buffer 
(8M urea, 2% w/v CHAPS, 40mM DTT and 0.5% v/v IPG buffer) containing the sample 
applying a voltage of 30V per hour (Vh). After rehydration, the strips were run until 100kVh 
was reached. Following IEF, the strips were equilibrated in SDS-buffer (6M urea, 2% w/v 
SDS, 30% v/v glycerol, 50mM Tris-HCl, pH8.8) containing 65mM DTT for 15 min and 
thereafter in SDS-buffer containing 135mM iodoacetamide, for 2 min. 2nd dimension gel 
electrophoresis was performed on 10% v/v Duracryl gels (Genomic Solutions, Perkin 
Elmer, Boston, MA, USA) using the Ettan Dalt gel caster and electrophoresis device 
(Amersham Biosciences) at a constant power of 3W for 30 min and 180W for 3-4 hours, 
depending on the amount of gels run simultaneously, at 25 C. Gels were fixed overnight in 
40% v/v methanol, 5% v/v ortho-phosphoric acid, and stained with colloidal Coomassie 
using a Colloidal Blue staining kit (Invitrogen, Paisley, UK). Images were scanned with the 
Bio-Rad GS800 densitometer and analysed using the PDQuest software package (Bio-Rad). 
 
Mass spectrometry 
Peptide samples were prepared as described previously 514. Briefly, proteins of interest 
were manually excised from the gel, destained twice with 30% v/v acetonitrile (ACN) in 
50mM ammoniumhydrogen carbonate for 15 min, dried in a Speed Vac Plus (Savant, NY, 
USA) for 30 min and enzymatically digested overnight using sequencing grade trypsin 
(Promega, Madison, WI, USA). Peptides were eluted from the gel with 30% v/v ACN/0.1% 
v/v trifluoric acid, and 0.5 µl peptide sample was mixed with 4 volumes matrix solution (2 
mg alpha-cyano hydroxycinnamic acid in 100% ACN), which was spotted on an 
AnchorChipTM target plate (Bruker Daltonik, Bremen, Germany). Mass spectra were 
generated on a Biflex III MALDI-TOF-MS (Bruker Daltonik) and peptide fingerprints were 
analysed using BioTools (Bruker Daltonik) and Mascot software (Matrix Science) and the 
NCBI database. 
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Immunoprecipitation, SDS-PAGE, and Western immunoblotting 
Immunoprecipitation was performed on 25 µg protein from total tissue lysate from rat 
E19 tissues cultured in the absence or presence of 10nM R1881. Goat anti- rabbit-agarose 
beads were coupled to RhoGDIα antibodies for 1 hour at room temperature, cell lysate in 
PBS was added and the mixture rotated for 2 hours at 4 C. The agarose-antibody precipitate 
was washed with PBS and the pellet was resolved in 25 µl Laemmli sample buffer for SDS-
PAGE. Total tissue lysate (12.5 µg protein) or immunoprecipitate were loaded on 10% v/v 
and 15% v/v acrylamide gels. Gels were run on the mini PROTEAN gel system (Bio-Rad) 
and proteins were blotted to a nitrocellulose membrane (Schleicher & Schuell Keene, NH, 
USA). Western immunobloting was performed using polyclonal antibodies against α-
fetoprotein (clone E19, 1:1000) and RhoGDIα (clone A20, 1:1000) both from Santa Cruz 
(CA, USA). Proteins were visualized by chemiluminescence detection (Western Lightning, 
Perkin Elmer, Boston, MA, USA). 
 
Histology and immunohistochemistry 
Tissues were fixed in Bouin’s solution for 24 hours and were then washed in 70% v/v 
ethanol for 24 hours. The fixed tissues were first embedded in 2% w/v agar before they 
were embedded in paraffin. Paraffin sections were cut at 7 µm and stained with 
hematoxylin/eosin. For immunohistochemistry, paraffin sections from E17 and E21 were 
incubated with an α-fetoprotein antibody at a dilution of 1:500. Paraffin sections of E19 
tissues cultured either in the absence or presence of R1881 for 48 hours were used for 
immunohistochemistry with the RhoGDIα antibody (1:500). Antibody incubations were 
performed overnight at 4 C. Secondary antibodies were coupled to peroxidase using the 
Strept ABComplex/HRP (DAKO A/S Denmark), visualized with DAP stain (Pierce, 
Rockford, Ill, USA) and counterstained with hematoxylin. 
 
Results 
Analysis of growth-related proteins in developing epididymis and vas deferens  
Epididymides and vasa deferentia from developing rats were isolated as a whole on 
E17, E18, E19, E19.5, E20 and E21. The developmental changes in these tissues are 
illustrated in Figure 1. On E17, the epididymis is relatively small and underdeveloped. The 
epithelial duct consists of single layer of cuboidal cells with a small lumen, and no coiling of 
the duct is apparent (Figure 5.1A). On E21, the epididymis has grown much larger and the 
epithelial duct shows multiple coiling, which is apparent in the figure as multiple small cross-
sections through the duct (Figure 5.1B). It is obvious that marked tissue remodeling is 
needed to achieve such large changes in tissue structure, and this may require, and result in, 
differential expression and modification of a variety of proteins. To get more information 
about the spectrum and identity of proteins involved in growth-related tissue remodeling, 
we used a 2DE-driven proteomic approach, to identify proteins that are differentially 
regulated in time during this process of growth. Tissue lysates from the combined 
epididymides and vasa deferentia isolated on E17-E21 were used to separate proteins on 2D 
gels. All samples were run either in duplicate or triplicate. Protein expression profiles from 
E17-E21 were compared using the PDQuest software package. 
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Figure 5.1. Rat epididymis and vas deferens on E17 and E21  
Whole mount epididimis and vas deferens photographed on E17 (A) and E21 (B). On E17, the Wolffian duct 
organs have not fully developed yet, which is clearly visible by the presence of Müllerian duct remnants next to 
the vas deferens. On E21, the development of the Wolffian duct tissues is obvious by the gain of size and 
heavily coiling of the epithelial duct of the epididymis. C and D are histological sections of the tissues from A 
(E17) and B (E21). Hematoxylin/eosin staining. MD, Müllerian duct; e, epithelium, m, mesenchyme; im, 
interstitial mesenchyme. Scale bar in all pictures = 500 µm. 
 
Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS), we have identified 20 distinct proteins (numbered in Figure 5.2) 
representing at least 30 protein isoforms (Table 5.I). Analysis of the Coomassie-stained 2D 
gels, showed up-regulation of 37 protein isoforms (Figure 5.2, red circles) and down-
regulation of 18 protein isoforms (Figure 5.2, green circles), which were consistently 
regulated throughout all duplicate gels and statistically significant. Inconsistently regulated 
proteins spots (e.g. doublet of spots 10 o’clock of spots 9) were excluded from the analysis. 
Furthermore, for three proteins we observed a shift in pI or other changes in one or more 
of the protein isoforms during development (Figure 5.2, blue circles). These changes most 
probably represent post-translational protein modifications.  
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Figure 5.2. 2D gel analysis of total tissue lysates (100 µg protein) from epididymis/rat vas deferens at 
E17 and rat E21  
Proteins were separated by isoelectric focussing on pH3-10 gel strips, and according to molecular mass (MM) on 
SDS-PAGE. Proteins that were down-regulated during development are encircled in green, up-regulated proteins 
are encircled in red, and the proteins that shifted in position are encircled in blue. The protein encircled in black 
did not change in expression. All proteins identified by MALDI-TOF-MS are numbered. Proteins that were 
identified to represent isoforms of one and the same protein, have the same number (2,4,7,9,10,13). 
 
Table 5.I. Identification of proteins by peptide mass fingerprinting* 
Spot Protein MM (kDa) pI Regulation (fold) Accession # 
1 α-Fetoprotein precursor (AFP) 68 5.8 6-10 down A93561 
2 ΑFP fragments 26, 38 6.0-6.7 2-3 up A93561 
3 Serum albumin precursor (SA) 68 6.1 no A93872 
4 SA fragments 45, 50, 60 6.0-6.8 4-6 up A93872 
5 Transferrin  76 6.9 3 up BAA07458 
6 Tubulin α-chain 50 4.9 3x down A92869 
7 Tubulin α-chain, fragments  30 5.3 3-4x up A92869 
8 β-Actin 42 5.3 3x down A38571 
9 β-Actin, fragments 25 5.3 5x up A38571 
10 Tropomyosin 5 29 4.7 4-6x up P97726 
11 Fibrinogen γ-chain precursor 50 5.4 2-3x up P02680 
12 Fibrinogen β-chain 54 7.9 11x up AAA64866 
13 α-Enolase 47 6.2 2-3x down P04764 
14 F-Actin capping protein α-2 33 5.6 2-3x up AAC00567 
15 HSP-47 precursor 46 8.9 2x up A40968 
16 Triosephosphate isomerase (TPI) 27 6.5 Acidic ptm P48500 
17 Probable thioredoxin peroxidase 2 22 8.3 3-4x down I52425 
18 Glyceraldehyde 3-phosphate dehydrogenase 36 8.4 Acidic ptm P04797 
19 Heterogeneous nuclear ribonucleoprotein  (hnRNP) 
A2/B1 
36 8.7 Acidic ptm AF073993 
20 hnRNP A3 39 8.7 5-7x up P51991 
a RhoGDI1 23 4.9-5.1  Acidic ptm Q99PT1 
b TPI 27 6.5 Acidic ptm P48500 
c Glyceraldehyde 3-phosphate dehydrogenase 37 8.4 Acidic ptm P04797 
d hnRNP A3 39 8.7 3x up P51991 
e hnRNP A2/B1 36 8.7 Acidic/ Basic  
ptm 
AF073993 
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* Identification with p<0.05 (Mascot, Matrix Science, UK). Numbering according to Figure 5.2; lettering according 
to Figure 5.6A.  Accession # according to the NCBI database. PI, isoelectric point; ptm, post-translational 
modification. 
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Figure 5.3. Zoom-in regions of E17-E21 2DE gels  
A) Down-regulation of one of the full-length α-fetoprotein (AFP) precursor isoforms (spot 1 according to 
Figure 5.2). 
B) Up-regulation of one of the serum albumin precursor fragments (spot 4 according to Figure 2). 
C) Up-regulation of tropomyosin 5 (spot 10 according to Figure 5.2). 
D) Up-regulation of an AFP fragmented isoform (spot 2 according to Figure 5.2), with peak intensity at E19.5. 
All tissue lysates were run on duplicate gels and all gels were analyzed using the PDQuest software package. 
Corresponding arbitrary spot intensities of encircled (A) and boxed (B, C, D) proteins are represented as bars in 
the adjacent histograms. Proteins were selected to be up- or down-regulated at least 2-fold with a significance of 
p<0.05, as calculated by PDQuest software.  
 
Analyzing the gels in more detail revealed that temporal up- or down-regulation of the 
proteins occurred gradually. One of the proteins that was regulated in time was α-
fetoprotein precursor, AFP (spot 1, Figure 5.2). AFP occurred in the 2D gel as a 68 kDa 
multi-isoform protein and was down-regulated in time (Figure 5.3A). However, 2 separate 
and fragmented isoforms of AFP were up-regulated in time. The up-regulation of the 
smaller AFP fragments was gradual but peaked at E19.5, after which the expression was 
going down again. The expression pattern of one of the AFP fragments is shown in Figure 
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5.3D. Tropomyosin 5 was also up-regulated with a peak intensity at E19.5 (Figure 5.3C). 
MALDI-TOF-MS revealed that fragmentation not only occurred for AFP but also for 
serum albumin precursor (SA), β-actin and α-tubulin. Fragmentation of these proteins has 
been reported in relation to particular physiological roles 603-605. All the SA fragments were 
up-regulated gradually in time, of which one is illustrated in Figure 5.3B.  
The presence of transferrin (spot 5, Figure 5.2), and the regulation of AFP (spots 1 and 
2, Figure 5.2) and SA fragments (spots 4, Figure 5.2), raised the question whether the tissue 
lysates contained serum proteins from infiltrating capillaries. To address this question, 
immunohistochemistry for AFP was performed on E17 and E21 tissues (Figure 5.4A and 
B). The staining shows that there is no detectable AFP in the epithelial duct, nor in the 
mesenchymal cells directly surrounding the duct, but there is positive staining in the 
cytoplasm of interstitial mesenchymal cells on E17. On E21, AFP staining in the interstitial 
mesenchyme was more abundant and some staining was also observed in the mesenchyme 
directly surrounding the epithelial duct. The staining was uniform and not restricted to 
capillaries, indicating that the tissue lysates contain serum proteins originating from the 
(interstitial) mesenchymal cells. Furthermore, no clear-cut difference in subcellular 
localization of the AFP staining between E17 and E21 tissue sections was visible. Western 
blot analysis of the tissue lysates showed a slight decrease of the two main bands of AFP (68 
kDa) and an increase of some of the fragments, in agreement with the data of the 2D gels 
(Fig. 5.4C).  
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 Figure 5.4. Immunohistochemistry for alpha-fetoprotein (AFP) of rat E17 (A) and E21 (B) epididymis 
sections 
On E17, AFP stained positive in the interstitial mesenchyme. On E21, some staining was also visible in the 
mesenchyme directly surrounding the epithelial duct. 
Scale bar = 100 µm (A and B), and 50 µm (A-1, A-2, and B-1); e, epithelium; m, mesenchyme; im, interstitial 
mesenchyme. 
C) Western immunoblot for AFP. Total tissue lysate (12.5 µg protein) from rat E17 and E21 epididymis/vas 
deferens was separated on SDS-PAGE and immunoblotted. Note the down-regulation of the two 68 kDa AFP 
form and up-regulation of some of the fragments (AFPf).  
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Figure 5.5. Rat E19 vas deferens and epididymis tissues 
A) Photographs of E19 tissues cultured in the absence (panels 1 and 3) or presence (panels 2 and 4) of 10nM 
synthetic androgen R1881 for 9 hours (panels 1 and 2) and 48 hours (panels 2 and 4). Scale bar = 100 µm. 
B) Histological sections of E19 epididymis cultured in the absence (panels 1 and 3) or presence (panels 2 and 4) 
of 10nM R1881 for 9 hours (panels 1 and 2) and 48 hours (panels 2 and 4). Scale bar = 100 µm. 
Hematoxylin/eosin staining. Epi , epididymis; vas, vas deferens; e, epithelium; m, mesenchyme. 
Note that the epithelial duct regressed in the absence of androgen, whereas it differentiated in the presence of 
R1881. 
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Analysis of androgen-regulated proteins in cultured epididymis and vas deferens 
During isolation of the epididymides and vasa deferentia from the different 
developmental stages, it became apparent that the largest morphological changes occurred 
between E19 and E20. Therefore, epididymides and vasa deferentia were isolated on E19 
and cultured in either the absence or presence of synthetic androgen R1881, for 9, 24, and 
48 hours, to analyze regulation of protein expression induced by androgen. At the time 
points mentioned, photographs were taken and some tissues were used for histology. 
Culturing the tissues for 9 hours in the absence or presence of R1881 did not result in 
macro- (Figure 5.5A) and microscopical (Figure 5.5B) changes.  After 9 hours of culture, the 
epithelial duct is clearly visible as a lighter part of the tissues, and shows some minor coiling 
starting in the epididymis (Figure 5.5A-1, 2). However, 48 hours of culture in the absence of 
androgen resulted in regression of the epithelial duct, as demonstrated by the absence of the 
lighter duct in the tissue (Figure 5.5A-3). In histological sections, some remnants of the 
epithelial duct are still present (Figure 5.5B-3). Culturing the tissues in the presence of 
androgen for 48 hours resulted in stabilization of the epithelial duct, and in most cases in 
increased coiling of the duct as a sign of differentiation (Figure 5.5A-4). In histological 
sections, this coiling and stabilization is visible as cross-sections at three different positions 
(Figure 5B-4). Comparing the sections of Figure 1B and Figure 5.5B-4 illustrates that 
development of the epididymis in vitro during a culture period of 48 hours, although much 
slower, occurs in a similar pattern as in vivo. Furthermore, we also noticed some swelling of 
the tissues in culture, irrespective of the presence or absence of androgen.  
Although morphological differences in the cultured tissues occurred visibly within 48 
hours (and to a lesser extent already visible after 24 hours), we expected that most molecular 
changes, which eventually lead to morphological differences, will precede these changes. 
Therefore, 2DE was performed on whole tissue lysates from organs cultured in the absence 
or presence of androgen and the gels were analyzed using PDQuest. At first instance, no 
major regulation in protein expression was observed between the different culture 
conditions, nor as compared to the in vivo situation. However, a closer examination of the 
Coomassie-stained gels revealed that 5 proteins spots were regulated upon androgen 
treatment. Four of these proteins showed regulation of one or more isoforms indicating 
post-translational modification (RhoGDI, TPI, G3PD, and hnRNP A2/B1; Figure 5.6A 
spots a-c and e, and Table I), and one protein was visibly up-regulated (hnRNPA3; Figure 
5.6A, spot d). Comparison of these results with Figure 5.2 and Table I showed that TPI, 
G3PD, hnRNP A2/B1, and hnRNP A3 were also regulated in the in vivo situation.  
RhoGDI1 was regulated by R1881 at the post-translational level in vitro (Figure 5.6B). 
One protein isoform of RhoGDI1 was identified in E19 tissues that were either directly 
frozen or cultured. However, culturing the tissues in the presence of androgen for 48 hours 
resulted in the appearance of a second, more acidic, protein isoform that was also identified 
by MALDI-TOF-MS as RhoGDI1. The glycolytic enzyme triosephosphate isomerase (TPI) 
was regulated by R1881 in vitro as well as in vivo at the level of post-translational modification 
(Figure 6C). In the presence of androgen (E19, t=0 and +10nM R1881 for 9 hours and 48 
hours), expression of a more basic isoform was relatively high, although the intensity 
decreased with increasing culture time. Androgen withdrawal resulted in a further decrease 
in the expression of the basic isoform, whereas a more acidic isoform appeared (Figure 5.6C 
and 5.6D). Apparently, androgens play a role in maintaining TPI in a more basic isoform. 
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Figure 5.6. 2DE gels of tissue lysates  from rat E19 epididymis/vas deferens 
A) 2DE gels of tissues cultured for 9 hours in the absence (-R) or presence (+R) of 10nM synthetic androgen, 
R1881. 
B) Zoom-in region B of gels from tissues cultured for 0, 9, or 48 hours in the absence or presence of 10nM 
R1881. Regulation of a second RhoGDI1 isoform, spot a*. 
C) Zoom-in region C of gels from tissues cultures for 0, 9, or 48 hours in the absence or presence of 10nM 
R1881. Regulation of two triosephosphate isomerase (TPI) isoforms, spots b and b*. 
D) Arbitrary spot intensities of TPI isoforms b and b* during 48 hours of tissue culture in the absence or 
presence of 10nM R1881. In the absence of R1881, spot b is down-regulated and spot b* is up-regulated. Each 
point in the graph represents the mean (SD) intensity of spots from two separate gels. 
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RhoGDI1 is an interesting candidate protein to analyze in more depth, since it was 
reported that this protein can increase transcriptional activity of the AR 606. We questioned 
whether addition of androgen resulted in a change in subcellular localization of RhoGDI1 
and whether the second isoform represented a differential phosphorylated isoform, since 
phosphorylation of RhoGDI1 has been reported 607. Immunohistochemical analysis of 
epididymis cultured in the absence of androgen for 48 hours, confirmed the cytoplasmic 
localization that was already reported 608. As expected, no nuclear localization of RhoGDI1 
was observed after androgen treatment (Figure 5.7A/C and B/D). Although the epithelial 
duct regresses in the absence of R1881, RhoGDI1 is still expressed in the cytoplasm of the 
remnants of the duct, and also in the surrounding mesenchyme. Western immunoblot 
analysis of tissue lysates showed an equal expression of RhoGDI under all culture 
conditions (Figure 7E). Immunoprecipitation of RhoGDI1 from the lysates with a 
RhoGDI1 antibody and subsequent immunoblot analysis with a phospho-serine antibody 
confirmed that RhoGDI1 is a phosphoprotein (Figure 5.7F). 
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Figure 5.7. RhoGDI1 expression 
Immunohistochemistry for RhoGDI1 in rat E19 epididymis cultured in the absence (A, C) or presence (B, D) of 
10nM R1881 for 48h. Scale bar = 100 µm (A, B), and 50 µm (C, D). 
E) RhoGDI1 Western immunoblot of E17 (lane 1), E19 (lanes 2-7), and E21 (lane 8) epididymis/vas deferens 
tissue lysates. RhoGDI1 protein expression was equal under all culture conditions. 
F) RhoGDI1 immunoprecipitation and phospho-serine Western immunoblot. Lane 1= E21 total lysate input; 
lane 2= E19 no hormone, 48h; lane 3= E19 + 10nM R1881, 48h; lane 4= E21. Phosphorylated RhoGDI1 was 
detected after immunoprecipitation in lanes 2-4. In lane 1 several other phosphorylated proteins were detected 
on the total tissue lysate. 
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Discussion 
Androgen-controlled growth and differentiation of the epididymis and vas deferens 
involves regulation of specific proteins. It was our aim to identify proteins that are involved 
in growth and differentiation, and more specifically proteins that are regulated by androgen 
during this process. The dramatic change in morphology of the epididymis, and to a lesser 
extent of the vas deferens, during the last phase of the fetal period, was the starting point 
for the present study.  
 
Identification of growth-related proteins 
Using 2DE driven proteomics, 20 proteins were identified that are regulated during 
fetal growth and development of the rat epididymis and vas deferens.  The proteins 
identified can be categorized into enzymes (α-enolase, TPI, glyceraldehyde 3-phosphate 
dehydrogenase (G3PD), probable thioredoxin peroxidase 2), cytoskeletal proteins 
(α−tubulin, β-actin, tropomyosin 5, F-actin capping protein α-2), transport proteins (AFP, 
SA, transferrin, fibrinogen β/γ), RNA binding proteins (hnRNP A2/B1/A3), and 
chaperones (Hsp-47 precursor). Furthermore, fragmented isoforms of SA, AFP, α-tubulin, 
and β-actin were identified, which were up-regulated in time during genital tract 
development.  
AFP is a specific fetal glycoprotein that is secreted by embryonic tissues and is involved 
in up- and down-regulation of cell growth 609, in immunosuppression, and in apoptosis 610. 
AFP belongs to the proteins encoded by the serum albumin multigene family, which present 
three structurally homologous domains I, II, and III 603. Fragmentation of AFP has been 
reported, with cleavage products of 32 and 38 kDa resulting from domains I and III. These 
products can be further fragmented into proteolytically stable isoforms of 23 and 26 kDa 604. 
A similar kind of fragmentation was described for SA, but with many more proteolytic 
cleavage products possible 611. These reported fragments of AFP correspond in size to the 
fragments that were identified in the present study. Furthermore, others have described that 
distinct AFP isoforms accumulate at different stages of fetal development 612,613 and that 
AFP can interact with nuclear receptors 614. Thus, the up-regulation of AFP fragmented 
isoforms may be physiologically relevant for growth and differentiation of epididymis and 
vas deferens.  
Glycolytic enzymes interact directly (α-enolase, G3PD), or indirectly (TPI), with 
structural proteins and complexes like actin and microtubules 615,616. It was recently 
described for TPI that it binds to the actin-binding protein cofilin, which in turn binds to 
Na,K-ATPase upon phosphorylation by the Rho-signaling pathway 617. TPI takes part in 
production of energy, which is transduced to the cytoskeleton that modulates cell function, 
proliferation, and differentiation 617. The cytoskeletal proteins actin and tubulin, and in 
particular specific cleavage of these proteins, have been implicated in several regulatory 
processes, including apoptosis 605 and other processes such as meiosis resumption in starfish 
oocytes (30) Our finding that fragments of β-actin and α-tubulin accumulate taken together 
with the observation of post-translational regulation of glycolytic enzymes could reflect the 
processes of vigorous tissue remodeling during the process of genital tract development. 
 
Identification of androgen-regulated proteins during growth 
Since it is known that androgen action is essential for growth and development of the 
male genital tract, it was our aim to identify androgen-regulated proteins that are involved in 
this process. Epididymides and vasa deferentia cultured in vitro in the absence and presence 
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of androgen were subjected to 2DE, and the differentially expressed proteins identified were 
compared to the proteins identified in vivo. Glycolytic enzymes G3PD and TPI, and nuclear 
proteins hnRNP A2/B1/A3 were identified to be regulated by androgen, as was also 
observed in vivo. In addition, RhoGDI1 was identified as a protein that was regulated by 
androgen at the level of post-translational modification. Although the regulation of these 
proteins occurs under the action of androgen, we cannot conclude that this is the result of a 
direct and/or indirect androgen action. Furthermore, we did not observe any obvious 
regulation of the AR protein in the 2D gels. However, the AR protein is of lower abundance 
and therefore not easily detectable in such a broad range 2D gel. 
Rho guanine nucleotide dissociation inhibitor 1(RhoGDI1 or RhoGDIα), is a 
cytoplasmic protein originally identified as a negative regulator of RhoGTPases 608. 
RhoGTPases are molecular switches that cycle between an active membrane-associated 
GTP-bound state and an inactive cytoplasmic GDP-bound state. This switch is carefully 
controlled by exchange factors (GEFs), activating proteins (GAFs), and dissociation 
inhibitors (GDIs) 618. RhoA, Rac and Cdc42 belong to the family of RhoGTPases, which 
regulate many signal transduction pathways, including those linked to the actin cytoskeleton, 
microtubule dynamics, vesicular transport dynamics, regulation of cell polarity, gene 
transcription, G1 cell cycle progression, and a variety of enzymatic activities 618,619. Members 
of the RhoGDI family block GDP dissociation from RhoGTPases and control cytoplasmic 
localization of RhoGTPases. In addition, it was described that RhoGDI1 specifically 
increases the transcriptional activity of estrogen receptors (ERα, ERβ), glucocorticoid 
receptor (GR) and AR 606. This activation is mediated via repression of RhoGTPases, which 
demonstrates that the Rho-mediated signaling pathway is an important regulator of ERs, 
GR, and AR transcriptional activity 606. Although RhoGDI1 is ubiquitously expressed in all 
tissues, RhoGDI1 knockout mice show specific and progressive impairment of kidneys and 
reproductive organs probably as a result of the destruction of the actin cytoskeleton 620, 
meaning that the function of RhoGDI1 in the kidney and reproductive organs is non-
redundant.  
The testis of RhoGDI1 -/- mice reveals structural abnormalities, the number of germ 
cells is dramatically decreased and mature sperm cells are only rarely detected in 
seminiferous tubules and epididymides 620. RhoGDI1 -/- female mice have an intrinsic defect 
in their reproductive system, which is most evident in the postimplantation development of 
RhoGDI1 -/- embryos. For the epididymis, no functional developmental defect in the 
knockout mice was reported 620.  
Bourmeyster et al., (1996) have detected RhoGDI1 on a 2D gel as a single protein spot 
with a pI of 5.1, which represents the free, unbound form of RhoGDI. In the case were 
RhoGDI was associated with RhoA GTPase, they detected two RhoGDI protein spots with 
pI 4.6-5.1, which could be reduced to one protein spot after phosphatase treatment 607. 
Furthermore, they have shown that RhoA-RhoGDI1 association depends on RhoGDI1 
phosphorylation. Thus, phosphorylation and dephosphorylation of RhoGDI1 determines 
the activation state of RhoA GTPase 607. In the present tissue culture experiments, 48 hours 
of androgen treatment resulted in the appearance of a second, more acidic, RhoGDI1 
isoform that could represent a phosphorylated isoform. If RhoGDI1 is indeed 
phosphorylated by androgens, this could lead to complex formation with Rho GPTase and 
repression of the Rho GTPase activity. Taken the fact that RhoGDI1 enhancement of AR 
transcriptional activity occurrs via RhoGTPase repression 606, one could postulate that 
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RhoGDI1 phosphorylation leads to enhanced AR transcription activation, and as a result 
regulation of RhoGDI1 activity by phosphorylation and dephosphorylation might function 
as a feed-back loop in androgen signaling. 
Heterogeneous nuclear ribonucleoproteins (hnRNP) form a large family of proteins 
that are categorized on the basis of structural/functional motifs, and of which the A/B type 
are the most abundant hnRNP proteins 591. Besides a large number of post-transcriptional 
isoforms, the hnRNP A/B proteins also show extensive post-translational modifications. 
For a specific subset of hnRNPs, hnRNP A2, hnRNP A3 and DBP40/CBF-A, an 
interaction with nuclear actin was described, and an interaction was suggested for 
cytoplasmic actin 591. In a previous study, we have identified CBF-A, which is a minor 
variant of hnRNP A2, to be regulated by androgen at the level of post-translational 
modification in the mouse fetal vas deferens cell line MFVD 514. This coincides with the 
present finding that androgens regulate hnRNPs post-translational modification in genital 
tract tissues.  
Glycolytic enzymes, like TPI and G3PD, are dependent on androgen action for their 
activity, as was demonstrated by castration experiments. Enzymatic activity was found to be 
decreased in rat epididymis and monkey seminal vesicle after castration, which was restored 
after androgen replacement 621-623. Our present results suggest that androgenic regulation of 
glycolytic enzyme activity is controlled at the level of post-translational modification.  
In summary, our study shows that changes in protein expression profiles can be 
detected on 2D gels, when developing genital tract tissues are followed in time in vivo. 
Analyses of androgen-regulated proteins in epididymis and vas deferens tissues exposed to 
androgen, also revealed several changes in protein expression profiles when grown in vitro. 
In the present system, androgen action occurs mainly at the level of post-translational 
modification. We hypothesize that during the process of androgen stimulation, which will 
lead to growth and differentiation of the male genital tract, post-translational modification 
of glycolytic enzymes regulates their activity and their association with cytoskeletal proteins. 
Furthermore, androgen-induced post-translational modification of RhoGDI1 and glycolytic 
enzymes may be an important functional link between signaling pathways and cytoskeletal 
rearrangements in control of growth and development of the male internal genital tract. 
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Introduction 
Actions of androgens are essential for male sexual development 2,624. The circulating 
androgen testosterone and its locally 5α-reduced metabolite DHT stimulate the Wolffian 
duct, urogenital sinus, genital tubercle, genital fold and swelling, to develop into the internal 
sex organs (epididymis, vas deferens, seminal vesicle, and prostate gland), and the external 
sex organs (penis, with urethra and scrotum). Testosterone and DHT can bind to the AR, 
which is present in mesenchymal cells of reproductive tract tissues during the critical time of 
development. The AR is a transcription factor that recognizes specific androgen response 
element sequences in promoter regions or in far upstream enhancer regions of androgen-
target genes, thereby facilitating regulation of gene expression, and ultimately of protein 
expression (described in Chapter 1). Paracrine factors play an important role in transmitting 
the androgenic signal from AR positive mesenchymal cells to AR negative epithelial cells, 
but the underlying mechanism, how androgens drive the mesenchymal cells to produce and 
secrete these factors, is largely unknown. In the neonatal and adult epididymis and vas 
deferens, numerous androgen-regulated proteins have been identified, of which many play a 
role in sperm cell maturation or maintenance of organ physiology (Chapter 1.3, Table 1.II). 
However, only a few studies describe androgenic regulation of proteins that are involved in 
differentiation and development of other male internal sex organs, or the external sex 
organs. 
For the research described in this thesis, a proteomic approach was chosen, to try to 
identify androgen-regulated proteins in an androgen target cell line, MFVD cells, and in 
target tissue, epididymis and vas deferens (Chapters 4 and 5). The results of these studies 
are discussed below in a broader perspective. 
 
Proteomics and androgen-regulated male development 
Proteomics research involves a technology-driven approach to systematically determine 
diverse properties of proteins, such as identity, quantity, subcellular distribution, and 
structure. The first applications were in the field of “discovery science”, meaning that 
identification and cataloguing of all proteins in a system were the goal, irrespective of any 
hypothesis in relation to a function of that system. The completion of the draft human 
genome sequence, together with the continuous development of technology, has resulted in 
incorporation of proteomics research into studies on understanding biological systems 625,626. 
As described in Chapter 3, proteomics research can be divided into a “2DE-driven”, 
classical approach or a “non-2DE-driven” approach, which is becoming more easily 
accessible and therefore gaining popularity. Both approaches have their advantages and 
disadvantages, but starters in the field will most probably begin their proteomics research 
with 2DE for two reasons. First of all, 2D gels can be easily run on the bench, although 
preparation of the 2D gels remains a tedious task, and secondly, 2DE-driven proteomics 
does not have to be overwhelmingly expensive. In contrast, multi-dimensional protein 
separation and identification strategies omitting the 2D gel often require the use of highly 
specialized and expensive equipment, which is usually not readily accessible for many 
researchers. Whatever protein separation technique is used, ultimately proteins need to be 
identified, and the mass spectrometer is the apparatus of choice. Many different types of 
mass spectrometers are available, which all have certain specific properties, but accuracy and 
sensitivity are issues that apply to all. However, one of the most easily accessible mass 
spectrometers is the MALDI-TOF, which has the capacity to relatively easily and quickly 
create peptide finger prints of, and screen, many samples.  
For these reasons, we have chosen to use 2D gels as a protein separation step, and 
MALDI-TOF mass spectrometry for protein identification. Two approaches were taken in 
an attempt to study androgen-regulated protein expression. In Chapter 4, the generation of 
an androgen-target cell line, MFVD, is described. Using this cell line for proteomics studies 
has the advantage of yielding relatively large quantities of sample, while the experiments are 
easily repeated, and the experimental conditions are reproducible. Furthermore, the effects 
of androgens on one particular cell type, mesenchymal vas deferens cells in this case, can be 
studied, without being influenced by surrounding factors. In addition, in Chapter 5 the 
effect of androgens has been studied in cultured tissues. In this organ culture system, both 
epithelial and mesenchymal cells are present, but also infiltrating blood cells (in capillaries) 
and connective tissue. As a consequence, the androgenic effects found in an organ culture 
system cannot be directly linked to a certain cell type. However, there is the advantage that 
such an ex-vivo system provides a more physiological environment in which the androgens 
act. A limitation of using fetal tissue for 2D analysis, is that many samples need to be 
collected before a small but workable amount of sample can be extracted.  
While in the experiments described herein, the organ-culture system was performed 
using fetal rat epididymis and vas deferens, the cell line was derived from fetal mouse vas 
deferens. Therefore, it was questioned whether the androgenic effects observed in 2D gels 
of the two systems would be similar and comparable. We did not identify identical proteins 
in the two systems studied that were regulated upon androgen treatment, but common 
observations include that: 
 
1. Androgens influence  post-translational modification of several proteins. 
2. Signaling molecules that appear to be regulated by androgens are associated with the actin cytoskeleton. 
 
The actin cytoskeleton mediates a variety of essential biological functions in all 
eukaryotic cells, by providing a structural framework, and the driving force for cells to move 
and divide. The Rho family of signaling molecules are key regulators of the actin 
cytoskeleton that link surface receptors to the organization of the actin cytoskeleton through 
interaction with multiple target proteins 619. In Figure 6.1, the effect of Rho activation on 
the actin cytoskeleton is illustrated. 
 
A B
 
Figure 6.1. The actin cytoskeleton 
A) Quiescent, serum-starved Swiss 3T3 fibroblasts contain very few actin filaments. 
B) Activation of Rho results in formation of actin stess fibers. 
Adapted from Hall, 1998 619. 
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Androgens, the actin cytoskeleton, and signaling molecules 
Androgenic treatment of MFVD cells resulted in post-translational modification of 
mElfin and CBF-A (Chapter 4). In fetal rat epididymis and vas deferens, post-translational 
modification upon androgen treatment occurred for hnRNP A2/B1, glycolytic enzyme TPI, 
and signaling protein RhoGDI1 (Chapter 5). These proteins can be categorized into certain 
functional protein families. CBF-A and hnRNP A2/B1 are members of the family of A/B 
type hnRNP proteins, which are present in pre-mRNP particles. CBF-A has been reported 
to have a dual function: transcriptional regulation, and post-transcriptional regulation at the 
RNA level 588,590. CBF-A and hnRNP A2/B1 shuttle between nucleus and cytoplasm 591,627, 
they are associated with either globular (G)- or filamentous (F)-actin, and are involved in 
transport of mRNA into the cytoplasm 591,628. Since a large fraction of mRNA is associated 
with cytoskeletal structures 629, it was proposed that mRNA undergoes a nuclear preparatory 
event by a subset of hnRNP proteins complexed to actin, in order to function properly in 
the cytoplasm 591,628. What role androgen-regulated post-translational modification plays in 
this process has, not yet, been described. One could, however, speculate that post-
translational modification of hnRNPs is necessary to become fully functional in regulation 
transcription and translation of androgen-target genes and mRNAs. Perhaps, it is also 
possible that post-translationally modified hnRNPs, bound to actin in the cytoplasm, 
regulate translation of mRNAs that are already present in the cytoplasm, thereby bypassing 
an AR mediated genomic event (this will be discussed in the next paragraph). 
What groups mElfin, RhoGDI1 and TPI together is their, direct or indirect, association 
with the cytoskeleton and their connection to signaling pathways. mElfin contains two 
protein-protein interaction domains, a PDZ and a LIM domain, with which it associates to 
F-actin through binding to α-Actinin, and through which it functions to recruit kinases to 
the cytoskeleton 595,596,630. RhoGDI1 is one of the players in the Rho-signaling pathway, and 
functions as an inhibitor of Rho GTPase activity. RhoGDI1 blocks GDP dissociation from 
Rho GTPase and keeps it in the cytoplasm in an inactive state, thereby preventing 
interaction with Rho GTPase and its effectors 608. Rho GTPases are key regulatory 
molecules that, in addition to many other pathways, link surface receptors to the 
organization of the actin cytoskeleton 618,619. RhoGDI1 plays a central role in regulation of 
signal transduction cascades mediated by Rho GTPases 631. The glycolytic enzyme TPI has 
also been found to be associated with the actin cytoskeleton, where it interacts with the F-
actin binding protein Cofilin 617. Cofilin can be phosphorylated by LIM-kinase, a member of 
the Rho signaling cascade, after which the Cofilin-TPI complex is directed to the cell 
membrane to provide glycolytic energy to Na+,K+-ATPase 617. What role post-translational 
modification of mElfin, RhoGDI, and TPI plays in androgenic regulation, and whether 
these modifications are a direct or indirect effect of androgen treatment is not known. 
Studies on related proteins, however, may provide clues about the regulatory mechanisms 
involved.  
FHL2, a LIM-only protein, was initially reported to function as an adaptor protein 
involved in integrin signaling pathways 632. Later on it was described as a tissue-specific co-
activator of transcription factors like CREM (cAMP response element modulator) and 
CREB (cAMP response element binding protein) 633. Furthermore, FHL2 appears to 
translocate from the cytoplasm to the nucleus upon activation of the Rho signaling pathway 
634, and it functions as a tissue-specific co-activator of the AR, thereby linking Rho signaling 
to the activation of transcription factors 238. Interestingly, FHL2 has also recently been 
identified as a co-activator for the Wnt signaling mediator β-Catenin, potentiating the 
Chapter 6 
122 
transcription of Wnt-response genes 635. Although β-Catenin itself has been identified as an 
AR co-activator as well 598, β-Catenin and FHL2 have no synergistic effect on AR-mediated 
transcription 635. Thus, it appears that the regulatory function of proteins like β-Catenin and 
FHL2 depends on the activating signal and the promoter context. Detailed analysis of the 
subcellular localization of mElfin upon androgen treatment and co-transfection studies with 
the AR, would provide more information about the role and function of mElfin in the 
androgen signaling pathway, since mElfin, like FHL2 and β-Catenin, may be involved in 
several different pathways, exerting different functions.  
Recently, more and more actin-binding cytoskeletal proteins and proteins of the Rho 
signaling pathway have been associated with AR translocation and transactivation, such as 
Supervillin 277, Filamin-A 275,276, and PAK6 636. Supervillin is an actin binding protein, and 
interacts specifically with the AR NH2-terminal and ligand binding domains in a ligand-
dependent manner. It enhances transactivation of AR, also in cooperation with other co-
activators, such as ARA55 or ARA70 277. Filamin-A is a component of the cytoskeleton and 
is involved in translocation of the AR to the nucleus 275. In the nucleus a fragmented form 
of Filamin-A binds to the hinge region of the AR and inhibits transcription activation by 
interfering with TIF2 binding 276. PAK6 (p21-activated kinase 6), which is primarily a 
cytoplasmic protein containing a Cdc42 Rho GTPase interacting domain and a kinase 
domain, inhibits AR transactivation by interacting with the hinge region 636. The inhibiting 
effect of PAK6 was not due to the sequestration of Cdc42, although Cdc42 itself can also 
inhibit AR (as well as ER and GR) transcription activation activity 606. The inhibiting activity 
of Cdc42 can be reversed by the Rho GTPase inhibitor RhoGDI1, which in turn activates 
transcription of AR, ER and GR 606. Thus, binding of Rho signaling proteins such as PAK6 
and RhoGDI1 to the AR, and other steroid hormone receptors, provides and regulates a 
mechanism of cross-talk between diverse signal transduction pathways and steroid hormone 
receptors.  
More evidence for cross-talk between the Rho signaling pathway and steroid hormone 
receptors comes from a study on the RhoA effector protein PRK1 (protein kinase C-related 
kinase1) 637. PRK1 is a serine/threonine kinase that stimulates the transcriptional activity of 
AR (and also PR, MR, and p160 co-activators) in the presence of testicular and adrenal 
androgens but also in the presence of antagonists, through interaction with the AR AF-5 
transactivation domain. This novel signaling pathway links RhoA effectors to AR 
transactivation. Since PRK1 is up-regulated in prostate tumors and activates the AR in the 
absence of testicular androgens, as well as in the presence of antagonists 637, it may be of 
importance in prostate cancer progression,. 
 
Non-genomic effects of androgens 
Apart from cross-talk with signaling pathways that regulate AR transcriptional 
activation activity, cross-talk between steroid hormone receptors and the MAPK (mitogen-
activated protein kinase) signaling pathway has been described, that is not directly associated 
with genomic actions. Rapid responses to steroid hormones (androgens, progestins and 
estrogens) can be effectuated by non-genomic mechanisms, still mediated by steroid 
receptors 341,342. In addition, some reports indicate that non-genomic effects may be 
mediated by plasma membrane-bound receptors 352-354. In LNCaP cells, a plasma membrane 
testosterone receptor was described, which is distinct from the classical AR. Androgen 
binding to this membrane receptor resulted in a rapid redistribution of the actin 
cytoskeleton, which may regulate trafficking and secretion of molecules 638.  
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Whether or not androgens stimulate AR to trigger gene transcription or not, might be 
dependent on the amount of receptor present in the cell, as was recently described for 
mouse embryo fibroblast NIH3T3 cells. The NIH3T3 cells express a very low level of AR, 
compared to LNCaP cells, and stimulation with androgen does not result in nuclear 
translocation and transcription activation of the AR 639. However, a very low androgen 
concentration (1 pM) stimulated AR association with c-Src, which induced S fase entry of 
quiescent NIH3T3 cells, and a much higher androgen concentration (10 nM) stimulated Src-
mediated activation of the Rho GTPase Rac, which rapidly caused changes in actin assembly 
resulting in membrane ruffling 639. Thus, a hormone-regulated correlation between 
cytoskeletal changes and the activation of Rho GTPase Rac would represent a new signaling 
pathway. Similar to NIH3T3 cells, other mesenchymal cells, such as MFVD cells, also 
contain low amounts of steroid hormone receptors 640,641. It might be possible that MFVD 
cells respond to androgen stimulation with cytoskeletal changes and activation of signaling 
pathways, not necessarily directed by transcriptional activity of the AR. In conclusion, 
increasing evidence shows that steroid hormones play an important role in controlling 
cytoskeleton function. This novel aspect of steroid hormone action opens an interesting 
area of research, where many questions are open to new research efforts. 
From the data presented in this thesis, it is not clear whether androgen-regulated post-
translational modification of the proteins mentioned is part of a transcription-mediated 
genomic effect, or rather represents a non-genomic mechanism. Arguments can be raised in 
favour of both possibilities. Post-translational modification of hnRNPs and RhoGDI1 were 
found to occur after 24 and 48 hours, respectively, and not at shorter time intervals after 
initiation of the exposure to androgen, excluding a rapid (within seconds to minutes) non-
genomic effect. Regulation of hnRNP proteins suggests that a transcription process has 
taken place, although hnRNPs also act in the cytoplasm. On the other hand, recruitment of 
signaling proteins in the cytoplasm, associating with the cytoskeleton, may indicate that 
signaling pathways are activated, exerting a non-genomic effect. Whether the effects 
described in this thesis are part of a pathway acting upstream of the AR, in parallel with the 
AR, or perhaps even completely bypassing the AR, will need to be established. 
Incorporating the data presented in this thesis into the present literature, a model of 
androgen-induced mechanism of action of post-translational modification is proposed in 
Figure 6.2. 
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Figure 6.2. Model of androgen induced post-translational modification and mechanism of action 
Genomic action: Androgens enter their target cell and bind to the androgen receptor (1), which becomes 
phosphorylated, translocates to the nucleus, binds to DNA response elements, and activates transcription. This 
process may be enhanced by phosphorylated RhoGDI1 (2). Post-translationally modified hnRNP proteins bind 
mRNA , which is transported into the cytoplasm and translated into protein (3). Subsequently, actin-associating 
proteins (mElfin, CBF-A, glycolytic enzymes) become post-translationally modified (4), which leads to a 
biological response (5).  
Non-genomic action*: Androgens enter their target cell and bind to the androgen receptor (1*), after which 
signaling molecules (RhoGDI1) and actin-associated proteins (mElfin, CBF-A, glycolytic enzymes) become post-
translationally modified by androgens, either directly or indirectly (4*). The activated signaling cascades result in a 
non-genomic biological action (5*). 
 
Defective androgen action 
While this thesis is mainly focused on the effect of androgens on protein expression in 
a target cell during normal male development, the syndrome of androgen insensitivity is a 
very appropriate example of defective androgen action in vivo. In order to understand the 
phenotypes observed in individuals with AIS, much attention has been paid to the effect of 
mutations on AR function 179,357 (Chapter 2). However, identification of molecular pathways 
that are disturbed by defective AR function is an area of research that is still at its infancy. 
Recently, Holterhus et al., 2003, have performed a genome wide screen in genital skin 
fibroblasts (GSFs) from normal males and compared it with gene expression patterns of 
GSF of 46,XY individuals with AIS 642. They have used cDNA microarrays representing 
33,000 genes, and identified 404 transcripts that were expressed at significantly different 
levels in GSFs from normal males as compared with those from AIS-affected individuals. 
Some of the differentially expressed genes were involved in sex steroid hormone 
metabolism, such as reductases, dehydrogenases, and in intracellular signal transduction, 
such as MAPK, and their expression was reduced in GSFs from AIS individuals. The 
different gene expression profiles observed between GSFs from 46,XY males and 46,XY 
AIS individuals, suggest that the AR is involved in setting long-lasting gene expression 
patterns in GSFs. In addition, the study indicated that GSFs from both normal and AIS 
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individuals did not show a detectable response to androgen treatment at the transcriptional 
level 642. It would be of interest to perform a proteome screen on these GSFs to see whether 
androgen treatment induces post-translational modification of signaling proteins, 
cytoskeleton-associated proteins, or glycolytic enzymes. This would yield an indication for a 
non-genomic effect of androgens in GSFs that express relatively low levels of androgen 
receptors. 
 
Conclusions 
This thesis describes the role of androgens, AR, and androgen-regulated proteins in the 
process of male genital tract development. To investigate these issues, several questions 
were raised in Chapter 1. Based on the results presented in the different chapters of this 
thesis, together with the discussion in Chapter 6, the questions can be addressed and 
answered as follows: 
 
1. Is it possible to develop an androgen-responsive cell line derived from Wolffian duct mesenchymal cells 
and use it as a model system for studying androgen-induced regulation of gene expression? 
We have developed a mouse fetal vas deferens cell line, MFVD, which was derived 
from WD mesenchymal cells, and which shows features of WD stromal cells. The MFVD 
cells express a relatively low amount of AR protein, similar to the expression level in human 
genital skin fibroblasts, but lower as compared to AR protein expression in the prostate 
cancer cell line LNCaP. The endogenous transcriptional activity of AR in MFVD cells is 
rather low, and therefore we performed transfection of AR cDNA into the MFVD cells, 
which resulted in a much higher transcriptional activity. We conclude that the MFVD cells 
are androgen-responsive and can function as a good model system for studying androgen-
regulated protein expression. 
 
2. Can detailed functional analysis provide insight into the effect of a novel mutation in the AR gene in an 
individual with PAIS, and do the results of this analysis correlate with the observed phenotype? 
Numerous mutations in the AR gene of AIS patients have been described, and most of 
them reside in the LBD. When a novel mutation is detected, the position of the mutation 
can be indicative for the effect of the mutation on AR functioning, but this is not always 
predictive, due to the lack of sufficient knowledge about AR structure-function relationship. 
The detailed functional analysis performed for ARQ902K, such as N/C interaction and 
TIF2 co-activation, appeared to result in information about the role of residue Q902 in AR 
functioning. Furthermore, several recent reports and our own results emphasize the 
importance of these intra- and intermolecular interactions in determination of the AIS 
phenotype. 
 
3. What are the changes in protein expression patterns of androgen target cells upon treatment with 
androgen as detected by means of 2DE analysis, and can differentially expressed androgen-regulated 
proteins be identified by mass spectrometry? 
Both MFVD cells as well as cultured epididymides and vasa deferentia show changes in 
the protein expression pattern on 2D gels upon androgen treatment. The differentially 
expressed proteins could be identified by peptide mass fingerprinting using a MALDI-TOF 
mass spectrometry approach. Upon protein identification, it appeared that the differentially 
expressed proteins were post-translationally modified isoforms of proteins also present in 
the untreated target cells. Further to these qualitative changes, no obvious quantitative 
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changes (up- or down- regulation) in protein expression were observed upon androgen 
treament, except for hnRNP A3 identified in cultured tissues.  
 
4. Do the androgen-regulated proteins identified in a cell line provide relevant information about the 
androgenic signaling pathway of a whole organ? 
In MFVD cells, androgen treatment resulted in post-translational modification of 
mElfin and CBF-A, whereas in cultured epididymides and vasa deferentia, post-translational 
modification was observed for RhoGDI1, hnRNP A2/B1, and TPI. Although not identical 
proteins appeared to be regulated by androgens in the two model systems used, the 
pathways involved are rather similar. In both systems the common protein scaffold 
interacting with proteins that undergo androgen-induced post-translational modification, 
seems to be the actin cytoskeleton. It is either regulated by the signaling pathway involved or 
functions as a site for interaction to which signaling molecules are recruited. 
 
Future directions 
Proteome analysis using 2DE and MALDI-TOF mass spectrometry is developing into 
a powerful technology, but it still has limitations when looking at the protein side of life. It 
is obvious that the 2D gels used for the studies described in Chapters 4 and 5 can resolve 
and visualize only a limited number of protein isoforms and are highly biased for high 
abundant proteins. Looking at the “tip of the iceberg”, we have been able to detect and 
identify androgen-regulated protein isoforms. However, the question is how many more did 
we miss, and is there a way to detect these missing pieces of the puzzle? Advances in 
proteomics technology have been described in Chapter 3, to indicate the possibilities of 
quantitation techniques and new types of mass spectrometers in combination with 
multidimensional sample separation methods in solution. Until current issues of sensitivity, 
accuracy, dynamic range, and data analysis have been solved in proteomics research, we will 
be unable to identify all components of a particular proteome. However, it can be predicted 
for the near future that proteomics will mature into a technology suitable for identifying 
more and more regulatory proteins in different biological systems 626. Therefore, to 
investigate the role of androgens in either normal or defective male genital tract 
development, application of a combination of genome and proteome screening and 
eventually high-throughput functional protein analyses will allow identification of multiple 
interconnected networks. 
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Summary 
 
Development of sex organs in both male and female embryos first requires formation 
of the so-called indifferent gonads and the indifferent genital tract. Once the indifferent 
stage has been established, the developmental program continues in either a male or a 
female direction, starting with differentiation of the gonads into testes or ovaries. Testicular 
androgens are essential for differentiation of the male genital tract into epididymis, vas 
deferens, and seminal vesicle, and absence of androgenic signals results in feminization of 
the genital tract. The action of androgens is exerted via the androgen receptor (AR), which 
is a transcription factor that belongs to the family of steroid hormone receptors. Upon 
ligand binding, the AR translocates to the nucleus, where it binds specific DNA sequences, 
so-called androgen-response elements, which are present in promoter and enhancer regions 
of androgen-regulated genes. Regulation of gene expression by androgens involves 
chromatin remodeling, interaction with co-factors, and assembly of the transcription 
initiation complex. During androgen-dependent male genital tract development in the fetus, 
AR is present in mesenchymal cells surrounding the epithelial ducts. Therefore, androgenic 
signals in mesenchymal cells must be transduced to epithelial cells via secreted paracrine 
factors. Some growth factors, such as KGF and FGF10, play an important role as paracrine 
factors, but do not appear to be regulated by androgens in vivo. Furthermore, it is still largely 
unknown which proteins are regulated by androgens in mesenchymal cells during fetal 
development. In Chapter 1, we have postutaled 4 questions that are being addressed in this 
thesis: 
1. Is it possible to develop a mouse fetal vas deferens cell line that can be used as a model system for 
studying androgen-regulated gene expression? 
2. Can detailed functional analyses of a novel AR mutation provide information that can be correlated to 
an AIS phenotype? 
3. Can changes in androgen-induced expression patterns of mouse fetal vas deferens cells (MFVD) be 
detected by 2-dimensional gel electrophoresis (2DE), and can androgen-regulated proteins be identified 
by mass spectrometry? 
4. Do androgen-regulated proteins as detected in cultured MFVD cells play a part in the androgenic 
signaling pathway of a whole organ? 
 
 Many different mutations, deletions, or insertions in the AR gene result in defective 
androgen binding or a defective action of the AR, which forms the basis of the androgen 
insensitivity syndrome. Individuals with AIS show a wide spectrum of phenotypes, 
depending on the severity of the AR defect. In Chapter 2, the effect of the Q902K 
mutation on AR transcription activation, co-activator association, and intramolecular 
interaction potential was studied. It could be demonstrated that residue Q902 is only 
partially involved in AR transcription activation, and plays a more pronounced role in co-
activator TIF2 association and in intramolecular interaction of the AR NH2-and COOH-
termini. From this study it is concluded that the severity of disturbance of intermolecular 
interactions of AR with co-activator TIF2 and also AR intramolecular N/C interaction is 
indicative for the severity of AIS phenotypes. 
 Gene regulation by transcription factors, such as the AR, precedes regulation of 
protein expression. Proteins are the effector molecules of gene expression in the cell, and 
can be further regulated at the post-translational level. Chapter 3 describes in which way 
great efforts in genomic research have resulted in the emergence of the field of proteomics. 
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The proteome is defined as the total protein complement of the genome, and it is estimated 
that a cellular proteome contains tens- to hundreds- of thousands of proteins. Proteomics is 
a field that combines classical protein separation techniques, such as 2-dimensional gel 
electrophoresis and liquid chromatography, with state-of-the art mass spectrometry and 
bioinformatics for protein identification. Proteomics as a technology is now becoming 
widely used for applications in a large variety of fields ranging from the biology of 
embryonic development to studies on human disease. In Chapter 3, some examples are 
given of applications in endocrinological research, and future developments are discussed. 
 To identify proteins that are regulated by androgens during genital tract 
development, a proteomic approach of 2DE and MALDI-TOF mass spectrometry was 
chosen. In Chapter 4, the development of a mouse fetal vas deferens cell line, MFVD, is 
described, which is an androgen-responsive target cell line of mesenchymal origin. In this 
cell line, two proteins, mElfin and CBF-A were found to be regulated by androgens at the 
post-translational level. It is suggested that mElfin and CBF-A are phosphorylated upon 
androgen treatment of MFVD cells. Since MFVD cells were derived from an isolated part 
of the genital tract, androgen-induced proteomic changes in whole organs were studied and 
described in Chapter 5. The differentiating epididymis in the fetus responds to androgens 
by heavily coiling of the epithelial duct and by overall organ growth. This response to 
androgens can be reproduced in vitro by culturing early stage epididymides in the presence of 
androgens. In this defined organ culture system, changes in proteome profiles can be 
ascribed to the direct and indirect effects of androgens. Androgen-induced regulation and 
post-translational modifications were observed for the glycolytic enzymes glyceraldehyde 3-
phosphate dehydrogenase and triosephosphate isomerase, for heterogeneous nuclear 
ribonucleoproteins A3 and A2/B1, and for the signaling protein RhoGDI1. It is 
hypothesized that post-translational modification of RhoGDI1 and glycolytic enzymes in 
genital tract tissues may be important functional links between signaling pathways and 
cytoskeleton rearrangements, in control of growth and development. 
The studies descibed in Chapters 4 and 5 have two overlapping features. First, 
androgen-induced regulation involves post-translational modification of proteins. Second, 
androgen-regulated proteins in both MFVD cells and whole organs interact with the actin 
cytoskeleton or cytoskeleton-binding proteins. In Chapter 6, these findings are 
incorporated into a broader context. It is discussed that androgens exert an effect on 
cytoskeleton function in various androgen target tissues by regulating post-translational 
modifications of key proteins. Furthermore, it is suggested that these effects can be achieved 
by a transcription-mediated genomic effect, but may also involve a non-genomic 
mechanism. 
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Samenvatting 
 
De ontwikkeling van geslachtsorganen in zowel mannelijke als vrouwelijke embryo’s 
begint met de vorming van zogenoemde indifferente gonaden en geslachtsgangen. Nadat de 
indifferente weefsels zijn gevormd vervolgt de ontwikkeling zich in ofwel een mannelijke 
ofwel een vrouwelijke richting, beginnend met de differentiatie van de gonaden tot ovaria of 
testikels. Testiculaire androgenen zijn essentieel voor de differentiatie van de mannelijke 
geslachtsgang tot de bijbal (epididymis), de zaadleider (vas deferens) en de zaadblaas 
(seminal vesicle), en afwezigheid van een androgeensignaal zorgt voor het vervrouwelijken 
van de geslachtsgangen. Het effect van androgenen wordt bewerkstelligd door de androgeen 
receptor (AR). De AR is een transcriptiefactor die tot de familie van 
steroidhormoonreceptoren behoort. Nadat de AR het androgeen heeft gebonden, verplaatst 
het zich naar de celkern waar het aan specifieke DNA sequenties bindt. Dit zijn 
zogenoemde androgeen responsieve elementen die zich in promotor en enhancer regionen 
van androgeen-gereguleerde genen bevinden. Bij de regulatie van gen expressie door 
androgenen wordt het chromatine gemodificeerd, vinden er interacties met co-factoren 
plaats en wordt het transcriptie initiatie complex geassambleerd. Tijdens de androgeen-
afhankelijke ontwikkeling van de mannelijke geslachtsgangen in de foetus is het AR eiwit 
aanwezig in mesenchymale cellen die de epitheliale gangen omringen. Epitheliale AR 
expressie is echter pas detecteerbaar nadat het androgeen doelwitweefsel is begonnen zich te 
ontwikkelen. Daarom zullen androgene signalen vanuit het mesenchym moeten worden 
overgedragen naar epitheliale cellen via zogenoemde paracriene factoren. Sommige 
groeifactoren, zoals KGF en FGF10, zijn belangrijke paracriene factoren, maar blijken in vivo 
niet te worden gereguleerd door androgenen. Verder is het nog grotendeels onbekend welke 
eiwitten worden gereguleerd door androgenen in mesenchymale cellen tijdens de foetale 
ontwikkeling. In Hoofdstuk 1 hebben we een viertal vragen gepostuleerd die in dit 
proefschrift worden behandeld. 
1. Is het mogelijk om een muize vas deferens cellijn te ontwikkelen en deze te gebruiken als modelsysteem 
om androgeen-gereguleerde genexpressie te bestuderen? 
2. Kunnen gedetailleerde functionele analyses aan een nieuwe AR mutatie informatie verschaffen die 
gecorreleerd kunnen worden aan een AIS fenotype? 
3. Kunnen androgeen-geïnduceerde veranderingen in expressiepatronen van vas deferens cellen van de 
foetale muis (MFVD) gedetecteerd worden met behulp van 2-dimensionale gel electroforese, en kunnen 
androgeen-gereguleerde eiwitten geïdentificeerd worden met behulp van massa spectrometrie? 
4. Spelen androgeen-gereguleerde eiwitten die zijn gedetecteerd in gekweekte MFVD cellen een rol in 
androgeen signaleringsmechanismen van een orgaan? 
 Vele verschillende mutaties, deleties en inserties in het AR gen resulteren in defecte 
androgeen binding of een defect androgeen werkingsmechanisme, hetgeen de basis vormt 
van het androgeen ongevoeligheidssyndroom (AIS).  In Hoofdstuk 2 is het effect 
bestudeerd van de Q902K mutatie op AR transcriptie activatie, co-activator associatie, en 
intramoleculaire interactie potentieel. Er is aangetoond dat aminozuur Q902 slechts 
gedeeltelijk betrokken is bij AR transcriptie activatie. Echter, het speelt een prominentere rol 
bij co-activator TIF2 associatie en intramoleculaire interacties tussen de NH2- en COOH 
uiteinden van de AR. Er kan geconcludeerd worden dat de mate van verstoring van inter-
moleculaire interacties van de AR met co-activator TIF2 en intra-moleculaire interacties van 
de NH2- en COOH uiteinden van de AR een indicatie is voor de ernst van het fenotype in 
AIS patienten.  
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Genregulatie door transcriptiefactoren, zoals de AR, gaat vooraf aan regulatie van eiwit 
expressie. Eiwitten zijn de uitvoerende moleculen van een cel, en kunnen verder gereguleerd 
worden op post-translatie niveau. In Hoofdstuk 3 wordt beschreven hoe grootschalig 
genoomonderzoek ertoe heeft geleid dat het proteomicsonderzoek van de grond is 
gekomen. De definitie van het woord proteoom wordt gegeven als het totale eiwit 
complement van het genoom, en een cellulair proteoom bestaat uit naar schatting 10 tot 100 
duizenden eiwitten. Proteomics is een onderzoeksgebied dat klassieke eiwit 
scheidingstechnieken, zoals 2DE en vloeistof chromatografie, combineert met moderne 
massa-spectrometrie en bioinformatica om eiwitten te identificeren. Als techniek wordt 
proteomics steeds vaker toegepast in zeer uiteenlopende onderzoeksgebieden, van 
ontwikkelingsbiologie tot studies aan humane ziektes. In Hoofdstuk 3 worden enkele 
voorbeelden gegeven van toepassingen in endocrinologisch onderzoek en worden 
toekomstperspectieven bediscussiëerd. 
Om eiwitten te identificeren die worden gereguleerd door androgenen tijdens de 
ontwikkeling van de geslachtsgangen, werd gekozen voor een proteomics toepassing van 
2DE en MALDI-TOF massa spectrometrie. In Hoofdstuk 4 wordt de ontwikkeling van 
een cellijn van MFVD beschreven. Deze cellijn is een androgeen responsieve doelwitcellijn 
van mesenchymale afkomst. Er werd gevonden dat mElfin en CBF-A worden gereguleerd 
door androgenen op post-translationeel niveau. Er wordt gesuggereerd dat mElfin en CBF-
A worden gefosforyleerd wanneer MFVD cellen worden gestimuleerd met androgenen. 
Aangezien MFVD cellen afkomstig zijn van een geïsoleerd stukje van de geslachtsgang, 
hebben we ook hele organen in kweek gebracht om androgeen-geïnduceerde veranderingen 
in expressiepatronen te bestuderen. Deze resultaten zijn beschreven in Hoofdstuk 5. Het 
effect van androgenen op de zich ontwikkelende epididymis van de foetus uit zich in de 
groei van het orgaan maar ook in het ontstaan van een kronkelende structuur van de 
epitheliale gang. Dit effect van androgenen kan in vitro nagebootst worden door middel van 
orgaankweek van de epididymis in aanwezigheid van androgenen. In dit gedefiniëerd 
orgaankweek systeem zijn veranderingen in eiwitexpressiepatronen geheel toe te schrijven 
aan directe of indirecte effecten van androgenen. In dit systeem worden de glycolytische 
enzymen glyceraldehyde 3-fosfaat dehydrogenase en trifosfaat isomerase, de heterogene 
nucleaire ribonucleo-eiwitten A3 en A2/B1, en het signaaleiwit RhoGDI1 gereguleerd door 
androgenen op post-translatieoneel nievau. Er wordt gehypothetiseerd dat post-translatie 
modificatie van RhoGDI1 en glycolytische enzymen een belangrijke functionele link is 
tussen signaleringspaden en veranderende activiteit van het cytoskelet, die betrokken zijn bij 
regulatie van groei en ontwikkeling. 
De studies die zijn beschreven in Hoofdstuk 4  en 5 hebben twee overlappende 
kenmerken. Allereerst worden in MFVD cellen en epididymis weefsel eiwitten op post-
translatie niveau gereguleerd door androgenen. Ten tweede hebben de androgeen-
gereguleerde eiwiten in MFVD cellen en gekweekte epididymides gemeen dat ze interacteren 
met het actine cytoskelet of met cytoskelet bindende eiwitten. In Hoofdstuk 6 worden deze 
bevindingen in een bredere context geplaatst. Er wordt bediscussiëerd dat androgenen een 
effect uitoefenen op het cytoskelet door post-translationele modificaties van belangrijke 
eiwitten te reguleren in verschillende androgeen doelwitweefsels. Verder wordt er 
gesuggereerd dat deze effecten bereikt kunnen worden door transcriptie-gemediëerde 
genomische effecten van androgenen, maar ook niet-genomische mechanismen kunnen 
omvatten. 
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Allebei heel erg bedankt dat jullie mijn paranimph wilden zijn! 
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komen van hoofdstuk 2 wil ik ook niet vergeten, Micheal Verbiest en Mai Van. Ik heb veel 
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Naast hard werken en ellende waren er gelukkig ook een heleboel leuke dingen in de 
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onvriendelijke opmerkingen. Brechje, Giulietta, Jeske, Machteld en Saskia, wanneer gaan we 
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